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Abstract
EFSA was asked to deliver a scientiﬁc opinion on the risks to public health related to the presence of
aﬂatoxins in food. The risk assessment was conﬁned to aﬂatoxin B1 (AFB1), AFB2, AFG1, AFG2 and
AFM1. More than 200,000 analytical results on the occurrence of aﬂatoxins were used in the evaluation.
Grains and grain-based products made the largest contribution to the mean chronic dietary exposure to
AFB1 in all age classes, while ‘liquid milk’ and ‘fermented milk products’ were the main contributors to the
AFM1 mean exposure. Aﬂatoxins are genotoxic and AFB1 can cause hepatocellular carcinomas (HCCs) in
humans. The CONTAM Panel selected a benchmark dose lower conﬁdence limit (BMDL) for a benchmark
response of 10% of 0.4 lg/kg body weight (bw) per day for the incidence of HCC in male rats following
AFB1 exposure to be used in a margin of exposure (MOE) approach. The calculation of a BMDL from the
human data was not appropriate; instead, the cancer potencies estimated by the Joint FAO/WHO Expert
Committee on Food Additives in 2016 were used. For AFM1, a potency factor of 0.1 relative to AFB1 was
used. For AFG1, AFB2 and AFG2, the in vivo data are not sufﬁcient to derive potency factors and equal
potency to AFB1 was assumed as in previous assessments. MOE values for AFB1 exposure ranged from
5,000 to 29 and for AFM1 from 100,000 to 508. The calculated MOEs are below 10,000 for AFB1 and also
for AFM1 where some surveys, particularly for the younger age groups, have an MOE below 10,000. This
raises a health concern. The estimated cancer risks in humans following exposure to AFB1 and AFM1 are
in-line with the conclusion drawn from the MOEs. The conclusions also apply to the combined exposure
to all ﬁve aﬂatoxins.
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Summary
Following a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) has provided a scientiﬁc opinion on the human health risks related to the presence of
aﬂatoxins in food. The opinion evaluates the toxicity of aﬂatoxins to humans, estimates the dietary
exposure of the European Union (EU) population to aﬂatoxins and assesses the human health risks to
the EU population due to the estimated dietary exposure. Aﬂatoxin B1 (AFB1), aﬂatoxin B2 (AFB2),
aﬂatoxin G1 (AFG1), aﬂatoxin G2 (AFG2) and aﬂatoxin M1 (AFM1) are considered in the risk
assessment. Aﬂatoxin total typically refers to the sum of AFB1, AFB2, AFG1 and AFG2. The risk
assessment carried out by the CONTAM Panel of EFSA in 2007 was used as a starting point.
AFB1, AFB2, AFG1 and AFG2 are mycotoxins produced primarily by toxigenic strains of the fungi
Aspergillus ﬂavus and Aspergillus parasiticus. In addition to the above-mentioned four aﬂatoxins, these
fungi also form other substances such as aﬂatoxicol and sterigmatocystin. The most frequently found
aﬂatoxin in contaminated food samples is AFB1 and the three others are generally not found in the
absence of AFB1. Aﬂatoxin-producing fungi are found in areas with a hot, humid climate and aﬂatoxins
in food are a result of both pre- and post-harvest fungal contamination. Climate change is anticipated
to impact on the presence of aﬂatoxins in food in Europe. AFM1 is the hydroxylated metabolite of
AFB1 and is found in milk and dairy products obtained from livestock that have ingested contaminated
feed, and also in human milk.
AFB1 is absorbed in the small intestine and distributed to the liver where it undergoes ﬁrst pass
metabolism. The metabolism of AFB1 in humans and laboratory animals has been well-characterised
with CYP1A2, 2B6, 3A4, 3A5, 3A7, 2A13 and GSTM1 all catalysing aﬂatoxin metabolism in humans.
AFB1, AFG1 and AFM1 are converted to their respective epoxides, which can bind covalently to both
DNA and proteins. AFB2 and AFG2 cannot form the 8,9-epoxide. AFB1 and its metabolites are both
excreted via the faecal and the urinary route. The percentage excreted via both routes varies
according to the species. AFM1 is also excreted in milk. A limited amount of new information has
become available regarding the toxicokinetics of AFB1 in humans since the previous assessment by the
CONTAM Panel in 2007. The new data on humans show that absorption of AFB1 and/or its metabolites
into the systemic circulation is rapid and high.
In short-term studies (7–90 days), AFB1 had multiple negative effects on rodents including
inhibition of normal growth, liver and kidney damage, as well as sustained alterations in the intestinal
microbiota. For AFG1, AFG2, AFB2 or AFM1, no new short-term toxicity or gut microbiota studies were
identiﬁed. AFB1 affects reproductive and developmental parameters and aﬂatoxins, especially AFB1,
can produce an immunotoxic effect in rodents. The no-observed-adverse-effect-levels (NOAELs) for
these effects were around 30 lg/kg body weight (bw) per day.
AFB1 is a genotoxic and carcinogenic substance. CYP3A and CYP1A2 activity is important for AFB1
genotoxicity. Upon epoxidation, DNA adducts such as AFB1-N7-gua and AFB1-FAPY are formed and
can lead to G-to-T transversions. In addition to DNA adduct formation, a broad spectrum of cellular
effects has been reported in response to AFB1 exposure. In humans living in areas where hepatitis B
virus (HBV) infection and AFB1 exposure are prevalent, hepatocellular carcinoma (HCC) samples show
a mutational hotspot (G-to-T transversion) at codon 249 of the TP53 gene, which is considered to be a
signature mutation for aﬂatoxin-induced HCC.
There is evidence for genotoxic effects of AFB1 in pregnant mice, fetuses and young animals.
Pregnancy appears to enhance the sensitivity to the genotoxicity of AFB1 for the mothers, possibly due
to elevated levels of CYP1A2 and CYP3A enzymes. A study with in utero exposure showed a greater
mutational impact of the lesions in the fetus. Early postnatal exposure resulted in higher adduct levels
in the liver compared to adult animals.
Besides DNA adduct formation, AFB1 induces oxidative stress including modulation of antioxidant
defence systems. Considering the potential sequence of events towards HCC, oxidative stress might
compromise critical AFB1 detoxiﬁcation pathways (e.g. glutathione (GSH) conjugation) and/or induce
additional DNA lesions.
In contrast to AFB1, fewer studies are available regarding the genotoxicity of the other aﬂatoxins.
When comparing the genotoxicity of the different aﬂatoxins, most studies have indicated that AFB1 is
the most genotoxic compound. AFG1 is slightly less genotoxic than AFB1; AFB2 and AFG2 are less
genotoxic than AFB1. It is not possible, based on these data, to make a quantitative comparison of the
genotoxic potency of these compounds. The genotoxic potency can be summarised as AFB1 > AFG1 
aﬂatoxicol » AFM1 based on the cH2AX in-cell western technique in cultured human liver cells, while
AFB2 and AFG2 showed no effects.
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AFB1, AFG1 and AFM1 are carcinogenic when delivered orally via the diet or by gavage. There is
limited evidence for the carcinogenicity of AFB2 and inadequate evidence for carcinogenicity of AFG2.
AFB1 is more potent than AFG1 with respect to liver carcinogenicity but AFG1 induced a higher
incidence of kidney tumours than AFB1. AFB1 is also more potent than AFM1 with respect to liver
carcinogenicity by approximately 10-fold.
AF-alb (AFB1-lys), urinary AF-N7-gua and urinary AFM1 are all biomarkers of exposure that have
been validated against dietary intake of aﬂatoxin. However, the levels of these biomarkers cannot be
converted reliably into dietary exposures in individuals. As AF-alb (AFB1-lys) better reﬂects longer-term
exposure (i.e. several weeks), it tends to be most widely used, while urinary AFM1 and AF-N7-gua are
suitable biomarkers for recent exposure.
The epidemiological studies reported since 2006 have added to the weight of evidence that aﬂatoxin
exposure is associated with a risk of developing HCC, with a higher risk for people infected with either
HBV or hepatitis C virus (HCV). Data suggest that HBV infection of the liver alters the expression of the
genes coding for the enzymes, which metabolise/detoxify aﬂatoxins such as an induction of CYP
enzymes or decrease in glutathione S-transferase (GST) activity. This may provide one mechanistic basis
for the higher risk of liver cancer among HBV-infected individuals exposed to aﬂatoxins.
Child health is an emerging area of interest for the ﬁeld of aﬂatoxin-related health outcomes but
not yet suitable for use in risk assessment. Child growth has been assessed in a growing body of
evidence outside European populations but with limited replicability in the observed associations. The
evidence related to the remaining child health outcomes is sparse, heterogeneous and with
methodological limitations.
The CONTAM Panel considers that liver carcinogenicity of aﬂatoxins remains the pivotal effect for
the risk assessment. In view of the genotoxic properties of aﬂatoxins, the CONTAM Panel considered
that it was not appropriate to establish a tolerable daily intake. Based on studies in animals, the
CONTAM Panel selected a BMDL10 of 0.4 lg/kg bw per day for the incidence of HCC in male rats
following AFB1 exposure to be used in a margin of exposure (MOE) approach. The calculation of a
BMDL from the human data was not appropriate; instead, the cancer potencies estimated by the Joint
FAO/WHO Expert Committee on Food Additives (JECFA) in 2016 were used.
Differences in carcinogenic potency are reported for the different aﬂatoxins. For AFM1, JECFA
concluded, based on a study in Fischer rats, that AFM1 induces liver cancer with a potency one-tenth
that of AFB1. No new evidence has become available that necessitates a change to this conclusion and a
potency factor of 0.1 was used in this assessment for AFM1. For the other aﬂatoxins, the available in vivo
data are not sufﬁcient to derive potency factors. In the absence of such potency factors, the CONTAM
Panel applied equal potency factors for AFB1, AFB2, AFG1 and AFG2 as used in previous assessments.
Chronic dietary exposure to AFB1, AFM1 and AFT (the sum of AFB1, AFB2, AFG1 and AFG2) +AFM1
was estimated using a data set comprising 209,802 analytical results from 69,166 samples. The highest
AFB1 and AFT mean concentrations were obtained for the food category ‘legumes, nuts and oilseeds’ (in
particular for pistachios, peanuts and ‘other seeds’). As expected, the highest AFM1 mean concentrations
were reported for ‘milk and dairy products’ and milk-based foods belonging to the food category ‘food for
infants and small children’. For adults, the mean lower bound (LB) exposure to AFB1 ranged from 0.22 to
0.49 ng/kg bw per day and the mean UB exposure from 1.35 to 3.25 ng/kg bw per day. For the younger
age groups, the mean LB exposure to AFB1 ranged from 0.08 to 1.78 ng/kg per day and the mean upper
bound (UB) exposure from 0.58 to 6.95 ng/kg per day. The LB P95 exposure to AFB1 ranged from 0.62
to 1.36 ng/kg bw per day for adults and from 0.35 to 6.22 ng/kg bw per day for the younger age groups.
The UB P95 exposure to AFB1 ranged from 2.76 to 6.78 ng/kg bw per day and from 2.79 to 14.01 ng/kg
bw per day, respectively. The highest estimated exposure to AFM1 was in infants with a mean exposure
of 1.6/2.0 ng/kg bw per day (LB/UB) and a P95 exposure of 6.2/7.9 ng/kg bw per day. Overall, ‘grains
and grain-based products’ made the largest contribution to the LB mean chronic dietary exposure to
AFB1 in all age classes. The main subcategories driving the contribution of this food category were
‘grains for human consumption’ (in particular corn grain), ‘bread and rolls’ and ‘ﬁne bakery wares’. The
food categories ‘liquid milk’ and ‘fermented milk products’ were the main contributors to the overall
AFM1 mean exposure throughout all age groups.
Based on a BMDL10 of 0.4 lg/kg bw per day for the induction of HCC by AFB1 in male rats, MOE
values (minimum to maximum) range from 5,000 to 225 for the mean LB exposure to AFB1 and from
690 to 58 for the mean UB exposure to AFB1 across dietary surveys and age groups. The MOE values
range from 1,143 to 64 for the P95 LB exposure to AFB1 and from 145 to 29 for the P95 UB exposure
to AFB1 across dietary surveys and age groups. The calculated MOEs are below 10,000, which raises a
health concern. For AFM1, based on the BMDL10 of 0.4 lg/kg bw per day derived for AFB1 and a
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potency factor of 0.1, MOE values that range from 100,000 to 2,564 for the mean LB exposure
estimates, from 66,667 to 2,020 for the mean UB exposure estimates, from 33,333 to 642 for the P95
LB exposure estimates, and from 25,000 to 508 for the P95 UB exposure estimates across dietary
surveys and age groups have been calculated. The CONTAM Panel noted that the calculated MOEs are
less than 10,000 for some surveys, particularly for the younger age groups, which raises a health
concern. The estimated cancer risks in humans following exposure to AFB1 are in-line with the
conclusion drawn from the animal data. This conclusion also applies to AFM1 and AFT + AFM1.
The CONTAM Panel recommends that data that would allow the derivation of potency factors are
generated. Research designed to quantify the relationship between biomarker levels and dietary intake
at the individual level, integrating exposure over time with biomarker levels, is recommended. Such
study would be performed in populations with an indigenous dietary exposure to aﬂatoxin resulting in
measurable biomarker levels. More data are needed regarding the occurrence of aﬂatoxicol and
aﬂatoxin M2 (AFM2), to clarify whether these substances should be included in the risk assessment.
There is a need to continue to monitor aﬂatoxin occurrence in the light of potential increases due to
climate change using methods with high levels of sensitivity for detection.
Aﬂatoxins in food
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
BACKGROUND
In the Codex Alimentarius and, more speciﬁcally, in the Codex Committee on Contaminants in Food
(CCCF), discussions on maximum levels (MLs) and an associated sampling plan for aﬂatoxins in
different foodstuffs are ongoing.
At the 12th session of the CCCF in March 2018 (CCCF, 2018), discussions on MLs for aﬂatoxin total
(AFT) in ready-to-eat peanuts (§103 – §115 of the report) and spices (§116 – §119 of the report) were
held but were suspended because of divergent views. The EU could not agree on the discussed MLs
for AFT in ready-to-eat peanuts (European Commission, 2018a), taking into account the outcome of
the EFSA risk assessment (EFSA CONTAM Panel, 2018), nor could it agree on the MLs discussed for
certain spices (European Commission, 2018b). New work was agreed at the 12th session of the CCCF
on setting MLs for aﬂatoxins in cereals and cereal-based food, including food for infants and young
children.
In view of the future discussions at the CCCF on MLs for aﬂatoxins in food and taking into account
the recommendations in the last above-mentioned Opinion of EFSA on the effect on public health of a
possible increase of the ML for AFT in peanuts (EFSA CONTAM Panel, 2018), it is necessary that EFSA
performs a comprehensive risk assessment related to the presence of aﬂatoxins in food.
TERMS OF REFERENCE
In accordance with Article 29 (1) of Regulation (EC) No 178/20021, the European Commission asks
the European Food Safety Authority for a Scientiﬁc Opinion on the human health risks related to the
presence of aﬂatoxins in food.
1.2. Interpretation of the Terms of Reference
The EFSA Panel on Contaminants in the Food Chain (CONTAM Panel) concluded that this Opinion
should comprise the:
a) evaluation of the toxicity of aﬂatoxins for humans, considering all relevant toxicological
endpoints;
b) estimation of the dietary exposure of the EU population to aﬂatoxins from food, including the
consumption patterns of speciﬁc groups of the population;
c) assessment of the human health risks to the EU population, including speciﬁc (vulnerable)
groups of the population, as a consequence of the estimated dietary exposure.
This risk assessment is conﬁned to aﬂatoxin B1 (AFB1), aﬂatoxin B2 (AFB2), aﬂatoxin G1 (AFG1),
aﬂatoxin G2 (AFG2) and aﬂatoxin M1 (AFM1). The inclusion of aﬂatoxin M2 (AFM2) in the risk
assessment was not possible due to the limited data available. Occurrence data for food of animal
origin were included in the assessment. However, the transfer from feed into food of animal origin was
not within the scope of the assessment. Although aﬂatoxin-producing fungi produce other mycotoxins
such as aﬂatoxicol, versicolorin and sterigmatocystin, these mycotoxins are not the subject of the
present assessment. This Scientiﬁc Opinion is an update of the Scientiﬁc Opinion on the potential
increase of consumer health risk by a possible increase of the existing MLs for aﬂatoxins in almonds,
hazelnuts and pistachios and derived products adopted by the CONTAM Panel of EFSA in January 2007
(EFSA, 2007a). Therefore, papers published from 2006 onwards were taken into account for the
current risk assessment when not yet included in the previous opinion.
1.3. Supporting information for the assessment
This section is an adapted and amended version of the corresponding section in the recently
published statement of the CONTAM Panel (2018).
Aﬂatoxins are bisfuranocoumarin compounds produced primarily by toxigenic strains of the fungi
Aspergillus ﬂavus and Aspergillus parasiticus. A. parasiticus produces AFB1, AFB2, AFG1 and AFG2,
whereas A. ﬂavus mainly produces AFB1 and AFB2. A. ﬂavus favours the aerial parts of the plants (e.g.
1 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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leaves and ﬂowers) while A. parasiticus is more adapted to a soil environment and is of more limited
distribution than A. ﬂavus (EFSA, 2007a). Many other species closely related to A. ﬂavus (A.
minisclerotigenes, A. korhogoensis, A. aﬂatoxiformans and A. texensis) or to A. parasiticus (A.
novoparasiticus and A. arachidicola) also produce aﬂatoxins B and G (Pildain et al., 2008; Adjovi et al.,
2014; Carvajal-Campos et al., 2017; Singh et al., 2018; Frisvad et al., 2019). In addition to the above-
mentioned four aﬂatoxins, these fungi also form other substances such as aﬂatoxicol, versicolorin and
sterigmatocystin (Yu, 2012s).
When concentrations or maximum limits mention ‘total’, it typically refers to the sum of AFB1,
AFB2, AFG1 and AFG2. The most frequently found aﬂatoxin in contaminated food samples is AFB1 and
the three others are generally not reported in the absence of AFB1 (FAO/WHO, 2018).
The aﬂatoxin-producing fungi are found especially in areas with a hot, humid climate and aﬂatoxins
are found in food as a result of both pre- and post-harvest fungal contamination. The rate and degree
of contamination depends on temperature, humidity, soil and storage conditions (EFSA, 2007a).
Climate change is expected to have an impact on the presence of AFB1 in maize in Europe. Battilani
et al. (2016) used a modelling approach to predict aﬂatoxin contamination in maize under increasing
temperatures and showed that a +2°C climate change scenario would increase the probability of
aﬂatoxin contamination from low to medium in European countries in which maize cultivation is
common (e.g. France, Italy and Romania). This is in line with the reports of an outbreak of A. ﬂavus in
maize in 2012 caused by high temperature and drought in Serbia (Levic et al., 2013) and increased
levels of AFM1 in milk due to high levels of AFB1 in maize in northern Italy in 2003 (Piva et al., 2006;
Battilani et al., 2008). The year 2003 had a hot and dry summer; with mean temperatures in the
period June–August that were about 2.5°C higher than the previous and following year.
AFM1 and AFM2 are the hydroxylated metabolites of AFB1 and AFB2 and are found in milk and
dairy products obtained from livestock that have ingested contaminated feed. AFM1 occurrence is also
reported in human milk (e.g. Kunter et al., 2017; Radonic et al., 2017; Bogalho et al., 2018; Valitutti
et al., 2018).
1.3.1. Chemistry
The structures of AFB1, AFB2, AFG1, AFG2, AFM1 and AFM2 are shown in Table 1. Aﬂatoxins are
colourless to pale yellow crystals and they ﬂuoresce in ultraviolet (UV) light: blue for AFB1 and AFB2,
green for AFG1 and AFG2 and blue violet for AFM1 (IARC, 2012). They are unstable in UV light in the
presence of oxygen, extreme pH (< 3 or > 10) and in the presence of oxidising agents (IARC, 2012).
Under alkaline conditions the lactone ring opens; however, the reaction is reversible. The lactone ring
also opens and results in decarboxylation when treated with ammonia at high temperatures and high
pressure (IARC, 2012). Aﬂatoxins are insoluble in non-polar solvents while they are freely soluble in
moderately polar organic solvents as chloroform and methanol. The solubility in water is 10–20 mg/L
(IARC, 2012).
Table 1: Chemical structures, CAS number, molecular formula and molecular weight of aﬂatoxins
B1, B2, G1, G2, M1 and M2
Name Aﬂatoxin B1 (AFB1) Aﬂatoxin B2 (AFB2) Aﬂatoxin G1 (AFG1)
Structure
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CAS number 1162-65-8 7220-81-7 1165-39-5
Molecular formula C17H12O6 C17H14O6 C17H12O7
Molecular weight 312.3 g/mol 314.3 g/mol 328.3 g/mol
Log P(a) 1.23 1.45 0.5
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1.3.2. Analytical methods
A wide range of methods have been used for the analysis of aﬂatoxins (Wacoo et al., 2014; Gacem
and Ould El Hadj-Khelil, 2016; Shephard, 2016; Danesh et al., 2018; FAO/WHO, 2018). The text below
describes examples of commonly used analytical methods and does not aim to be exhaustive. Methods
using older analytical techniques such as thin-layer chromatography are not included in this section.
For the analysis of AFB1, AFB2, AFG1 and AFG2, the most widely applied methods for quantitative
analysis are liquid chromatography (LC) combined with ﬂuorescence detection (FD) or mass spectrometry
(MS) (EFSA, 2007a; FAO/WHO, 2018).
For analysis using LC-FD, samples are typically extracted with methanol or mixtures of methanol and
water or hexane. The latter is used in the case of oil samples. Samples may be cleaned using an
immunoassay column speciﬁc for aﬂatoxins before separation with LC, post-column derivatisation and
quantiﬁcation by FD. Limits of detection (LODs) and limits of quantiﬁcation (LOQs) are typically reported
to be in the range of 0.001–0.20 lg/kg, depending on the matrix and the aﬂatoxin.
Mass spectrometry determination of aﬂatoxins has the advantage that no post-column
derivatisation is needed. Aﬂatoxins are typically extracted with acetonitrile, sometimes in mixtures with
water, formic acid, or hexane before analysis by liquid chromatography coupled to mass spectrometry
(LC–MS) or liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). The use of LC–
MS or LC–MS/MS also had a great impact on the development of multi-mycotoxin methods and several
papers describe the simultaneous determination of several mycotoxins (e.g. Garcıa-Moraleja et al.,
2015; Saladino et al., 2017; Skrbic et al., 2012, 2017; Cunha et al., 2018). According to Shephard
(2016), methods have been developed that determine over 100 mycotoxins in a single analysis. Limits
of quantiﬁcation are typically reported to be in the range of 0.007–3 lg/kg, generally with the highest
LOQs for the multi-mycotoxin methods. The MS techniques have also been used to determine
mycotoxins together with pesticides, plant toxins, veterinary drugs, and cyanogenic glycosides
(Shephard, 2016). However, the inclusion of a high number of substances in an analytical method may
lead to a reduced sensitivity.
For the determination of AFM1, the most common analytical method described in the literature is
enzyme-linked immunosorbent assay (ELISA). Commercially available kits speciﬁc for AFM1 in milk
typically have an LOD of about 0.005 lg/L. LC–MS and LC-FD methods are also used for the
determination AFM1 (e.g. Gomez-Arranz and Navarro-Blasco, 2010; Skrbic et al., 2014). The reported
LOQs for AFM1 are typically between 0.0007 and 0.014 lg/kg.
ELISA kits are also commercially available for the determination of aﬂatoxin total (AFT) and AFB1.
Other immunochemical-based methods have been developed for the analysis of aﬂatoxins and the
advantages and disadvantages of the different methods are discussed by Matabaro et al. (2017).
Proﬁciency testing in different matrices and certiﬁed reference materials are available. Standard
methods (EN-methods) also exist for the determination of aﬂatoxins. As described in the legislation
(see Section 1.3.4) there are requirements for performance and quality assurance of the methods used
for ofﬁcial control.
Name Aﬂatoxin G2 (AFG2) Aﬂatoxin M1 (AFM1) Aﬂatoxin M2 (AFM2)
Structure
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CAS number 7241-98-7 6795-23-9 6885-57-0
Molecular formula C17H14O7 C17H12O7 C17H14O7
Molecular weight 330.3 g/mol 328.3 g/mol 330.3 g/mol
Log P 0.71 1.21 1.16
(a): The predicted Log P values for AFB1, AFB2, AFG1 and AFG2 were extracted from the Hazardous Substances Data Bank
(HSDB), a database of the National Library of Medicine’s TOXNET system (http://toxnet.nlm.nih.gov) on 28 August, 2019.
The predicted Log P value for AFM1 and AFM2 were extracted from the Metabolomics Innovation Centre (https://www.me
tabolomicscentre.ca) and had been calculated with ALOGPS (http://www.vcclab.org/lab/alogps/).
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1.3.3. Previous assessments
Aﬂatoxins were previously evaluated by EFSA’s CONTAM Panel in 2007 when EFSA was asked to
advise on the potential increase in the risk to consumers’ health associated with a proposed change of
the existing EU ML in almonds, hazelnuts and pistachios (EFSA, 2007a). In 2009, the CONTAM
Panel issued a statement on the effects on public health of an increase in the levels for ‘aﬂatoxin total’
from 4 lg/kg to 10 lg/kg for tree nuts other than almonds, hazelnuts and pistachios (EFSA, 2009a), and
in 2012, EFSA published a technical report ‘Effect on dietary exposure of an increase of the levels for
aﬂatoxin total from 4 to 10 lg/kg for dried ﬁgs’ (EFSA, 2012). Finally, in 2018, a statement from the
CONTAM Panel was published on the ‘Effect on public health of a possible increase of the maximum level
for ‘aﬂatoxin total’ from 4 to 10 lg/kg in peanuts and processed products thereof, intended for direct
human consumption or use as an ingredient in foodstuffs’ (EFSA CONTAM Panel, 2018).
Aﬂatoxins were also evaluated at several meetings of the Joint FAO/WHO Expert Committee on
Food Additives (JECFA) (i.e. at its 46th, 49th, 56th, 68th meetings and last time at its 83rd meeting, in
2016) (FAO/WHO, 2018). The International Agency for Research on Cancer’s (IARC) latest evaluation
of aﬂatoxins was in 2012 (IARC, 2012).
Carcinogenicity and mode of action
The available toxicological knowledge on aﬂatoxins is mostly related to AFB1. Aﬂatoxins are
genotoxic and the critical effect of aﬂatoxins in all the previous assessments was liver cancer. Following
absorption, aﬂatoxins undergo ﬁrst pass metabolism in the liver where they exert their toxicity due to
the formation of toxic metabolites.
AFB1, AFB2 and AFG1 are mutagenic and induce DNA damage in bacteria and bind covalently to
isolated DNA as well as to DNA in cells of rodents treated in vivo. AFB1 and AFG1 also cause
chromosomal aberrations in mammalian cells both in vitro and in vivo (IARC, 1993). In addition, AFB1
induces point mutations, mitotic recombination in mammalian cells and genetic instability (IARC,
2012). AFM1 is mutagenic to bacteria and binds to DNA in vitro while AFG2 gave conﬂicting results
regarding mutagenicity in bacteria and did not cause DNA damage.
In experimental animals, AFB1, AFG1 and AFM1 are carcinogenic, whereas there is limited evidence
for carcinogenicity of AFB2 and inadequate evidence for carcinogenicity of AFG2 (IARC, 2012). There is
strong evidence that the carcinogenicity is due to a genotoxic mode of action (IARC, 2012). AFB1 is
more potent than AFG1 both with respect to mutagenicity and liver carcinogenicity (Wong and Hsieh,
1976), but AFG1 induced a higher incidence of kidney tumours than AFB1 (EFSA, 2007a). AFB1 is also
more potent than AFM1 (Cullen et al., 1987).
Co-exposure to hepatitis viruses, in particular hepatitis B, has a strong inﬂuence on the
carcinogenic risk of aﬂatoxins to humans. In epidemiological studies, there is an interaction between
aﬂatoxin exposure and hepatitis B infection, and subjects positive for hepatitis B surface antigen
(HBsAg) show a multiplicative risk for liver cancer when present together with aﬂatoxin exposure
(FAO/WHO, 2018). IARC (2012) classiﬁed aﬂatoxins as a group as carcinogenic to humans (Group 1)
causing hepatocellular carcinomas (HCCs).
The double bond in the furan ring of AFB1 and AFG1 can be oxidised and forms an 8,9-exo-epoxide
that readily reacts with DNA and other nucleophiles (FAO/WHO, 2018). AFB1 forms DNA adducts by
covalent binding to N7-guanine, resulting in persistent DNA lesions. These lesions may subsequently
lead to transversion mutations (IARC, 2012).
Detoxiﬁcation of AFB1 8,9-exo-epoxide can take place by several pathways such as hydrolysis, and
enzyme-mediated conjugations with glutathione (GSH), glucuronic acid and sulfate, and excretion. In
particular, GSH conjugation of the reactive epoxide catalysed by glutathione S-transferase (GST)
isoforms in the liver appears to be critical and accounts for interspecies susceptibility to AFB1 toxicity.
While mice with high GST activity are relatively resistant, hepatic GST activity is much lower in rats,
trout and humans and these species are therefore more susceptible to the adverse effects of
aﬂatoxins. Monkeys show intermediate activity (IARC, 2012; FAO/WHO, 2018). AFB1 is also directly
detoxiﬁed by oxidation. Due to human polymorphisms (e.g. in cytochrome P450 (CYP) enzymes
responsible for the activation of AFB1 and the inactivation of AFB1-8,9-exo-epoxide by GST isoforms),
there is interindividual variability in susceptibility to AFB1 among humans (EFSA, 2007a; IARC, 2012;
FAO/WHO, 2018).
AFB1 dihydrodiol, a hydrolytic product of AFB1 8,9-epoxide, may bind to lysine residues of proteins
forming adducts, i.e. in serum albumin, which is used as a biomarker of aﬂatoxin exposure in many
studies (Guengerich et al., 2002; EFSA, 2007a; FAO/WHO, 2018).
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Dose–response considerations
At its 49th meeting, JECFA (FAO/WHO, 1999) performed the ﬁrst detailed risk assessment and
evaluated a large number of epidemiological studies and identiﬁed the Chinese study on mortality from
liver cancer by Yeh et al. (1989) as the pivotal study. In this study, the mortality from liver cancer
associated with exposure to aﬂatoxins both in HBsAg-positive and negative individuals was examined.
JECFA estimated AFB1 potencies, which corresponded to 0.3 cancer cases/year per 100,000 subjects
per ng AFB1/kg body weight (bw) per day (uncertainty range: 0.05–0.5) in HBsAg-positive individuals.
For HBsAg-negative individuals the potency estimate was 0.01 cancer cases/year per 100,000 subjects
per ng AFB1/kg bw per day (uncertainty range: 0.002–0.03). At this meeting, JECFA also concluded
that AFM1 has a potency of inducing liver cancer approximately one order of magnitude less than that
of AFB1. The Committee based this potency estimate on a comparative carcinogenicity study in male
Fischer rats (i.e. Cullen et al., 19872).
At its 56th meeting, JECFA (FAO/WHO, 2001) noted that there were no adequate epidemiological
studies on the dose–response relationships between the intake of AFM1, exposure to hepatitis B or C
virus, and liver cancer. JECFA therefore assumed that AFM1 acts similarly to AFB1 with hepatitis B (and
possibly) C virus. JECFA used the comparative ﬁgure for carcinogenic potency derived at its 49th meeting
and assumed that the potency of AFM1 was one tenth of AFB1 in the Fischer rat.3 The carcinogenic
potency of AFM1 was estimated to be 0.001/100,000 person-years per ng/kg bw per day in HBsAg-
negative individuals and 0.03/100,000 per year per ng/kg bw per day in HBsAg-positive individuals.
In 2007, EFSA’s CONTAM Panel also considered a large number of epidemiological studies on aﬂatoxin
exposure and HCC and identiﬁed the liver carcinogenicity of aﬂatoxins as the pivotal effect for the risk
assessment (EFSA, 2007a). In its assessment of the cancer risk, the CONTAM Panel conducted benchmark
dose (BMD) analyses of the Chinese study on mortality from liver cancer (Yeh et al., 1989) and of a group
of studies from Africa on the risk of liver cancer (Peers et al., 1976 as corrected by Carlborg, 1979; Van
Rensburg et al., 1985; Peers et al., 1987). The prevalence of HBsAg-positive was 23% in the Chinese
cohort, between 21% and 28% for two studies from Africa, and unknown for one study. The CONTAM
Panel calculated a BMD lower conﬁdence limit for an extra cancer risk of 10% (BMDL10) on a background
risk of 10.5% of 870 ng/kg bw per day from the study by Yeh et al. (1989). From the other studies cited
above (not including the Yeh et al. (1989) study), a BMD lower conﬁdence limit for an extra cancer risk of
1% (BMDL01) on a background risk of 0.17–0.50% of 78 ng/kg bw per day was calculated. The CONTAM
Panel used these values for the risk characterisation. In addition, cancer rates for adults with a high AFB1
intake were estimated based on cancer potency estimates made by JECFA as referenced above for HBsAg-
negative and positive populations with 0.2% and 7% prevalence of HBsAg.
The CONTAM Panel also considered many studies on aﬂatoxin and liver cancer in rats and decided to
use in its hazard characterisation the two-year carcinogenicity study by Wogan et al. (1974), in which
male Fischer rats were given AFB1 in their diet. A BMDL10 of 170 ng/kg bw per day was calculated.
At its 83rd meeting in 2016, JECFA reviewed and updated the toxicological evidence on aﬂatoxin
hepatocarcinogenicity. JECFA conﬁrmed its previous conclusion that the lifetime dietary study in male
F344 rats (Wogan et al., 1974) is the most suitable study in experimental animals for modelling
toxicity. Male F344 rats appear to be particularly susceptible, and in this study, AFB1 as low as 1 lg/kg
diet produced liver tumours. Rainbow trout exposed for 4 weeks showed a hepatotumourigenic
response over a dose range of 0.05–110 lg/kg diet after 1 year (Williams et al., 2009; Williams, 2012).
JECFA (FAO/WHO, 2018) noted that the dose-related tumourigenesis did not seem to deviate from a
log-linear relationship and that a similar relationship was observed between the dose of AFB1 and
AFB1–DNA adducts in trout and rat liver (Bailey et al., 1998; Pottenger et al., 2014). These
observations with doses approaching human exposures lend support to the application of a linear non-
threshold model in AFB1 cancer risk assessment.
JECFA (FAO/WHO, 2018) concluded at its 83rd meeting that the prospective Chinese study by Yeh
et al. (1989), which demonstrated a close to linear relationship between aﬂatoxin exposure and mortality
from HCC, was still the pivotal study for the risk assessment. The risk was recalculated using a Bayesian
model averaging approach, as model uncertainty was a concern. Potency estimates of 0.017 (mean) and
0.049 (95% upper bound (UB)) per 100,000 person-years per ng/kg bw per day were calculated for
2 Cullen et al. (1987) estimated a potency of AFM1 of 2–10% of that of AFB1, based on a comparison of the tumour incidence
induced in male Fischer rats by AFM1 in their study (0.5, 5.0, and 50.0 µg/kg of AFM1 or 50 µg/kg of AFB1 in the diet) with
the tumour incidence induced by AFB1 in the Wogan et al. (1974) study (1, 5, 15, 50 and 100 µg/kg in the diet).
3 The 56th JECFA also calculated the relative potency of AFB1 and AFM1 from the data in Cullen et al. (1987) by time
extrapolation of the tumour incidence of the respective 50 µg/kg dietary dose groups (6 µg/kg bw vs 0.57 µg/kg bw).
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HBsAg-negative individuals. For HBsAg-positive individuals, potency estimates of 0.269 (mean) and 0.562
(95% UB) per 100,000 person-years per ng/kg bw per day were calculated (FAO/WHO, 2018). The
resulting central potency estimates were practically identical to those calculated by the 49th JECFA (i.e.
0.01 and 0.3 per 100,000 person-years per ng/kg bw per day for HBsAg-negative and positive individuals,
respectively, see above). These recalculated cancer potencies were also used by the CONTAM Panel for
the risk characterisation in its statement on ‘Effect on public health of a possible increase of the maximum
level for ‘aﬂatoxin total’ from 4 to 10 lg/kg in peanuts and processed products thereof, intended for direct
human consumption or use as an ingredient in foodstuffs’ (EFSA CONTAM Panel, 2018).
JECFA at its 83rd meeting also modelled the rat studies of Wogan et al. (1974) using model
averaging. The dose that increased the probability of tumours by 1 in 1,000 was calculated. Using
linear extrapolation of the potency to a risk associated with an AFB1 exposure of 1 ng/kg bw per day
and using a conversion factor for body weight of 0.75 to extrapolate from rats to humans, a unit risk
for humans of 4.7 per 100,000 person-years per ng/kg bw (95% conﬁdence interval (CI): 1.3–74.9)
was calculated (FAO/WHO, 2018).
Risk characterisation
In 2007, the CONTAM Panel calculated margins of exposure (MOEs) based on both BMDL10 and
BMDL01 values derived from the epidemiological data and the BMDL10 value derived from the animal
data. When evaluating AFT (i.e. the sum of AFB1, AFB2, AFG1 and AFG2), the CONTAM Panel took into
account that AFG1 and AFB2 were also shown to be carcinogenic in rodents and assumed that the
carcinogenic potency of AFTwould be similar to that of AFB1. The Panel (EFSA, 2007a) considered this to
be a conservative approach. The MOEs based on the BMDL10 from the animal data and estimated dietary
exposure in adults (see Section 3.3.4) were considered to indicate a potential concern for human health.
The BMDLs from the epidemiological studies on populations with a high rate of HBsAg indicated a
sensitivity similar to that of the rats. However, other subgroups were considered likely to be less sensitive.
JECFA calculated, at its 83rd meeting, the cancer risk associated with estimated aﬂatoxin exposure
in different regions and concluded that the lowest cancer risks were estimated for clusters G07 and
G08, which include European and other developed countries. The cancer risk estimates for these
clusters ranged from < 0.01 to 0.1 aﬂatoxin-induced cancers per year and per 100,000 subjects. The
highest cancer risk was estimated for cluster G13 (sub-Saharan African countries and Haiti) and ranged
from 0.21 to 3.94 aﬂatoxin-induced cancers per year and per 100,000 subjects (FAO/WHO, 2018).
1.3.4. Legislation
In this Opinion, where reference is made to Regulations, the reference should be understood as
relating to the most recent amendment, unless otherwise stated.
In order to protect public health, Article 2 of Council Regulation (EEC) No 315/934 of 8 February
1993, laying down Community procedures for contaminants in food, stipulates that, where necessary,
maximum tolerances for speciﬁc contaminants shall be established. Subsequently, a number of MLs for
aﬂatoxins and other mycotoxins in various foodstuffs were laid down in the Annex, Section 2 of
Commission Regulation (EC) No 1881/20065 of 19 December 2006 setting MLs for certain contaminants
in foodstuffs. The MLs for aﬂatoxins are set following the principle of ‘as low as reasonably achievable’
(ALARA), derived from the frequency distribution of the respective food classes (usually at the 90–95th
percentile), taking into account the outcome of the risk assessment and the analytical capabilities.
Maximum levels are set for AFB1 and the sum of AFB1, AFB2, AFG1 and AFG2 in tree nuts, apricot
kernels, ground nuts (peanuts) and other oilseeds, dried fruit, cereals, and some species of spices as
well as processed products thereof. For AFB1, MLs are also set for baby food and processed cereal-
based food for infants and young children as well as in dietary foods for special medical purposes
intended specially for infants. In ruminants fed with contaminated feed, AFB1 is metabolised to AFM1
and therefore MLs are set for AFM1 in raw milk, heat-treated milk and milk used in milk-based
products, infant formula and follow-on formula for children as well as in dietary foods for special
medical purposes intended specially for infants.
According to Article 1 of Commission Regulation (EC) No 1881/2006, foodstuffs shall not be placed
on the market when they contain aﬂatoxins at a level exceeding the MLs. Article 3 of the Regulation
4 Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
5 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
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stipulates that foodstuffs not complying with the MLs shall not be used as food ingredients and/or shall
not be mixed with foodstuffs complying with the MLs.
Criteria for sampling and analysis of aﬂatoxins are speciﬁed in Commission Regulation (EC) No
401/20066 of 23 February 2006. In addition, speciﬁc import conditions have been put in place for certain
feed and food commodities from certain third countries related to the presence of aﬂatoxins (i.e.
Commission Regulation (EC) No 669/20097 and Commission Implementing Regulation (EU) No 884/20148).
2. Data and methodologies
2.1. Supporting information for the assessment
The CONTAM Panel used its previous risk assessments on aﬂatoxins issued in 2007 and 2018 as a
starting point for drafting the supporting information. The data were summarised in a narrative way
based on expert knowledge/judgement and updated when new information became available as
identiﬁed in reviews and relevant scientiﬁc evaluations by national or international bodies. Following a
request from the European Commission to look into the effect of roasting on aﬂatoxin levels in nuts, a
literature search was conducted as outlined in Appendix I, Section I.3.
In addition, the draft scientiﬁc opinion underwent a public consultation from 4 October 2019 until
15 November 2019. The comments received and how they were taken into account when ﬁnalising the
scientiﬁc opinion were published in an EFSA Technical Report (EFSA, 2020).
2.2. Hazard identiﬁcation and characterisation
2.2.1. Collection and selection of evidence
A comprehensive search for literature was conducted for peer-reviewed original research pertaining to
adverse health effects in experimental animals and humans. The search strategy was designed to identify
scientiﬁc literature dealing with toxicokinetics, toxicity and mode of action. Since this Scientiﬁc Opinion is
an update of the Scientiﬁc Opinion on the potential increase of consumer health risk by a possible
increase of the existing MLs for aﬂatoxins in almonds, hazelnuts and pistachios and derived products
adopted in January 2007, the literature search was restricted to papers published in 2006 and after.
The literature search was not restricted to publications in English. A ﬁrst literature search was
performed in May 2018 and has been updated to include publications up to the end of May 2019. Web
of Science9, PubMed10, SciFinder and Scopus were identiﬁed as databases appropriate for retrieving
literature for the present evaluation. An overview of the search terms is given in Appendix I, Section I.1.
The references obtained from the literature search were imported and saved using a software package
(EndNote11). The references obtained were screened based on title and abstract using Distiller SR to
identify the relevant literature, and the exclusion criteria are shown in Appendix I, Section I.2.
Additionally, relevant scientiﬁc evaluations by national or international bodies and reviews were
considered for the current risk assessment.
2.2.2. Appraisal of evidence
The information retrieved has been screened and evaluated by relevant domain experts from the
CONTAM working group on aﬂatoxins in food and has been used for the present assessment.
Limitations in the information used are documented in this Scientiﬁc Opinion.
6 Commission Regulation (EC) No 401/2006 of 23 February 2006 laying down the methods of sampling and analysis for the
ofﬁcial control of the levels of mycotoxins in foodstuffs. OJ L 70, 9.3.2006, p. 12–34.
7 Commission Regulation (EC) No 669/2009 of 24 July 2009 implementing Regulation (EC) No 882/2004 of the European
Parliament and of the Council as regards the increased level of ofﬁcial controls on imports of certain feed and food of
nonanimal origin and amending Decision 2006/504/EC. OJ L 194, 25.7.2009, p. 11–21.
8 Commission Implementing Regulation (EU) No 884/2014 of 13 August 2014 imposing special conditions governing the import
of certain feed and food from certain third countries due to contamination risk by aﬂatoxins and repealing Regulation (EC) No
1152/2009. OJ L 242, 14.8.2014, p. 4–19.
9 Web of Science (WoS), formally ISI Web of Knowledge, Thomson Reuters. Available at: http://thomsonreuters.com/thomson-
reuters-web-of-science/
10 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
11 EndNote X5, Thomson Reuters. Available at: http://endnote.com/
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Selection of the scientiﬁc papers for inclusion or exclusion was based on consideration of the extent to
which the study was relevant to the assessment or on general study quality considerations (e.g. sufﬁcient
details on the methodology, performance and outcome of the study, on dosing, substance studied and
route of administration and on statistical description of the results), irrespective of the results.
2.3. Occurrence data submitted to EFSA
2.3.1. Data collection and validation
Following a European Commission mandate to EFSA, a call for the annual collection of data on the
occurrence of chemical contaminants in food, including aﬂatoxins, was issued by the former EFSA
Dietary and Chemical Monitoring Unit (now DATA Unit)12 in December 2010.13 European national
authorities and similar bodies, research institutions, academia, food business operators and other
stakeholders were invited to submit analytical data on aﬂatoxins in food. The data for the present
assessment were provided by organisations from 29 European countries.
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of
food consumption and occurrence data’.
Data on aﬂatoxins in food submitted to EFSA by the end of December 2018 were considered for
the present assessment. Data received after that date were not included.
2.3.2. Data analysis
Following EFSA’s SOP on ‘Data analysis of food consumption and occurrence data’ to guarantee an
appropriate quality of the data used in the exposure assessment, the initial data set was carefully
evaluated by applying several data cleaning and validation steps. Special attention was paid to the
identiﬁcation of duplicates and to the accuracy of different parameters such as ‘Sampling country’,
‘Sampling year’, ‘Sampling strategy’, ‘Analytical methods’, ‘Result express’, ‘Reporting unit’, ‘Limit of
detection/quantiﬁcation’, and the codiﬁcation of analytical results under FoodEx classiﬁcation (EFSA,
2011a). The outcome of the data analysis is presented in Section 3.2.1.
The left-censored data (results below the LOD or below the LOQ) were treated by the substitution
method as recommended in ‘Principles and Methods for the Risk Assessment of Chemicals in Food’
(WHO/IPCS, 2009). The same method is indicated in the EFSA scientiﬁc report ‘Management of left-
censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010b) as an option for
the treatment of left-censored data. The guidance suggests that the lower bound (LB) and UB
approach should be used for chemicals likely to be present in the food (e.g. naturally occurring
contaminants, nutrients and mycotoxins). The LB is obtained by assigning a value of zero (minimum
possible value) to all samples reported as lower than the LOD (< LOD) or LOQ (< LOQ). The UB is
obtained by assigning the numerical value of LOD to values reported as < LOD and LOQ to values
reported as < LOQ (maximum possible value), depending on whether the LOD or LOQ is reported by
the laboratory. Additionally, the middle bound is calculated by assigning a value of LOD/2 or LOQ/2 to
the left-censored data. The middle bound was only used to calculate the relative contribution of AFB1,
AFB2, AFG1 and AFG2 to AFT (see Section 3.2.1). The substitution method was applied only to
individual aﬂatoxins (AFB1, AFB2, AFG1, AFG2 and AFM1) while for the AFT a speciﬁc approach, as
described below, was followed.
The mean concentration of any aﬂatoxin for a given food was calculated based on the analytical
results from all samples analysed for that aﬂatoxin.
The occurrence data for AFT were calculated from the analytical results of the individual aﬂatoxins
considering only the samples for which all four (AFB1, AFB2, AFG1 and AFG2) aﬂatoxins were analysed
and reported. In practice, analytical results for AFT were generated by summing up the available
individual concentrations of the four aﬂatoxins for each sample. Since AFB1 is the aﬂatoxin most
frequently found and at the highest concentration, and that not all aﬂatoxin-producing moulds produce
all four aﬂatoxins, simply adding the four LOQs for samples in which none of the aﬂatoxins are
quantiﬁed, would overestimate the UB AFT level. Therefore, the concentration of AFT was calculated
for each sample as follows:
12 From 1 January 2014 onwards, Evidence Management Unit (DATA).
13 http://www.efsa.europa.eu/en/consultations/call/180307
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• when quantiﬁed results were available for all four aﬂatoxins, the concentration of AFT was
calculated as the sum of all concentrations;
• when the results for all four aﬂatoxins were left-censored, the UB concentration of AFT was
calculated as twice the LOD/LOQ for AFB1 (the main contributor) unless the sum of the four
LODs/LOQs was lower;
• when there were both quantiﬁed and left-censored results, the UB concentration of AFT was
calculated as the sum of quantiﬁed values and twice the LOD/LOQ for AFB1, unless the sum of
the quantiﬁed values and the LODs/LOQs of the left-censored aﬂatoxins was lower.
Recovery rates were reported for only 12% of the data. Nevertheless, the analytical results were
submitted to EFSA as corrected for recovery in approximately 64% of cases. The results were not
corrected for the recovery in 14% of the cases and for the remaining results this information was not
provided. For results which were submitted as not corrected for recovery, the results were corrected
either by using the recovery rate reported, if available, or the mean of recovery rates retrieved from
the data set, which was 92%.
2.4. Food consumption data
The EFSA Comprehensive European Food Consumption Database (hereinafter referred to as the
Comprehensive Database) provides a compilation of existing national information on food consumption at
the individual level. It was ﬁrst built in 2010 (EFSA, 2011b; Huybrechts et al., 2011; Merten et al., 2011).
Details on how the Comprehensive Database is used have been published in the Guidance of EFSA (EFSA,
2011b). The latest version of the Comprehensive Database, updated in 2018,14 contains results from a
total of 60 different dietary surveys carried out in 25 different Member States covering 119,458 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as follows:
Infants: < 12 months old
Toddlers: ≥ 12 months to < 36 months old
Other children: ≥ 36 months to < 10 years old
Adolescents: ≥ 10 years to < 18 years old
Adults: ≥ 18 years to < 65 years old
Elderly: ≥ 65 years to < 75 years old
Very elderly: ≥ 75 years old
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (≥ 15
years to ≤ 45 years old, Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old, Greece).
Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering 3–7 days per subject. Owing to the
differences in the methods used for data collection, direct country-to-country comparisons can be
misleading.
Detailed information on the different dietary surveys used in this report is given in Annex A
Table A.1, including the number of subjects and days available for each age class.
2.5. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011a).
FoodEx is a food classiﬁcation system that was developed by EFSA in 2009 with the objective of
simplifying the linkage between occurrence and food consumption data when assessing the exposure
to hazardous substances. The system consists of a large number of individual food items aggregated
into food groups and broader food categories in a hierarchical parent–child relationship. It contains 20
main food categories (ﬁrst level), which are further divided into subgroups having 140 items at the
second level, 1,261 items at the third level and reaching about 1,800 endpoints (food names or
generic food names) at the fourth level.
14 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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2.6. Exposure assessment
The CONTAM Panel estimated chronic dietary exposure to aﬂatoxins. As suggested by the EFSA
Working Group on Food Consumption and Exposure (EFSA, 2011a), dietary surveys with only 1 day per
subject were not considered as they are not adequate for assessing repeated exposure. Similarly, subjects
who participated in the dietary studies for only 1 day when the protocol prescribed more reporting days
per individual were also excluded for the chronic exposure assessment. When, for one particular country
and age class, two different dietary surveys were available, only the most recent one was used.
Thus, for the chronic exposure assessment, food consumption data were used from 38 different
and most recent dietary surveys carried out in 22 different European countries present in the latest
version of the Comprehensive Database (Annex A, Table A.1).
To calculate chronic dietary exposure to aﬂatoxins, food consumption and body weight data at the
individual level were accessed in the Comprehensive Database. Occurrence data and consumption data
were linked at the relevant FoodEx level. In addition, the different food commodities were grouped
within each food category to better explain their contribution to the total dietary exposure to
aﬂatoxins. The food categories represented by either a very low number of samples (< 6 samples) or
for which all data were below the LOD or LOQ were considered not suitable and were not used for the
exposure calculation.
The mean and the high (95th percentile) chronic dietary exposures were calculated by combining
aﬂatoxin mean occurrence values for food samples collected in different countries (pooled European
occurrence data) with the average daily consumption for each food at individual level in each dietary
survey and age class. Consequently, individual average exposures per day and body weight were
obtained for all individuals. On the basis of distributions of individual exposures, the mean and 95th
percentile exposure were calculated per survey and per age class. Dietary exposure was calculated
using the overall European LB and UB mean occurrence of aﬂatoxins.
Before linking the consumption data to the corresponding occurrence data, the following
adjustments to the occurrence and consumption data were made to reduce uncertainty and reach
more accurate exposure estimates:
• Consumption events for cereal-based food for infants and young children were adjusted by a
factor of 0.25 (when reconstituted with water) or 0.15 (when reconstituted with milk) when
the eating occasions were reported as consumed (liquid) since the occurrence data mainly
referred to the analysis of the food as purchased. This correction is based on the information
given by the data provider whether the product is reconstituted with milk or water.
• Occurrence and consumption events for solid forms of certain foods (tea leaves, cocoa powder,
cocoa powder preparations and cocoa beans) were adjusted by an appropriate dilution factor
and these consumption events were reclassiﬁed to the liquid forms as this is considered more
appropriate for the current assessment.
• Occurrence data and consumption events for solid forms of infant formula and follow-on
formula were adjusted by a dilution factor of 8 and reclassiﬁed to the liquid forms (as ready
for feed) as this is considered more appropriate in the context of the current assessment
(EFSA, 2018b).
In addition, the CONTAM Panel considered that it is of interest to also estimate a short-term
exposure. AFB1 affects reproductive and developmental parameters in rodents and these effects may
occur following a short-term exposure (see Section 3.1.2.5). To evaluate whether these effects should
be considered in the risk characterisation of aﬂatoxins in humans in the EU, the CONTAM
Panel decided to compare the identiﬁed doses with a scenario of short-term exposure. A scenario was
developed to estimate the short-term exposure to AFB1 among peanut butter consumers. The
CONTAM Panel selected peanut butter as a type of food product that has a relatively homogeneous
AFB1 concentration and that might be eaten on a daily basis. The short-term dietary exposure was
calculated on a per day basis (only consuming days considered). The exposure was assessed by
multiplying the total consumption amount of each consumption day by the 95th percentile UB
occurrence level (2.25 lg/kg) of peanut butter.
The calculations were based on 43 different dietary surveys carried out in 25 European countries
present in the latest version of the Comprehensive Database (Annex A, Table A.1). Finally, for each
age group and dietary survey, the mean and 95th percentile of exposure were estimated.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 9.4).
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2.7. Risk characterisation
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO/IPCS (2009), which include hazard identiﬁcation and characterisation,
exposure assessment and risk characterisation. In addition to the principles described by WHO/IPCS
(2009), EFSA guidance pertaining to risk assessment has been applied for the present assessment.
EFSA guidance documents applied for this risk assessment are the guidance on the approach for risk
assessment of substances which are both genotoxic and carcinogenic (EFSA, 2005), on uncertainties in
dietary exposure assessment (EFSA, 2007b), on transparency in the scientiﬁc aspects of risk
assessments (EFSA, 2009b), on standard sample description for food and feed (EFSA, 2010a), on
management of left-censored data in dietary exposure assessments (EFSA, 2010b), on use of the EFSA
comprehensive food consumption database in intakes assessment (EFSA, 2011b), on genotoxicity
testing (EFSA Scientiﬁc Committee, 2011), on selected default values to be used in the absence of
data (EFSA Scientiﬁc Committee, 2012a), on risk assessment terminology (EFSA Scientiﬁc Committee,
2012b) and on the BMD approach (EFSA Scientiﬁc Committee, 2017).
3. Assessment
3.1. Hazard identiﬁcation and characterisation
3.1.1. Toxicokinetics
The toxicokinetics of AFB1 in humans and experimental animals have been detailed by different risk
assessment bodies. Since the previous assessment by the CONTAM Panel in 2007 (EFSA, 2007a),
limited new information has become available regarding the toxicokinetics. The text below gives a
description of previous knowledge complemented with new data. In general, human data on the
toxicokinetics of aﬂatoxins are not as abundant as in animal species.
3.1.1.1. Absorption, distribution, metabolism and excretion
3.1.1.1.1. Absorption
Animal data
Kumagai (1989) injected [3H]-AFB1 into the stomach and small intestine of Wistar rats. The results
suggest that AFB1 is absorbed mainly from the small intestine, most efﬁciently from the duodenum by
passive diffusion (AFB1 has a low molecular weight and is lipophilic). The author demonstrated that the
lipophilicity of the aﬂatoxins determines the rate of absorption (by comparing the rate of disappearance
of the aﬂatoxin from the perfusion medium). For AFB1, the rate of absorption was considerably higher
than for AFG1, which is a less lipophilic analogue. As shown in Table 1, the lipophilicity of the aﬂatoxins
differs between compounds, and could explain the difference in absorption.
Wogan et al. (1967) showed that the distribution of radioactivity after oral or intraperitoneal (i.p.)
injection of [14C]-labelled AFB1 in male Fischer (F344) rats was similar, suggesting an efﬁcient
absorption following oral exposure.
Human data
Few data are reported in the literature regarding human absorption of AFB1. The relative
contribution of various sites of the gastrointestinal (GI) tract to aﬂatoxin absorption remains unknown.
Since the previous assessment, a TK study with human male volunteers (n=3) was published. The
volunteers received orally a low dose of [14C]-labelled AFB1 (30 ng, 185 Bq). The maximum radioactivity
in plasma was observed at 1 h after exposure, suggesting rapid absorption through the GI tract.
According to the authors, 95% of the radioactivity was eliminated by urinary excretion, suggesting high
oral absorption (Jubert et al., 2009).
3.1.1.1.2. Distribution
It has been shown in three studies with [14C]-labelled AFB1 that the liver was the major site for
accumulation of radioactivity, especially at low doses in the rhesus monkey and the rat (Holeski et al.,
1987; Wogan et al., 1967; Wong and Hsieh, 1980). It is also a site of accumulation in the mouse
(Wong and Hsieh, 1980; Wogan, 1969). Wogan et al. (1967) showed after a single i.p. dose of [14C]-
labelled AFB1 (0.07 (n = 4), 2.13 (n = 1) or 4.95 (n = 1) mg/kg bw), that the radioactivity in the liver
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of Fischer rats was 5- to 15-fold higher than in other tissues at 30 min after administration. Between 8
and 24 h, the liver contained as much radioactivity as the remainder of the carcass, and at the end of
24 h the liver retained nearly 10% of the administered radioactivity.
In a distribution study in pigs (n = 2), L€uthy et al. (1980) found after oral administration of [14C]-
labelled AFB1 that the highest radioactivity was found in the liver, followed by the kidney and then the
lung, 1 and 2 days after dosage.
Cupid et al. (2004) showed that after oral administration of [14C]-labelled AFB1 in Fischer rats both
AFB1-albumin adduct and AFB1-DNA adduct formation were linear over a wide dose range (0.16 ng/kg
bw to 12.3 lg/kg bw). The order of adduct formation within the tissues studied was liver > kidney >
colon > lung = spleen.
Placenta/fetus transfers
In humans, the transfer of aﬂatoxins into the placenta has been conﬁrmed by showing the
presence of aﬂatoxin and/or its metabolites in cord serum and in placenta (De Vries et al., 1989;
Denning et al., 1990; Turner et al., 2007; Partanen et al., 2010). Although several metabolites have
been identiﬁed in cord serum, it is not clear whether they are formed in the placenta or are of
maternal origin.
In animals, after a single dose of AFB1 (5 mg/kg bw dissolved in dimethyl sulfoxide (DMSO)) either
i.p. or orally on gestation day (GD) 14 to gpt delta B6C3F1 mice, the AFB1-N7-guanine (AFB1-N7-gua)
and AFB1 formamidopyrimidine (AFB1-FAPY) adducts were found in the livers of both the mothers and
the fetuses, with the range in the fetuses being about 1% that of the mothers (Chawanthayatham
et al., 2015; see Section 3.1.2.3).
3.1.1.1.3. Metabolism
Intestinal metabolism
AFB1 is metabolised during its passage through the GI tract but the main site and the extent of
metabolism remains unknown. The absorption rate and the extent of the metabolism in the GI tract
determine the concentrations of AFB1 and its metabolites in the hepatic portal ﬂow and therefore the
degree of hepatic exposure (Hsieh and Wong, 1994).
In the study by Kumagai (1989) where [3H]-AFB1 was injected into the stomach and small intestine
of Wistar rats, the author reported metabolism of AFB1 by the duodenum and jejunum, but the
metabolic activity was not quantiﬁed or compared with that of the liver.
Patients (n = 7) undergoing GI tract surgery for cancer received 1 lg [14C]-AFB1 orally in a gelatine
capsule 3.5–7 h prior to surgery (Cupid et al., 2004). The authors reported the formation of AFB1-DNA
adducts in the colon of two out of seven patients. In similar experiments on Fischer rats, with similar
dose ranges, the authors found that humans form fewer AFB1-DNA adducts in the colon than rats.
Lung metabolism
Some studies have shown that CYP2A13, which is predominantly expressed in human respiratory
tissues, was able to metabolise AFB1 (He et al., 2006) and AFG1 (Zhang et al., 2013). He et al. (2006)
incubated in vitro different concentrations of AFB1 with CYP2A13. At both 15 and 150 lM of AFB1, the
formation of AFM1-8,9-epoxide was equivalent for CYP2A13 and CYP1A2, but the activity of CYP2A13
was approximately one-third of CYP1A2 in the formation of AFB1-8,9-epoxide.
Liver metabolism
In the liver, aﬂatoxins are substrates for CYP monooxygenases, including CYP3A4, 3A5 and 1A2. A
critical activation step represents the formation of AFB1-exo-8,9-epoxide. The exo-epoxide is prone to
adduct formation with macromolecules like DNA or proteins. However, there is no evidence identiﬁed
that the respective endo-epoxide binds to DNA (see Figure 1). The predominant site for DNA adduct
formation by AFB1-exo-8,9-epoxide is N7-gua, resulting in trans-8,9-dihydro-8-(N7-guanyl)-9-
hydroxyaﬂatoxin B1 (AFB1-N7-gua), which in turn can be transformed into the ring-opened, and more
stable and therefore more persistent, AFB1-FAPY adduct (Figure 2). Since only AFB1, AFG1 and AFM1
have a double bond at the 8,9-position, only these compounds are activated by CYPs to the reactive
8,9-epoxide. In comparison with AFB1, less AFG1-N7-guanine DNA adducts are formed for a given
dose. This is due to a reduced ability of the AFG1-8,9-epoxide to intercalate into the DNA helix
because of the reduced planarity of the ring structure (EFSA, 2007a).
AFB1 can be converted to aﬂatoxicol in the liver by the reduction of AFB1 mediated by a (NADPH)-
dependent reductase. CYP3A4 and 1A2 oxidise AFB1 to various metabolites other than epoxides, the
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major ones being the hydroxylated metabolites AFM1 and aﬂatoxin Q1 (AFQ1) (see Figure 1). In
addition, aﬂatoxin P1 (AFP1) is formed by demethylation. The oxidation products (AFQ1 and AFM1) as
well as AFP1 are potential detoxiﬁcation products, since they represent weaker substrates for
epoxidation than AFB1. AFB1-8,9-dihydrodiol, resulting from hydrolysis of the 8,9-epoxide, is unstable
and undergoes base-catalysed rearrangement to a dialdehyde, primarily reacting with proteins such as
albumin, but may not reach the DNA. Members of the NADPH-dependent aldo-keto-reductase (AKR)
family play a key role in the reduction of the reactive AFB1 dialdehyde to the less reactive AFB1-
dialcohol. Enzymatic hydrolysis by epoxide hydrolase is discussed in the literature, but according to the
fast rate of non-enzymatic hydrolysis, the contribution in vivo of this pathway remains unclear (EFSA,
2007a).
In 2007, the CONTAM Panel acknowledged an ongoing discussion concerning the relevance of the
different CYPs with regards to aﬂatoxin metabolism in humans. CYP3A4, one of the CYP isoforms
usually highly expressed in liver tissue, predominantly forms the reactive AFB1-exo-8,9-epoxide,
whereas CYP1A2 has been reported to catalyse the formation of both the exo and the endo forms
(Pottenger et al., 2014). In a study using human liver microsomes (n = 13), 12-fold variability in the
production rate of AFB1-exo-8,9-epoxide and 22-fold variability in the formation of the detoxiﬁcation
product AFQ1 was observed. In individuals with low CYP3A4 expression, CYP3A5 appears to play an
important role, exclusively generating the AFB1-exo-8,9-epoxide (Kamdem et al., 2006). The CONTAM
Panel noted the reported variability in the activity of human CYP3A4 which in part can be due to
polymorphisms (Klein and Zanger, 2013) The contribution of CYP1A2 is not fully clariﬁed. Kamdem
et al. (2006) suggest that CYP1A2 is ‘negligible’ for the formation of the reactive AFB1-exo-8,9-
epoxide. In contrast, in a study with a lower number of samples of human liver microsomes (n = 3)
Gallagher et al. (1996) concluded that CYP1A2 dominates the activation of AFB1.
A major pathway for detoxiﬁcation of the 8,9-epoxides is GST-mediated conjugation with GSH
(Pottenger et al., 2014). The extent of GSH conjugation differs between species (mouse > rat >
human) with humans exhibiting comparatively low conjugation rates (EFSA, 2007a). The relevance of
GSH conjugation for detoxiﬁcation of aﬂatoxins relates to the levels of individual GST expression in the
human liver. The interindividual variation is known to be considerable, presumably reﬂecting
differences in inducibility of GSTs and genetic polymorphisms of the relevant genes (EFSA, 2007a).
There are two types of GSTs that are involved in AFB1 detoxiﬁcation: GST-l encoded by the GSTM1
gene and GST-h encoded by GSTT1. Except for GSTM1-1, human GST enzymes are poor catalysts for
the conjugation of AFB1 8,9-epoxide. In several studies, it has been shown that only the GSTM1-null
genotype carriers are at increased risk of HCC in populations exposed to aﬂatoxins (Wild et al., 2000;
see also Section 3.1.4.6.2).
AFM1, AFP1, AFQ1 and aﬂatoxin-dialcohol can be conjugated with glucuronic acid and excreted in
faeces and urine.
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Figure 1: Metabolism and disposition of AFB1 (adapted from FAO/WHO, 2018)
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In comparison to AFB1, the information on the metabolism of other aﬂatoxins is limited. Only a
short communication on the metabolism of AFB2 was identiﬁed (Groopman et al., 1981).
Neal et al. (1998) incubated in parallel [3H]-labelled AFM1 and [3H]-labelled AFB1 with human liver
microsomes during 9 h and 6 h, respectively, in order to compare both compound’s metabolism. For
[3H]-labelled AFM1, the authors detected the formation of a metabolite (probably AFM1-dihydrodiol).
Compared to AFB1, the authors suggested its limited production was probably explained by a low level
of epoxidation of AFM1. No AFB1-GSH was detected.
3.1.1.1.4. Excretion
Human data
Jubert et al. (2009) analysed blood and 24 h urine samples collected until 72 h after administration
of a low dose of [14C]-labelled AFB1 (30 ng, 185 Bq) from human volunteers. The faeces were not
analysed. According to the authors, the kinetic proﬁle of AFB1 and its metabolites ﬁts with a two-
compartment model, with a rapid distribution/elimination phase (half-life (t1/2) a= 2.9 h) followed by a
slower elimination phase (t1/2b = 64.4 h). The authors did not discriminate between free AFB1 and its
various metabolites or conjugates. According to the authors, urinary elimination of AFB1 was 95%
complete by 24 h.
Previous studies have reported the presence of AFM1 in human urine. Zhu et al. (1987) analysed
252 human urine samples from people exposed to AFB1. They found a strong correlation (R = 0.66,
p-value not provided) between dietary AFB1 intake and excretion of AFM1 in human urine.
AFM1, AFQ1, AFP1, AFB1-N7-gua and AFM1-N7-guanine are excreted through the urinary route
(Egner et al., 2003; Groopman et al., 1985; Mykk€anen et al., 2005). Other metabolites (e.g.
mercapturic acids arising from GSH conjugation) are also excreted in the urine (Scholl et al., 1997).
AFM1, the hydroxylated metabolite of AFB1, is excreted in human milk. Zarba et al. (1992) estimated
that 0.1–0.4% of the amount of AFB1 ingested via the diet is excreted in human milk as AFM1.
Animal data
Aﬂatoxins are excreted in the faeces in two ways, biliary excretion to the intestine from the
absorbed fraction and excretion of the unabsorbed fraction from the lumen of the GI tract.
In Fisher rats (n = 1–4), Wogan et al. (1967) showed that after i.p. administration of [14C]-labelled
AFB1 (ring or methoxy-labelled), 70–90% of the radioactivity was eliminated during the ﬁrst 24 h.
Biliary excretion into faeces accounted for 54–57% of the administered [14C]-ring-labelled AFB1,
whereas excretion through the urinary route was 22–34%. After administration of [14C]-methoxy-
labelled AFB1, biliary excretion into faeces accounted for 24% or the recovered radioactivity, and
excretion through the urinary route for 20%.
In another study, Degen and Neumann (1978) described that within 6 h of an i.p. administration of
[14C]-labelled AFB1, more than 50% of total radioactivity was excreted in the bile of Wistar rats
(n = 6), mostly as hydrophilic metabolites and a GSH conjugate was the main metabolite. Less than
30% of the total radioactivity was excreted in the bile after oral administration (the authors studied
only biliary excretion).
Dalezios et al. (1973) conducted a study in male rhesus monkeys with a single oral dose of 0.4 mg/kg
bw (n = 3), or 0.015 mg/kg bw (n = 3), and showed that approximately 40% was excreted in the faeces
and 40% was excreted in urine during days 1–4 (excretion was not affected by the dose). Total excretion
of radioactivity during days 1–4 amounted to 80–85% of the administered dose.
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Figure 2: Formation of the aﬂatoxin-FAPY DNA adduct
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Holeski et al. (1987) showed that the major biliary metabolite was AFB1-glutathione, accounting for
more than 50% of the total biliary excretion, and AFP1-glucuronide accounts for 4–15% of total biliary
radioactivity in Sprague–Dawley rats (the authors studied only biliary excretion).
Coulombe and Sharma (1985) showed that after an oral dose of [3H]-labelled AFB1 (0.6 mg/kg bw)
in Sprague–Dawley rats, 55% of the total radioactivity is excreted in the faeces and urinary excretion
accounted for 15% after oral exposure.
Raj and Lotlikar (1984) showed that approximately 10–16% of a single dose of AFB1 was excreted in
urine 24 h after i.p. administration to the rat and hamster. Glucuronide and sulfate conjugates of
hydroxy-metabolites were approximately 60% of the total excretion. In addition, various thiol conjugates
were observed and of these AFB1-GSH and AFB1-cysteinglycine were the major thiol conjugates
Hsieh and Wong (1994) estimated that the glucuronidated aﬂatoxin metabolites can be excreted
both by biliary and. urinary routes.
As in humans, AFM1 is excreted in animal milk. More information regarding the transfer of aﬂatoxins
into milk from livestock can be found in EFSA (2004) and in the review by Fink-Gremmels (2008).
Enterohepatic circulation
Hsieh and Wong (1994) suggested that the released AFB1 metabolites in the bile could be
reabsorbed (enterohepatic circulation), intestinal microbiota of rats can hydrolyse some glucuronide
metabolites leading to a reabsorption of aﬂatoxin. To asses this hypothesis, the authors injected bile
from [14C]-labelled AFB1 treated rat in to ligated small intestine. They found that the radioactivity
remained in the small intestine. They concluded that there was no reabsorption of the [14C]-labelled
AFB1 metabolites from the bile.
3.1.1.1.5. Summary
New information on humans shows that absorption of AFB1 and/or its metabolites into the systemic
circulation is rapid, with peak plasma concentrations reached within approximately 1 h. This study
shows that AFB1 and/or its metabolites follow a biphasic kinetic proﬁle: they are ﬁrst rapidly eliminated
from the plasma with a ﬁrst half-life (t1/2a = 2.86), followed by a second more longer excretion
pattern with a terminal half-life (t1/2b = 64.4 h). According to the authors, urinary elimination was
95% complete by 24 h.
Following administration of [14C]-labelled AFB1, radioactivity is highest in the liver in different
species (rats, monkeys), irrespective of the route of exposure. The relative contribution of metabolism
of aﬂatoxin within the GI tract compared with the liver remains unknown. The metabolism of AFB1 in
humans and laboratory animals has been well characterised: CYP1A2, 2B6, 3A4, 3A5, 3A7, 2A13 and
GSTM1 are enzymes that catalyse aﬂatoxin metabolism in humans. CYP enzymes convert AFB1, AFG1
and AFM1 to their respective epoxide, which is capable of binding covalently to both DNA and
proteins. AFB2 and AFG2 cannot form the 8,9-epoxide.
AFB1 and its metabolites are both excreted via the faecal and the urinary route. Nevertheless, the
percentage excreted via both routes varies according to the species. AFM1 is also excreted in milk.
3.1.1.2. Kinetic modelling
No physiologically based pharmacokinetic (PBPK) model has been developed for humans. Qian
et al., 2013 developed a PBPK model in the Fischer rat on AFB1 and evaluated the toxicokinetics of
serum AFB-lys adduct with different scenarios and doses relevant to acute or chronic human exposure.
Nevertheless, this model cannot be extrapolated to humans due to lack of human data for calibration
and validation of the model.
3.1.2. Toxicity in experimental animals
3.1.2.1. Acute toxicity (single exposure)
In 2007, the CONTAM Panel concluded that AFB1 causes acute hepatotoxicity in experimental
animals. No conclusions could be drawn for other aﬂatoxins in 2007. In rodents, oral LD50 values for
AFB1 have been reported between 1 and 18 mg/kg bw, while for other species LD50 values < 1 mg/kg
bw have been reported (Dhanasekaran et al., 2011; Eaton et al., 2018). Wogan et al. (1971)
measured LD50 values of 1.16 and 1.5–2.0 mg/kg bw for AFB1 and AFG1, respectively, in male Fischer
rats. Neither AFB2 nor AFG2 showed any lethality in rats at single doses up to 200 mg/kg bw.
Aﬂatoxins in food
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2020;18(3):6040
For the current assessment, the CONTAM Panel identiﬁed two recent studies describing the acute
toxicity of AFB1, but no studies were identiﬁed for the other aﬂatoxins that are the subject of this
Opinion.
Rat
McKean et al. (2006a,b) orally administrated AFB1 (0, 1, 2.15, 4.64 and 10 mg/kg bw) dissolved in
DMSO to male F344 rats. Within 72 and 96 h post-treatment, all animals treated with 4.64 and 10 mg/kg
bw AFB1 died, respectively. In animals treated with 2.15 mg/kg bw, 20% died during the 1-week study
period. No mortality was observed in animals treated with the lowest dose (1.0 mg/kg bw) or in the
DMSO control group. An LD50 of 2.71 mg/kg AFB1 was determined.
Qian et al. (2013) orally exposed male F344 rats to a single dose of AFB1 (0, 50, 250 or 1,000 lg/kg
bw) in DMSO by gavage. Animals were sacriﬁced at 2 h, 1, 3, 5, 7, 14 and 21 days after the gavage.
Biochemical and histological changes were assessed together with the formation of AFB1-lysine adduct
(AFB1-lys) and liver foci positive for the placental form of GST, a speciﬁc and reliable preneoplastic
marker. Serum aspartate transaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase
(ALP) showed dose-related elevation, with maximal changes observed (> 100-fold) at day 3 after
treatment. Animals that received 250 lg/kg AFB1 showed concurrent bile duct proliferation, liver necrosis
and hepatocytes positive for the placental form of GST at day 3, followed by the appearance of liver foci
positive for the placental form of GST at 1 week. Animals that received 1,000 lg/kg AFB1 also showed
concurrent bile duct proliferation at day 3, and at this time point they also displayed massive periportal
necrotic foci with inﬂammatory cell inﬁltration, excessive red blood cells appearing around hepatocytes,
and destruction of liver lobes. All animals exposed to the highest dose died at day 7.
Mice
Ishikawa et al. (2017) performed an acute toxicity study in male C57BL/6 mice. AFB1 diluted with a
mixture of saline and ethanol (95:5) was administered to groups of ﬁve mice by oral gavage at single
doses of 44, 442 and 663 lg/kg bw. The animals were sacriﬁced 5 days later and liver function (ALT,
c-glutamyl transpeptidase (GGT) and total protein), cytokines (interleukin-4 (IL-4), interferon-gamma
(IFN-c) and IL-17), histopathology and the spleen lymphoproliferative response to concanavalin A and
lipopolysaccharide were evaluated. AFB1 did not induce signiﬁcant changes in the biochemical
parameters. The highest dose of 663 lg/kg bw induced a hepatic upregulation of IL-4 and IFN-c, along
with liver tissue injury and suppression of the lymphoproliferative response to concanavalin A (p < 0.05).
3.1.2.2. Short-term toxicity (7–90 days)
A number of studies were identiﬁed that covered subacute and short-term toxicity. These are
described below. Appendix II, Table II.1 summarises the identiﬁed short-term toxicity studies.
Newly weaned inbred F344 Fischer rats were fed AFB1-supplemented diets (0, 1, 5 10 and 20 mg/kg
feed) for 6 weeks. Using a default factor of 0.12 for a subacute study in rats (EFSA Scientiﬁc Committee,
2012a), these concentrations correspond to doses of 0, 0.12, 0.6, 1.2 and 2.4 mg/kg bw per day. All
doses decreased body weight signiﬁcantly, while a concentration of 5 mg/kg or greater shortened tibia
length. The concentration of AFB1-alb (ng/mg protein) in the serum increased with an increasing dose of
AFB1. Changes in liver function parameters (serum ALT and hepatocellular bromodeoxyuridine staining)
increased with dose, indicating liver injury. Dose-related changes in gut morphology (decreased villous
length) suggested that gut absorption might be affected by AFB1. The authors concluded that while
dietary AFB1 caused stunting, wasting, suppression of hepatic targets of growth hormone signalling and
dose-dependent liver injury, it did not induce liver failure (Knipstein et al., 2015). A second study
comparing outbred Sprague Dawley with the inbred Fischer rats on body weight and levels of AFB1-
albumin adducts showed no difference in sensitivity of the two rat strains for the effect of AFB1 on growth
impairment (Knipstein et al., 2015).
Rotimi et al. (2017) showed that oral administration of AFB1 induced liver damage and
dysregulation of lipid and lipoprotein metabolising genes. Inbred male albino rats were exposed to
AFB1 in olive oil (0, 0.25, 0.5, 1 mg/kg bw per day) by gavage for 7 days. Histological damage was
observed in the liver at 0.5 mg/kg bw and above. Plasma cholesterol, triglycerides and free fatty acids
increased in a dose-dependent manner after treatment while plasma phospholipid was not affected.
Liver triglycerides and phospholipids also increased. AFB1 decreased expression of genes for Ahr, Cpt1,
LCAT and LIPC while SCARB1 gene expression increased, all of which are associated with lipid and
lipoprotein metabolism. The largest changes were observed in the Cpt1 and SCARB1 genes identiﬁed
as the most sensitive.
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Administration of AFB1 to Wistar male rats (0, 0.5, 1, 2 mg/kg bw per day) by gavage for 7 days
caused a decrease in total blood antioxidant status (TAS) in all AFB1-treated animals. The two highest
doses also increased plasma uric acid concentration. These data indicate signiﬁcant oxidative stress
caused by AFB1 exposure (Wojtowicz-Chomicz et al., 2011).
Hussain et al. (2009) showed that treatment with AFB1 by gavage (0, 0.5, 1.0 mg/kg bw per day)
for up to 40 days decreased feed intake and body weight in adult male rats. These changes were
accompanied by liver toxicity including fatty change, necrosis and increased size of both hepatocytes
and their nuclei. Toxicity was also observed in the kidney, with tubular necrosis, serum ALT and
creatinine increasing while total protein, albumin, serum cholesterol and triglycerides decreased.
Nephrotoxicity was studied in male Albino Swiss mice, after exposure to AFB1 (0, 0.75, 1.5 mg/kg
bw per day) by gavage for 30 days (Jha et al., 2014). The exposure resulted in decreased body weight
and an increase in relative kidney weight. Increases in a number of enzyme activities were observed in
kidney homogenates including AST, ALT, acid phosphatase as well as an increase in serum creatinine.
There were decreases in the activities of ALP, succinate dehydrogenase and adenosine triphosphatase
and serum protein content. Histopathology showed massive disorganisation in glomerular and tubular
structures.
Little is known so far about the potential endocrine or neuroendocrine effects of AFB1. A study with
adult male Wistar rats, treated by oral gavage twice a week for 5 weeks with AFB1 (cumulative dose
either 1.5 or 3 mg/kg bw) observed reduced body weight gain and suggested that this was associated
with a dose-related decrease in the expression of hypothalamic neuropeptides. Thus, consumption of
AFB1 can disrupt the hypothalamic regulation of orexigenic or anorexigenic neuropeptides involved in
feeding behaviour, leading to decreased body weight (Trebak et al., 2015).
Qian et al. (2013) carried out an integrated toxicopathological evaluation of Fischer rats exposed to
repeated doses (0, 5, 10, 25 and 75 lg/kg bw given by gavage) of AFB1. Over the 5 weeks of the
study, the authors observed the changes on a weekly basis. There were no changes in the biochemical
proﬁle after week 1 or 3 at all doses and serum AST and ALT increased only at week 5. Bile duct
proliferation was found from week 3 onwards in all animals from the highest dose group and at
5 weeks in all animals exposed to 25 lg/kg bw. Periportal necrosis was found with doses higher than
10 lg/kg bw and was observed from week 3 at the highest dose tested. At the highest dose tested,
serum AFB-lys adducts were increased and reached a peak at week 2. Thereafter, the adducts declined
slowly. In the two highest dose groups, liver cells positive for the placental form of GST were detected
after week 1, developing into foci by week 3. In the 10 lg/kg bw dose group, this was after weeks 2
and 5, respectively. In the lowest dose group, liver cells positive for the placental form of GST were
found after week 3 but no foci positive for the placental form of GST over the 5 weeks of the study. A
decrease in body weight was observed from week 2 onwards.
In summary, AFB1 at all doses tested has multiple negative effects on rodents including inhibition
of normal growth, liver and kidney damage. No studies on short-term toxicity caused by AFG1, AFG2,
AFB2 or AFM1 were identiﬁed.
Effects on the gut microbiota
The gut microbiota is critical for healthy development of the gut. In humans and animals, changes
in the gut microbial population are associated with multiple health problems. In humans, this includes
obesity and inﬂammatory bowel disease.
Wang et al. (2016a) explored the effects of AFB1 on the gut microbiota in Fischer F344 rats treated
by gavage (0, 0.005, 0.025, 0.075 mg/kg bw per day) for 4 weeks (5 days/week) and found that AFB1
modiﬁed the gut microbiota in a dose-dependent manner. Microbial communities were assessed by 16S
rRNA sequence analysis. Increasing the dose of AFB1 decreased the diversity of the microbial
community and increased the evenness of the resulting community. Speciﬁcally, some lactic acid
bacteria were depleted. The same group, using the same rat strain and exposure protocol, later
showed that exposure for up to 4 weeks affected the gut-dependent metabolism. In particular, faecal
short-chain fatty acids were decreased with all treatments after only 2 weeks (Zhou et al., 2018).
Yang et al. (2017a) exposed Kunming mice (average weight at start 20 g) for 2 months by gavage to
AFB1 (0, 0.1, 0.16 and 0.4 mg/kg bw per day). The dominant ﬂora were Lactobacillus and Bacteroides
and all treatments decreased the genera and phyla of the gut microbiota from control to the highest
dose indicating a reduction in microbial diversity in response to AFB1 exposure in the colon. In the
higher dose groups, increases in some beneﬁcial and in some pathogenic bacteria were observed.
In another study on Kunming mice with the same dosing protocol and duration as described for
Yang et al. (2017a), He et al. (2018) showed that the number of bacteria increased in all dose groups
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with Biﬁdobacterium species increasing signiﬁcantly in the highest dose group. Intestinal enzyme
activities also increased (amylase, xylanase and cellulose). Despite these changes, there was no effect
on the body weight of the mice. The composition of the communities of microbiota is important as it
has been observed that some bacterial species can detoxify AFB1 (Wu et al., 2009b).
In summary, AFB1 at all doses tested altered the microbial communities generally decreasing the
diversity of the community. No studies on AFG1, AFG2, AFB2 or AFM1 for this endpoint were identiﬁed.
3.1.2.3. Genotoxicity
The genotoxicity of AFB1 has been the subject of comprehensive reviews and is well-established
(IARC, 1987, 1993, 2002; EFSA, 2007a; FAO/WHO, 1999, 2018). AFB1 is mutagenic in Salmonella
Typhimurium strains TA98 and TA100, and mutagenicity is enhanced about 1,000-fold by the presence
of S9 (IARC, 2002), thus underlining the role of the bioactivation system. The double bond in the furan
ring of AFB1 and AFG1 can be oxidised by CYPs to the reactive AFB1-exo-8,9-epoxide that readily reacts
with DNA and other nucleophiles (FAO/WHO, 2018). Covalent binding at the N7 position of guanine
(AFB1-N7-gua adduct) causes primarily G-to-T transversions in Escherichia coli, although at a low
frequency (4%) (EFSA, 2007a). Based on the available information, the CONTAM Panel concluded in
2007 that the ring-opened AFB1-FAPY adduct is likely to be responsible for AFB1 mutagenicity. Indeed,
in E. coli the persistent AFB1-FAPY adduct causes a higher frequency of G-to-T mutations than the short-
lived AFB1-N7-gua (EFSA, 2007a). In rodent and human cells, gene mutations, chromosomal
aberrations and micronuclei, sister chromatid exchanges and unscheduled DNA synthesis are increased
by incubation with AFB1 (Pottenger et al., 2014). In rats, AFB1 exposure increases mutations at the
HPRT-locus in circulating T lymphocytes (FAO/WHO, 2018). In humans living in areas where hepatitis B
virus (HBV) infection and AFB1 exposure are prevalent, HCC samples show a mutational hotspot (G-to-T
transversion) at codon 249 of the TP53 gene. This is considered to be a signature mutation for aﬂatoxin-
induced HCC (Hussain et al., 2007).
In contrast to AFB1, fewer studies were available to the previous assessments regarding the
genotoxicity of the other aﬂatoxins and a few studies examined all the compounds simultaneously. It is
not possible, based on these data, to make a quantitative comparison of the genotoxic potency of
these compounds. However, in general the order is considered to be AFB1 > AFG1 > AFB2 > AFG2
(Wogan et al., 1971).
Since the previous assessment by the CONTAM Panel, new studies have become available that
support the previous conclusions. New information regarding the hotspot at codon 249, the role of
different CYP isoenzymes in the bioactivation of AFB1 and the genotoxicity of AFB1 in pregnant mice,
fetuses and young animals is described below.
In vitro genotoxicity
Recent studies addressed the role of different CYP isoenzymes in the bioactivation of AFB1.
Following AFB1 exposure, DNA adduct formation and increased recombination levels were observed in
the DNA repair-deﬁcient Saccharomyces cerevisiae rad4 rad51 strain only when this one expressed the
human CYP3A4 (Fasullo et al., 2017). AFB1 exposure induced micronuclei in differentiated HepaRG
cells which express high levels of CYP3A4 (Le Hegarat et al., 2010). Inhibition of CYP3A4 or CYP1A/1B
activity by ketoconazole signiﬁcantly suppressed AFB1 genotoxicity in HepG2 cells as measured by the
activation of p53 (Boehme et al., 2010). Similarly, in a co-culture system of TK6 and Caco-2 cells,
ketoconazole inhibition of CYP3A4 suppressed cytotoxicity and micronuclei induced in both cell lines by
AFB1 exposure (Le Hegarat et al., 2010).
A recent study compared the in vitro genotoxic potential of AFB1, AFG1, AFB2, AFG2, AFM1 and
aﬂatoxicol in the HepG2 HCC, the LS-174T colorectal carcinoma and the ACHN renal carcinoma cell
lines applying a cH2AX In-Cell Western technique (Theumer et al., 2018). This assay assesses the
phosphorylation of histone H2AX which is an early, sensitive genotoxic biomarker induced by various
types of DNA damage, including DNA double-strand breaks, DNA bulky adducts, DNA single-strand
breaks (SSBs), DNA replication or transcription blocking lesions (DNA oxidation and alkylation). The
relative genotoxic potency in vitro of these aﬂatoxins was in the following order: AFB1 > AFG1 
aﬂatoxicol » AFM1. AFG1 resulted in a 10-fold less genotoxicity than AFB1 in all the cell lines.
Aﬂatoxicol showed some variation in the effect depending on the tested cell line. Thus, in comparison
to AFB1, aﬂatoxicol was 10-fold less potent in HepG2 cells, equally genotoxic in LS-174T cells and
devoid of genotoxicity in ACHN cells. AFM1 increased genotoxicity only in one cell line (LS-174T cells).
AFB2 and AFG2 did not cause genotoxicity in the three human cell lines.
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An in vitro study with AG1521 human diploid ﬁbroblasts exposed to AFB1 reported an increase in
mutation frequency at the TP53 gene. Several missense mutations occurred in well-known human
tumour hotspots (codons 175, 245 and 282), with G-to-A transitions being the most prevalent class
(35%) followed by G-to-T transversions (22%) and A-to-G transitions (22%). No G-to-T transversions
were found at codon 249 which is described as a hotspot for AFB1 exposure in HCC (Paget et al.,
2008, 2012).
In summary, in a study with human cell lines the order of aﬂatoxins to induce genotoxicity was
AFB1 > AFG1  aﬂatoxicol » AFM1. Recent reports on AFB1 are in accord with numerous earlier
publications concerning the genotoxic potential of AFB1. The recent literature highlights the
importance of CYP3A4 activity for AFB1 genotoxicity.
Genotoxicity in vivo
Information on the experimental design of the in vivo genotoxicity studies, including details on the
outcome are presented in Appendix II, Table II.2.
In a study aiming to investigate the consequences of a combined treatment of AFB1 and ochratoxin
A, a signiﬁcant increase of micronuclei in the bone marrow and SSBs in the liver was observed in male
Fischer rats treated with a single oral administration of AFB1 (0.25 mg/kg bw) (Corcuera et al., 2015).
In particular, SSBs, as measured by Comet assay, were signiﬁcantly enhanced only following cleavage
with the bacterial formamidopyrimidine-DNA glycosylase (Fpg). This indicates that AFB1 induces
oxidative damage to DNA. The authors speculate that these Fpg-sensitive sites might derive from Fpg
recognition and cleavage of AFB1-FAPY lesions.
In a series of publications, researchers focused on the impact of AFB1 exposure during pregnancy
and early life (Chen et al., 2010; Woo et al., 2011; Wattanawaraporn et al., 2012; Chawanthayatham
et al., 2015, 2017; Sriwattanapong et al., 2017). Pregnant gpt delta B6C3F1 mice received a single
dose of AFB1 either i.p. or orally on GD 14. Measurements of AFB1-N7-gua and AFB1-FAPY (by ultra
performance liquid chromatography (UPLC)–MS) were performed 6 h post-dosing in liver DNA of
mothers and embryos. A parallel cohort gave birth and mutations in the livers of this F1 were analysed
at the gpt gene at 3 and 10 weeks of age. When AFB1 was administered via i.p., fetal liver adduct
levels were 100-fold lower than in the maternal liver. A similar effect on DNA adduct levels in fetal liver
was also observed after gavage, although total DNA adduct formation was about 2.5-fold lower. The
relative risk of gpt mutations in fetuses and adult livers from AFB1-DNA adducts indicates that there is
a higher mutational impact of the lesions in the fetus. Namely, 1% of DNA adducts in comparison to
the mothers, but 20% in mutation frequency (Chawanthayatham et al., 2015).
The impact of pregnancy on AFB1 exposure was also investigated in C57BL/6 J mice at GD 14 and
matched non-pregnant controls administered a single i.p. dose of 6 mg/kg AFB1. A twofold higher
level of AFB1-N7-gua adducts was observed in the liver of pregnant C57BL/6J mice in comparison to
non-pregnant counterparts. The enhanced adduct levels were accompanied by elevated expression
levels of CYP1A2 and the mouse equivalent of CYP3A4 (Sriwattanapong et al., 2017).
Four-day-old male gpt delta B6C3F1 mice were treated with a regimen of AFB1 that induces HCC
within 72 weeks (6 mg/kg bw by i.p.). High-resolution mutational spectra were acquired in the liver, 10
weeks after birth (in the absence of neoplasia) as well as in tumour DNA (after 72 weeks). The
spectrum of mutations at 10 weeks in non-tumour cells of the liver represents the mutagenic imprint
of AFB1 exposure (hotspot of G-to-T transversions at CGC sequence). This 10-week spectrum persisted
in the tumour tissue, although accompanied by a more heterogeneous set of mutations that emerged
during tumour outgrowth (Chawanthayatham et al., 2017).
In an attempt to explain the higher incidence of HCC in males vs females when treated as infants,
Woo et al. (2011) investigated DNA adduct formation and mutational patterns in gpt delta B6C3F1
mice treated 4 days after birth with a single dose of AFB1 (6 mg/kg bw, i.p.). Similar levels of DNA
damage and mutations were observed in the liver of newborn males and females. At 21 days, no
signiﬁcant differences were found in the types of mutations between males and females, with the main
mutational classes being G-to-T transversions and G-to-A transitions.
Using a similar AFB1 exposure protocol as in the paragraph above and a post-dosing period of 3
and 10 weeks, AFB1-induced mutational spectra were investigated at a second locus, the red/gam
genes in the kEG10 transgene of gpt delta B6C3F1 mice (Spi– phenotype). Although some small
insertions and deletions were observed, the Spi– spectrum was still dominated by G-to-T transversions.
Similarly to the gpt mutations, no signiﬁcant gender differences were observed (Wattanawaraporn
et al., 2012).
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Big Blue B6C3F transgenic mice were treated at postnatal ages of 4, 7 and 10 days with a dose of
AFB1 (6 mg/kg bw by i.p.), while adult animals were treated at day 120, 123 and 126 with 6 or
60 mg/kg bw. All animals were sacriﬁced 6 weeks later. In the liver of the neonatal mice, the mutation
frequency at the cII gene was 22-fold higher in AFB1-treated compared with control animals (82-fold
increase in G-to-T transversions). Although in AFB1-treated adult animals no increase in mutation
frequency was observed, molecular analysis of the mutants identiﬁed a signiﬁcant increase (ﬁvefold) in
G-to-T transversions (Chen et al., 2010). These results are in line with an earlier report on lower levels
of GST in the liver of neonatal mice, associated with enhanced formation of AFB1-DNA adducts (Shupe
and Sell, 2004).
Taken together, pregnancy appears to enhance sensitivity to the genotoxicity of AFB1 for the
mothers, presumably resulting from elevated levels of CYP1A2 and CYP3A4. A study with in utero
exposure showed a lower frequency of DNA adducts formed in the fetus compared with the mothers
(about 1%), while the mutation frequency differed only by a factor of about ﬁve, indicating a greater
mutational impact of the lesions in the fetus. Early postnatal exposure resulted in higher adduct levels
in the liver compared with treatment of adult animals.
Mutational signatures of aﬂatoxin B1 exposure
Several studies investigated the role of chronic infections with HBV or hepatitis C virus (HCV), and
exposure to dietary AFB1 in the aetiology of HCC (see also Section 3.1.3). Codon 249 in the TP53
tumour suppressor gene represents a hotspot for AFB1-mediated mutagenesis, predominantly via a G-
to-T transversion (AGG to AGT, R249S). In HCC cell lines, the R249S variant was found to lack the
capacity to bind to p53 response elements and to transactivate p53 target genes (Gouas et al., 2010).
Studies indicate a strong association between high levels of R249S and HBV-related HCC, whereas low
to intermediate levels of R249S were detectable in asymptomatic subjects exposed to AFB1 (Ortiz-
Cuaran and Hainaut, 2011).
Two recent studies investigated the potential genome-wide mutational signatures of AFB1 exposure
(Huang et al., 2017; Zhang et al., 2017). Sequencing of the genomes of 4915 HCC cases collected in
the AFB1 high-risk region Qidong, China, (Zhang et al., 2017) were compared with 1,072 HCCs in the
general population without known exposure to aﬂatoxin (obtained from China, the United States,
France and Japan). The dominant mutational signature was characterised by increased G-to-T
transversions, in the sequence motif GGC and preferential localisation in the non-transcribed strand.
The genes most frequently mutated were TP53, TERT, AXIN1, CTNNB1 and ADGRB1 (Zhang et al.,
2017). The authors calculated that HCC with aﬂatoxin signature in the general population were up to
9.8% in China, 3.5% in the United States, 1.7% in France and 0.4% in Japan.
In the other study, whole genome sequencing was applied to analyse the mutation spectra of two
human cell lines, liver tumours in wild-type mice and mice carrying an HBV surface antigen transgene.
There was considerable agreement between mutation patterns observed in the different experimental
systems. There was also considerable overlap with mutational spectra from HCCs from known high
aﬂatoxin exposure regions, providing conﬁrmatory evidence that such mutational spectra can be used
as signatures for aﬂatoxin exposure. These HCC samples were preselected for the presence of somatic
TP53 R249S mutations (Huang et al., 2017). Based on comparison of the genome-wide analysis of
mutational signatures including previously published data, the authors estimated the proportion of
AFB1 exposure related to HCCs to be 0.7% in North America, 1% in Japan and 16% in Hong Kong
(Huang et al., 2017). Thus, the analysis of mutational spectra by whole genome sequencing appear to
provide a useful tool to identify AFB1 exposures in western countries.
3.1.2.4. Long-term toxicity (including carcinogenicity)
In 2007, the CONTAM Panel concluded that AFB1 is clearly carcinogenic in a variety of animal
species. In rodents, the principal tumours were in the liver, primarily HCC, but tumours have also been
observed in the lung, kidney and colon. The CONTAM Panel noted that the male Fischer rat is the most
sensitive species. The CONTAM Panel selected the study by Wogan et al. (1974) as the pivotal study.
In this chronic exposure study, male Fischer rats (approximately 80 g) were fed a semi-synthetic
diet containing AFB1 at concentrations of 0, 1, 5, 15, 50 and 100 lg/kg for up to 105 weeks. A clear
dose–response relationship was observed between AFB1 and the incidence of HCC at the two highest
doses (Table 2). In 2007, the CONTAM Panel converted the dietary concentrations of AFB1 into daily
15 n = 36 whole genome sequencing; n = 13 whole-exome sequencing.
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doses using a factor of 0.04 and by adjusting16 for the shorter study duration in some of the groups.
However, EFSA currently uses a default factor of 0.05 for chronic studies in the rat (EFSA Scientiﬁc
Committee, 2012a), which was also applied by JECFA. In 2016, JECFA used a dose-correction factor
reﬂecting the squared dependence17 of dose on time. This approach was recommended by Peto et al.
(1984) to avoid overcorrection, but this may lead to under-correction if the study is substantially
shorter than the ‘standard lifespan’ of 104 weeks (e.g. due to high mortality). The CONTAM
Panel noted that this approach resulted in an inconsistency between the time-adjusted dose and the
incidence of tumours at the highest concentration. Therefore, this correction is not used by the
CONTAM Panel for the calculation of time-adjusted doses in the paper by Wogan et al. (1974) and
instead the time adjustment was made as in 2007.
In 2007, the CONTAM Panel concluded that AFB1 and AFG1 can be considered to be equally potent
regarding carcinogenicity. This conclusion was based on the higher potency of AFB1 to cause tumours
in the liver versus the higher potency of AFG1 to cause tumours in the kidney. Butler et al. (1969)
exposed male and female MRC rats (8–9 weeks old) to AFB1, AFG1 and AFB2 via drinking water. AFG1
caused about six times fewer liver tumours than AFB1 (Table 3). However, AFG1 caused a higher
incidence of kidney tumours in male rats in the middle-dose group than AFB1 (Table 3). AFB2 did not
cause liver or kidney tumours, but 6 out of the 15 animals showed other neoplasms (unspeciﬁed).
Further, Wogan et al. (1971) reported the occurrence of renal adenocarcinomas in 4 out of 26 male
Fischer rats exposed to AFG1 via gavage, while this tumour was not reported for the animals exposed
to AFB1. No dose–response information was provided for this tumour. HCCs were observed after
treatment with AFB1 over a timeline of 14–45 weeks whereas with AFG1 tumours were seen at 20–64
weeks. In the same study, AFB2 was reported to cause HCC following i.p. exposure (total dose 150
mg) but no HCC were observed following gavage treatment (total dose 1 mg).
Table 2: Incidence of hepatocellular carcinomas in male Fischer rats after dietary administration of
AFB1 (Wogan et al., 1974)
Concentration in
feed (lg/kg)(a)
Time of appearance
of earliest tumour
(weeks)(a)
Duration of
experiment
(weeks)(a)
Tumour
incidence(a)
Dose
(lg/kg bw
per day)(b)
Time-adjusted
dose (lg/kg bw
per day)(c)
0 – 74–109 0/18 0 0
1 104 78–105 2/22 0.05 0.05
5 93 65–93 1/22 0.25 0.22
15 96 69–96 4/21 0.75 0.69
50 82 71–97 20/25 2.5 1.97
100 54 54–88 28/28 5 2.60
bw: body weight.
(a): As reported by Wogan et al. (1974).
(b): Dose calculated by the CONTAM Panel by using a default factor of 0.05 for chronic studies in the rat (EFSA Scientiﬁc
Committee, 2012a) without adjustment for study duration.
(c): Time adjustment based on time of appearance of earliest tumour as performed by the CONTAM Panel in 2007 (i.e. if a
1-year exposure is corrected to a 2-year exposure, then the dose is multiplied by a factor or 0.5).
Table 3: Incidence of liver and kidney tumours in MRC rats exposed to AFB1, AFG1 and AFB2 via
drinking water (Butler et al., 1969)
Total dose (mg per rat)(a)
0 1(b) 2 6
M F total M M F total M F total
Liver tumours
AFB1 0/15 0/15 0/30 3/10 8/15 11/15 19/30 – – –
AFG1 0/15 0/15 0/30 1/10 2/15 1/15 3/30 9/11 12/15 21/26
AFB2 0/15 0/15 0/30 0/10 – – – – – –
16 If a 1-year exposure is corrected to a 2-year exposure, then the dose is multiplied by a factor of 0.5.
17 If a 1-year exposure is corrected to a 2-year exposure, then the dose is multiplied by a factor of 0.52.
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No risk assessment for AFM1 has been carried out by the CONTAM Panel. At its 49th and 56th
meetings, JECFA decided on a potency factor for AFM1 based on the study by Cullen et al. (1987).
They evaluated the carcinogenicity of AFM1 in male Fischer rats and compared this with AFB1. AFM1
(0, 0.5, 5.0 and 50 lg/kg feed) and AFB1 (50 lg/kg feed) were fed to rats over 22 months. AFB1
induced HCC (19/20 rats) at 17 months of treatment while AFM1 resulted in no tumours until 21
months. At the highest dose tested, AFM1 induced HCC in 2/18 rats at 21 months. No tumours were
observed at 0.5 and 5.0 lg/kg of AFM1. AFM1 was therefore found to be a hepatic carcinogen but
with lower potency than AFB1.
No new long-term toxicity studies in rodents were identiﬁed since the previous assessment by the
CONTAM Panel in 2007.
Studies in rainbow trout (Oncorhynchus mykiss)
Halver (1968) ﬁrst suggested the rainbow trout as a test animal for oncology. He tested 13
potential carcinogens including AFB1 and observed liver tumours in all animals fed the carcinogen-
containing diet over 6–9 months.
In a study of 7,200 trout fry, Bailey et al. (1998) found relative tumourigenic potencies of aﬂatoxins
as individual compounds in the liver as AFB1 = 1; aﬂatoxicol = 0.936; AFM1 = 0.086; aﬂatoxicol M1 =
0.041. Fish were exposed to aﬂatoxins for 2 weeks in diet and monitored at 1 year. The dose–response
curves for AFB1 and aﬂatoxicol were similar. The authors suggested that the differences in
tumourigenicity were due to alterations in uptake and metabolism and the resultant DNA adduct
formation.
The same group carried out a number of other studies with large numbers of ﬁsh (Williams, 2012)
including ultra-low dose studies to determine the virtually safe dose. The data available at this time
indicated that for AFB1 at low concentrations in the feed (0–110 lg/kg) there was a linear dose–
response (Williams, 2012; Williams et al., 2009).
In summary, a group at Oregon State University has used the rainbow trout as a model for liver
cancer, testing a range of potential carcinogens including AFB1. The trout are sensitive to AFB1 and
showed a linear dose–response across a wide range of concentrations.
3.1.2.5. Developmental and reproductive toxicity
The CONTAM Panel identiﬁed several developmental and reproductive toxicity studies that
employed multiple dose groups and used the oral exposure route. The in vivo studies in rodents are
summarised in Appendix II, Table II.3.
In a pre- and postnatal developmental toxicity study, Sprague Dawley rats (n = 12 per dose group)
were exposed daily from GD 6 to postnatal day (PND) 21 to 0, 0.1, 0.3 or 1.0 mg AFB1/kg diet.
Offspring were examined at PND 21 and PND 77. Dose levels equalled 0, 7.1, 20.7 or 66.7 lg AFB1/kg bw
per day during the gestation period, and 0, 13.6, 41.7 and 132.7 lg/kg bw per day during the lactation
period. Maternal AFB1 exposure affected hippocampal neurogenesis targeting type-3 progenitor cells at
PND 21 which the CONTAM Panel considered to be adverse, whereas no changes in neurogenesis-related
parameters were observed at PND 77, implying that this effect is reversible. The no-observed-adverse-
effect-level (NOAEL) for offspring neurogenesis was 0.1 mg/kg feed (7.1–13.6 lg/kg bw per day)
(Tanaka et al., 2015; Shibutani, 2019).
In a prenatal developmental toxicity study, ICR mice (n = 10 per dose group) were dosed daily
during GD 13.5–16.5 by gavage with AFB1 administered in ethanol/corn oil (1:9 v/v) at 0, 50, 500 and
Total dose (mg per rat)(a)
0 1(b) 2 6
M F total M M F total M F total
Kidney tumours
AFB1 0/15 0/15 0/30 0/10 2/15 0/15 2/30 – – –
AFG1 0/15 0/15 0/30 0/10 5/15 0/15 5/30 6/11 0/15 6/26
AFB2 0/15 0/15 0/30 0/10 – – – – – –
F: female; M: male; –: not tested; AFB1: aﬂatoxin B1; AFG1: aﬂatoxin G1; AFB2: aﬂatoxin B2.
(a): The total dose refers to the dose during the entire exposure which was 10 weeks for the dose of 1 mg and 20 weeks for
the doses of 2 and 6 mg.
(b): Dose of 1 mg/rat was tested in male rats only.
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5,000 lg/kg bw. A shortened time to delivery and low birth weight were observed at 500 and 5,000 lg
AFB1/kg bw. The NOAEL was 50 lg/kg bw (Wang et al., 2016b).
Groups of seven male or female adult Wistar rats were exposed to 0, 4, 8 or 16 lg AFB1/kg bw per
day via sterile distilled water by gavage, for either 25 days (f) or 48 days (m) (Hasanzadeh and Amani,
2013; Hasanzadeh and Rezazadeh, 2013). Dose-related effects were observed at all doses, being
reduction in the population of healthy primordial, primary, secondary and tertiary follicles (f), and
reduced spermatogonia types A, B, and spermatozoa. Primary spermatocytes and spermatids were
decreased only at the highest dose. Fertility by mating was not tested in these studies. Considering
that effects were observed at the lowest dose tested (4 lg/kg bw per day), only a lowest-observed-
adverse-effect-level (LOAEL) was identiﬁed from these studies. In an earlier study in male adult Wistar
rats (n = 5 per group) from the same researchers (Hasanzadeh et al., 2011), the same dosing regimen
was shown to result in decreased serum concentrations of luteinising hormone and testosterone, and
increased follicle-stimulating hormone (FSH) and prolactin, with dose-dependent effects at all doses.
In a male fertility study, adult NMRI mice were treated daily for 35 days with AFB1 (100 or 700 lg/kg
bw) by gavage. Both dose levels reduced sperm viability and motility and caused sperm DNA damage.
Upon mating treated males, fertility rate was reduced, and embryo arrest increased at both dose levels
(Mohammadi et al., 2014).
A study on the impact of AFB1 on spermatozoa obtained from bull ejaculate reported enhanced
levels of DNA fragmentation and an increased proportion of dead sperm. These effects were observed
at 10–100 lM (Komsky-Elbaz et al., 2018). In porcine oocytes, impairment of maturation was observed
in vitro at 50 lM AFB1 (Liu et al., 2015).
In a metabolomics study, zebraﬁsh embryos were exposed to AFB1 in DMSO at concentrations of 0,
0.25, 0.5, 1 and 2 lM. Embryos were exposed to AFB1 for 24 h at 4, 24, 72 and 96 h post-fertilisation
(hpf). AFB1 was more toxic to embryos when exposed at 96 hpf compared to 24 hpf with LC50 of 0.5
and 2.1 lM, respectively. Concentrations of AFB1 below the LC50 values resulted in deformities such as
malformation of the head and bending of the tail. Using high-resolution NMR and principal components
analysis 28 metabolites were identiﬁed and quantiﬁed from AFB1-treated zebraﬁsh. Of these
metabolites, 19 were shown to be altered after 24 h exposure including increases in several amino
acids (phenylalanine, tryptophan, tyrosine, isoleucine, glutamate, glutamine and glycine) while cysteine
decreased. Increases were also noted in many metabolites associated with carbohydrate metabolism
and in the neurotransmitter, gamma aminobutyric acid. Increases in fatty acids and cholesterol were
observed but GSH decreased. All of these changes were statistically signiﬁcant (Zuberi et al., 2019).
This study was consistent with ex vivo metabolomics studies in mammals.
In summary, exposure to AFB1 was shown to cause effects on brain development in rats with a
NOAEL of 7.1–13.6 lg/kg bw per day. It also caused shortened time to delivery and low birth weight in
mice, with a NOAEL of 50 lg/kg. In addition, adverse effects have been found on spermatogenesis
and folliculogenesis at the lowest dose tested, 4 lg/kg bw, but fertility was not tested. Thus, AFB1
affects reproductive and developmental parameters at low doses in rodents and these effects may
occur following a short-term exposure.
3.1.2.6. Immunotoxicity
The immuno-modulatory effects of aﬂatoxins have been studied both in vitro and in vivo and their
immunotoxic potential was shown in several animal species (review in Meissonnier et al., 2006; EFSA,
2007a; Bondy, 2008; Bondy, 2008). In rodents, the NOAELs for AFB1 for impaired immune response
were mostly in the region of 30 lg/kg bw per day (EFSA, 2007a).
AFB1 reduces complement activity (EFSA, 2007a). In several animal species, AFB1 has also been
demonstrated to inhibit macrophage functions such as phagocytosis, oxygen radical production and
cytokine secretion, but also neutrophils chemotaxis and natural killer (NK) cell activity (EFSA, 2007a;
Bondy, 2008).
Many studies conducted in poultry, pigs and rats showed that exposure to aﬂatoxins, mainly from
naturally contaminated feed that may also contain other mycotoxins, resulted in suppression of the
cell-mediated immune response with lymphocyte depletion, atrophy of the lymphoid organs,
decreasing delayed-type hypersensitivity response to mitogens and modifying cytokine production
(Meissonnier et al., 2006; EFSA 2007a; Bondy, 2008; Jolly et al., 2008). Recent studies also described
an effect of AFB1 on target dendritic cells of porcine and human origin (Mehrzad et al., 2014, 2015,
2018a). In human monocyte-derived dendritic cells exposed in vitro to 10 ng/mL (0.03 lM) of AFB1,
an impairment of their phagocytic capacity was observed. The toxin also upregulated the expression
level of mRNA encoding for several CYPs, MyD88, nuclear factor kappa-light-chain-enhancer of
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activated B cells (NF-jB), tumour necrosis factor-alpha (TNF-a), toll-like receptor 2 (TLR2), TLR4, COX-
2, HLA-DR, CCR7, CD209, lymphocyte function-associated antigen 3 (LFA3) and CD16 and
downregulated the expression of AhR, transforming growth factor b (TGF-b), CD11c and CD64 within 2–
12 h post-exposure (Mehrzad et al., 2018a). In human microglia cells (CHME5 cell line), in vitro exposure
to 20 ng/mL AFB1, a low concentration of AFB1, upregulates the mRNA expression of many
proinﬂammatory molecules, such as TLRs, MyD88, NF-jB and CxCr4, and increases the protein secretion
of IFN-c and GM-CSF (Mehrzad et al., 2018b).
Qian et al. (2014) exposed rats to 0, 5, 25 or 75 mg AFB1/kg bw, by daily gavage, for 1 or 5 weeks.
At both time points no histological changes were observed in spleen tissue. However, after 1 week of
exposure, a dose-dependent decrease in the percentage of splenic CD8+ T cells and CD3-CD8a+ NK cells
was observed. An inhibition of the expression of IL-4 and IFN-c by CD4+ T cells, IL-4 and IFN-c by CD8a+
cells, and TNF-a expression by NK cells was also observed. Five-week exposure with AFB1 signiﬁcantly
increased the percentages of CD3+ and CD8+ T cells, especially at low doses (5 and 25 mg/kg bw). At
this time point, a signiﬁcant decrease of IL-4 expression by CD4+ T cells and a signiﬁcant increase of IFN-
c expression by CD4+ T cells and TNF-a expression by NK cells was also observed.
As far as humoral immunity is concerned, experiments mainly carried out with naturally contaminated
feed, gave less consistent results; only a prolonged exposure to high doses of aﬂatoxins led to a
signiﬁcant reduction in plasma antibody concentrations in both rodents and farm animals (Jolly et al.,
2008).
Data concerning the immunotoxicity of AFM1 are scarce. An in vitro study, on the human
lymphoblastoid T-cell line Jurkat, indicates that AFM1 signiﬁcantly decreases cell proliferation. Only minor
effects were noted on IL-2 and IFN-c cytokines mRNA expression in stimulated cells that had been pre-
incubated with AFM1 (Luongo et al., 2014). Another in vitro study from the same team, performed on the
human hepatoblastoma HepG2 cell line, demonstrated a decreased cell viability, an increase in the
concentration of three pro-inﬂammatory cytokines, IL-6, IL-8 and TNF-a, and a decrease of the anti-
inﬂammatory interleukin, IL-4 (Marchese et al., 2018). An in vivo study performed with an i.p.
administration of AFM1 (25 and 50 lg/kg bw) for 28 days also demonstrated an effect on some immune
parameters including proliferative response to lipopolysaccharide and phytohemagglutinin-A,
hemagglutination titre, delayed type of hypersensitivity, serum haemolytic activity, serum immunoglobulin
G level and cytokine production (Shirani et al., 2018).
In mice, i.p. injection of AFB1 (daily injection of 10, 20 or 40 lg/kg bw for 15 days) increased the
susceptibility of intranasal infection with Swine inﬂuenza virus as demonstrated by viral replication, lung
inﬂammation and damage (Sun et al., 2018a,b). This increased susceptibility is associated with a
macrophage polarisation from M1 to M2 as indicated by the decreased level of mRNA encoding for TNF-a
and the increased amount of IL-10 (Sun et al., 2018b) and involved a TLR4-NF-jB signalling mechanism
(Sun et al., 2018a). In several other studies performed in farm and laboratory animal species, the
immunosuppressive effects of aﬂatoxins has been correlated with an increased susceptibility to microbial
infections (bacterial, parasitic and viral) and to an impaired efﬁcacy of vaccination (Meissonnier et al.,
2006).
In conclusion, an immunotoxic effect of aﬂatoxins, especially of AFB1, has been described. The
toxin mainly acts on the cellular immune response. As already mentioned, the NOAELs for these
effects were around 30 lg/kg bw in rodents.
3.1.3. Observations in humans
3.1.3.1. Biomarkers of exposure
Several biomarkers of exposure have been used to investigate aﬂatoxin exposure and three of them
have been validated against dietary intake of aﬂatoxins. These will be discussed in the following order:
DNA adducts in urine, AF-alb adducts in serum and AFM1 excreted in urine and breast milk.
Aﬂatoxin epoxide binds to DNA to form N7-guanine adducts (AF-N7-gua), which are mutagenic if
not repaired (see Section 3.1.2.3 Genotoxicity). AF-N7-gua adducts excised from DNA are excreted in
urine. These urinary DNA adducts have been used as biomarkers in a number of early studies,
employing HPLC with UV detection and using standard curves to quantify AF-N7-gua from the urine of
exposed individuals. A correlation between dietary intake of aﬂatoxin and urinary AF-N7-gua was
reported for populations in China (Groopman et al., 1992a; correlation coefﬁcient 0.8, p < 0.00000001)
and Gambia (Groopman et al., 1992b; correlation coefﬁcient 0.82, p < 0.0001) and so urinary AF-N7-gua
is considered a validated biomarker of exposure. This adduct, together with other urinary metabolites of
AFB1, was used as a measure of aﬂatoxin exposure in a pivotal nested case–control study from a large
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prospective liver cancer study among middle-aged men in Shanghai (Qian et al., 1994). In this study, the
urinary aﬂatoxin metabolites revealed a strong association for risk of subsequently diagnosed liver
cancer, especially among individuals also infected by HBV.
Aﬂatoxin epoxide in liver cells and aﬂatoxin dialdehyde in blood can bind covalently to lysine in
albumin to form aﬂatoxin albumin adducts. As albumin has a serum half-life of around 20 days, levels of
aﬂatoxin albumin adducts reﬂect exposure over the previous 6–8 weeks. Methods to quantify aﬂatoxin
albumin adducts require isolation and digestion of albumin from serum. The three main methods that
have been applied to quantify these adducts are competitive inhibition ELISA, LC-FD and LC–MS/MS. In
this Opinion, where the LC–MS or LC-FD is applied, then AFB1-lys is used as these methods measure this
amino acid adduct. Where the ELISA method is applied, AF-alb is used because the ELISA method is not
speciﬁc for the AFB1-lys adduct. Isotope dilution LC–MS/MS can be considered to be the gold standard
method for quantiﬁcation of this adduct. A comparison of the three methods showed that there was an
excellent correlation between them, but on average ELISA gave a value 3.2-fold higher than isotope
dilution LC–MS/MS (McCoy et al., 2008). In an earlier comparison across a lower range of adducted
samples, the ratio between ELISA and LC–MS/MS was 2.6 (Scholl et al., 2006). The LC-FD method gave
slightly lower values than the LC–MS/MS method, which was attributed to the lack of adjustment for
recovery in the LC-FD method that is part of the isotope dilution LC–MS/MS method. The ELISA method
used in these studies has shown good correlation between dietary aﬂatoxin intake and AF-alb levels in
adults in Gambia (Wild et al., 1992) and children in Tanzania (Routledge et al., 2014). Recently, a
modiﬁed form of isotope dilution LC–MS, termed high-resolution MS (HRMS) has been applied to
measuring AF-lys in a case–control study (McMillan et al., 2018).
Wild et al. (1992) measured AF-alb levels in the serum of Gambian adults (n = 20), for whom
aﬂatoxin intake was assessed by testing food samples from each meal over a 7-day period. The
biomarker sample was taken on day 8. There was a correlation between aﬂatoxin intake and AF-alb
levels (correlation coefﬁcient = 0.55; p < 0.05). This study found that on average 1 lg aﬂatoxin intake
per day was equivalent to about 30 pg AF-alb/mg alb. As the average body weight of the individuals
was 50 kg, this equates to 20 ng aﬂatoxin/kg bw per day giving 30 pg AF-alb/mg alb.
Routledge et al. (2014) measured AF-alb adducts in 148 children (aged 12–22 months) exposed to
dietary aﬂatoxin in Tanzania. Aﬂatoxin intake was estimated by measuring aﬂatoxin contamination
levels in maize ﬂour samples from the households in which the children lived and calculating intake
based on this and the amount of food eaten as recorded in a 24-h dietary recall questionnaire. A
correlation was seen between the two measurements (correlation coefﬁcient = 0.43; p < 0.01), with a
lot of interindividual variation which could reﬂect differences in absorption, metabolism, detoxiﬁcation
and/or measurement error.
Aﬂatoxin M1 is a hydroxylated metabolite of AFB1 that can be used as a biomarker for aﬂatoxin
exposure as it is present in the urine and breast milk of exposed individuals. Most AFM1 is excreted in
urine within 24 h of exposure, which means that AFM1 is a good biomarker of very recent exposure.
In published reports, methods used for measuring AFM1 in human urine include commercial direct
ELISA kits (Chen et al., 2018a; Kang’ethe et al., 2017; Schwartzbord et al., 2017), LC-FD after
immunoafﬁnity column puriﬁcation (Piekkola et al., 2012) and LC–MS/MS multi-biomarker approaches
(Solfrizzo et al., 2014; Warth et al., 2012). In breastmilk, similar methods are used but with different
sample preparation and clean-up (Omar, 2012; Kang’ethe et al., 2017; Sadeghi et al., 2009; Ghiasian
and Maghsood, 2012; Diaz and Sanchez, 2015; Polychronaki et al., 2006). The multi-mycotoxin
biomarker methods enable the rapid detection of biomarkers of several mycotoxins simultaneously.
However, this advantage tends to come with a loss of sensitivity for some biomarkers, which may be
important for some study populations exposed to lower levels of AFB1.
A correlation between dietary AFB1 intake and urinary AFM1 was reported by Zhu et al. (1987) in a
study in the Guangxi Region of China. Analysis of AFB1 contamination of corn and peanut oil samples
collected from 32 households each day for 6 days, coupled with careful recording of corn and peanut
oil consumption was used to assess AFB1 intake in 52 individuals from whom total urine was collected
on days 4–7 of the study. A correlation coefﬁcient of 0.66 was observed. A correlation between dietary
intake and AFM1 was also reported for another Chinese adult population (Groopman et al., 1992a).
More recently, Chen et al. (2018a) collected urine and blood samples from 84 children aged 6–14
months in Tanzania, with AFB1 intake estimated from analysis of food samples and a 24 h dietary
recall questionnaire administered to parents on the day the urine was collected. A correlation between
urinary AFM1 levels and dietary intake of AFB1 in maize (r = 0.442, p < 0.001), as well as between
AFM1 in urine and AF-alb in serum of the children (r = 0.468, p < 0.001) was observed. Hence, AFM1
has been validated against dietary intake for short-term exposure, although the correlation is not as
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strong as reported for urinary N7-guanine (see above). AFM1 in breastmilk has not been validated
against dietary intake.
A few studies have measured AFB1 in urine or serum as a measure of exposure, but these have
not been validated against dietary intake.
In summary, AF-alb (AFB1-lys), urinary AF-N7-gua and urinary AFM1 are all validated biomarkers of
dietary exposure to aﬂatoxin. However, the levels of these biomarkers cannot be converted reliably
into dietary exposures in individuals, owing to the large interindividual variation, and the fact that all
sources of dietary intake and/or chronic exposure to aﬂatoxin have not always been taken into account
when determining the correlations. As AF-alb (AFB1-lys) better reﬂects longer-term exposure (i.e.
several weeks), it tends to be most widely used, while urinary AFM1 and AF-N7-gua are suitable
biomarkers for recent exposure.
3.1.3.2. Liver disease
The CONTAM Panel identiﬁed 31 studies on liver disease published since 2006. Of these, 14 were
selected as relevant for the risk assessment including 9 on primary HCC and 4 on other liver disease.
Altogether, these include two reports of the same cohort study (reported at two time points), three
nested case–control studies, seven case–control studies and two cross-sectional studies, which are
detailed below and summarised in Table 5.
3.1.3.2.1. Primary liver cancer
Prior to 2006, it was established that AFB1 exposure was an independent risk factor for primary
HCC, with aﬂatoxin enhancing risk among HBV carriers (see Section 1.3.3). A previous Opinion (EFSA,
2007a) considered the study by Yeh et al. (1989) on the role of aﬂatoxin exposure and HBV infection
in the southern Guanxi Provence, a high-risk region for liver cancer in China, as the pivotal study for
the risk assessment. That study established a linear relationship between estimated mean annual
dietary intake of aﬂatoxin at the community level and primary liver cancer mortality in a cohort of
7,917 men. The estimated aﬂatoxin intake per person per year was calculated by multiplying the
aﬂatoxin contamination determined by regular testing of food samples by the annual intake of food
commodities within a community, divided by the number of people in the community. Of note, in these
data is that even communities with the lowest estimated aﬂatoxin intake, i.e. 12 ng/kg bw per day
(see Table 4) had high liver cancer mortality. Prevalence of HBV was high within the population but
whereas estimated aﬂatoxin intake varied 3.5-fold across the ﬁve communities in the study, HBV
prevalence did not. This suggests that variations in the incidence of HCC between communities was
not driven by HBV prevalence, even though HBV-positive status was a high-risk factor for the
development of HCC. Yeh et al. (1989) reported that an intake of 60 mg/person per year was
associated with primary liver cancer mortality of 600/100,000 person-years. For HBsAg-positive and
negative subjects, the mortality rates of primary liver cancer were 953.8 and 17.5/100,000 person-
years, respectively. More detailed information on the dose–response relationship for HBsAg-positive
and negative subjects is provided in the paper by Wu-Williams et al. (1992) and is presented in
Table 4.
Table 4: Aﬂatoxin dose, number of primary hepatocellular carcinoma cases and adjusted person-
years of follow-up from the cohort studied by Yeh et al. (1989) and reported by Wu-
Williams et al. (1992)
Estimated dose of AFB1
(ng/kg bw per day)
Number of primary
hepatocellular
carcinoma cases
Total person-years
Number of primary
hepatocellular
carcinoma cases per
total person-years
HBsAg
positive
HBsAg
negative
HBsAg
positive
HBsAg
negative
HBsAg
positive
HBsAg
negative
12 12 0 2,737 9,932 0.0044 0.0000
90 7 1 2,017 6,114 0.0035 0.0002
705 12 4 2,537 7,733 0.0047 0.0005
2028 23 2 1743 5,803 0.0132 0.0003
AFB1: aﬂatoxin B1; HBsAg: hepatitis B surface antigen; bw: body weight.
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The nine studies on aﬂatoxin and HCC published since 2006 include one cohort study (reported at
two time points), three nested case–control studies and ﬁve case–control studies. Between 2007 and
2018, three nested case–control studies from Taiwan and one cohort study from China have been
reported that used validated biomarkers to assess aﬂatoxin exposure prior to cancer development. The
Chinese 21-year prospective cohort study (1988–2009) involved collecting monthly 24 h urine samples
over an eight month period at the beginning of the study for a cohort of high-risk individuals who were
all positive for HBV infection (n = 515) from Qidong City, Jiangsu Province, an area of China with a
high prevalence of HCC (Lu et al., 2010). Aﬂatoxin exposure was assessed by analysing monthly
urinary AFM1 levels, averaged over an eight-month urine collection period. During the follow-up
21-year period, 109 of the 515 patients died of liver cancer. Hepatitis B infection was strongly associated
with a risk of liver cancer (relative risk = 7.79) in comparison with the uninfected population. Within this
cohort of HBV-positive individuals, the relative risk for liver cancer in aﬂatoxin-exposed vs non-exposed
individuals was 2.23 (p = 0.008). The observations in this study were extended to 148 patients over a
23-year follow-up period (Lu et al., 2012). This paper reports an increased relative risk for new incident
liver cancer associated with aﬂatoxin exposure of 2.37 (95% CI: 1.29–4.33).
A nested case–control study (241 cases and 1,052 controls from an initial cohort of 24,000) in
Taiwan (Wu et al., 2009a) measured serum AF-alb and urinary aﬂatoxin metabolites stored at
enrolment. The authors grouped individuals based on whether their biomarker levels were higher or
lower than the mean for the study. An increased risk of HCC was found in non-HBV carrier individuals;
for AF-alb the odds ratio (OR) was 1.54 (95% CI: 1.01–2.36) and for urinary AF metabolites the OR
was 1.76 (95% CI: 1.18–2.58). HBV status had a much stronger effect, with an OR of 7.49 (95% CI:
5.13–10.93) for HBV carriers independent of aﬂatoxin exposure. The association increased to an OR of
10.38 (95% CI: 5.73–18.82) for HBV carriers with above-mean AF-alb and an OR of 15.13 (95% CI:
7.83–29.25) for HBV carriers with above-mean AF urinary metabolite levels.
Two later nested case–control studies in Taiwan investigated the risk of HCC in individuals infected
with either HBV (Chu et al., 2017) or HCV (Chu et al., 2018). Serum AF-alb was measured in samples
collected at enrolment, which was up to nine years before the disease outcome was assessed. In the
ﬁrst study, Chu et al. (2017) looked at chronically infected HBV subjects (232 cirrhosis cases, 262 HCC
cases and 577 controls from an initial cohort of 24,000). High AF-alb levels compared with
undetectable AF-alb were associated with an increased risk of cirrhosis at entry (OR 2.45, 95% CI:
1.51–3.98), cirrhotic HCC nine years after entry (OR 5.47, 95% CI: 2.20–13.63) and non-cirrhotic HCC
4 years after entry (OR 5.39, 95% CI: 1.11–26.18). In the second study (Chu et al., 2018), the role of
HCV and alcohol as risk factors were considered and included 506 HCC cases and 2,636 controls. High
vs low serum AF-alb levels were associated with HCC risk in habitual alcohol consumers (OR = 4.22,
95% CI: 1.16–15.37) and in HCV-infected participants (OR = 3.39, 95% CI: 1.31–8.77).
Four case–control studies examining the association of validated aﬂatoxin biomarkers with HCC
were published between 2007 and 2018. However, it should be noted that all the assessed cancer
case–control studies examined exposure biomarkers in samples that were collected after disease
occurrence. Liu et al. (2008) reported signiﬁcantly higher levels of AF-alb adducts in the serum of HCC
patients (n = 71) from Guanxi Zhang Autonomous Region, compared with controls in four HBV
categories (n = 71 for each) from the same region. All cases were HBV-positive, compared with
75/694 controls from three regions of China including high and low HCC risk regions. Various markers
of HBV infection were not associated with AF-alb levels in controls. In a study on newly diagnosed
HCC cases (n = 214) and controls (n = 214) in Chongqing, China, Zheng et al. (2017) found an OR of
1.9 (95% CI: 1.1–3.4) for AF-alb adduct, and 2.1 (95% CI: 1.0–4.2) for AF-N7-gua adduct, after
adjustment for various confounders including HBV. HBV was the most important risk factor associated
with HCC in this population, and there was an interaction between both aﬂatoxin biomarker levels and
HBV, alcohol consumption and diabetes. Habibi et al. (2018) measured AF-alb in 41 hepatitis-related
HCC patients and 41 controls with HBV or HCV and reported higher mean levels of AF-alb in the
cancer patients (3.87 pg/mL) than in the controls (2.63 pg/mL). However, they reported AF-alb as
pg/mL serum and did not correct for albumin levels, which could be different for cases and controls.
Manda et al. (2018) examined AFB1-lys adducts in the serum of HCC patients (n = 33) and controls
(n = 33 HBV-positive controls and 33 blood donor controls) from Co^te d’Ivoire. They did not ﬁnd any
signiﬁcant difference (p > 0.05) between AFB1 adduct levels in HCC patients (mean: 36.57 pg/mg
albumin) and control patient groups. Mean adduct levels were lower, but not statistically different
(p > 0.05), in the 33 blood donor controls (25.63 pg/mg albumin) compared to 33 HBV-positive
controls (34.95 pg/mg albumin).
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In summary, the studies reported since 2006 have added to the weight of evidence that aﬂatoxin
exposure is associated with a risk of developing HCC, with a higher risk for people infected with either
HBV or HCV.
3.1.3.2.2. Other liver disease
Since 2006, four case–control studies and two cross-sectional studies have investigated liver
diseases other than cancer as endpoints associated with aﬂatoxin exposure. In an endemic HCV area
of Taiwan, Chen et al. (2007) found an association between AF-alb levels and HCV infection (> 8 ng/mg
vs. < 8 ng/mg, OR = 2.019 (95% CI: 1.09–4.0)) and between AF-alb levels and advanced liver disease in
HCV-infected subjects (> 8 ng/mg vs. < 8 ng/mg, OR = 2.29 (95% CI: 1.23–1.47)). Taking all subjects
(HCV positive and negative), mean levels of AF-alb were 10.5 ng/mg alb in advanced liver disease versus
5.5 ng/mg in mild/no liver disease. The CONTAM Panel noted that the biomarker levels are about 1,000
times higher than those in other studies and that there is only an abstract given as a reference for the
method. Jolly et al. (2007) examined AFB1-lys and various measures of liver function and illness in a
cross-sectional study in Ghana (n = 140). There was a positive association between AFB1-lys and both
serum total protein and ALT. Kuniholm et al. (2008) examined the role of aﬂatoxin as a risk factor for
cirrhosis in a Gambian population. Using a questionnaire to estimate lifetime peanut consumption as a
proxy for aﬂatoxin exposure, there was an association between high exposure and cirrhosis (OR = 2.8,
95% CI: 1.1–7.7). Using the mutation at codon 249 in the TP53 gene in circulating DNA as a biomarker of
past exposure, the association with cirrhosis increased (OR = 3.8, 95% CI: 1.5–9.6). There was a
stronger association for HBV infection (HBsAg, OR = 8.0, 95% CI: 4.4–14.7; hepatitis B e antigen
(HBeAg), OR = 10.3, 95% CI: 2.0–53.9). In a study in Malaysia (n = 71), Mohd-Redzwan et al. (2014)
observed a higher total bilirubin and creatinine level, but no differences for other markers of liver
function, in subjects with above-the-mean AFB1-lys measured in this study (6.85 pg/mg alb). Anitha
et al. (2014) found an association between HBV infection and AFB1-lys levels with liver cirrhosis in a
case–control study in India. AFB1-lys was detected in 8/108 controls (mean 19.25 pg/mg alb) compared
with 18/18 with initial liver disease and 11/112 with cirrhosis. Of these the mean AFB1-lys increased with
severity of disease up to 575 pg/mg. No controls were positive for HBV, whereas 128/130 patients were
HBV-positive. Patients with both HBV- and AFB1-lys-positive results had more severe liver disease. Afum
et al. (2016) found no signiﬁcant difference in urinary AFM1 levels between cases with liver disease and
controls (n = 276) in a study in Ghana. While increased levels of AF biomarkers have been associated with
HBV or HCV infection, it is not clear whether the toxin exposure makes infection more likely (e.g. due to
liver damage or suppressed immune function) or hepatitis leads to increased levels of biomarker
formation. Wild and Montesano (2009) reviewed the interactions between hepatitis virus and aﬂatoxin in
2009, including discussion of some animal and cell experiments supporting the hypothesis that aﬂatoxin
exposure could increase HBV infection or viral genome integration, but did not come to a conclusions
regarding the mechanism underlying the interaction.
AFB1 can cause acute toxicity in humans (acute aﬂatoxicosis) exposed to high levels of dietary
AFB1 in a short time period. Symptoms of acute aﬂatoxicosis include GI distress, jaundice, hepatitis
and liver failure and such outbreaks often have a high mortality rate. Because symptoms may be
similar to some types of bacterial food poisoning or infectious disease, conﬁrmation of acute
aﬂatoxicosis has not always been possible. However, several cases have been conﬁrmed by measuring
aﬂatoxin in food or aﬂatoxin biomarkers in affected individuals. In an outbreak in India in 1974, cases
were associated with an estimated consumption of 2–6 mg aﬂatoxin/day. Out of 397 patients, 106
died (Krishnamachari et al., 1975). In 1981, 12/20 affected adults died in Kenya after consuming high
levels of aﬂatoxin in family food (Ngindu et al., 1982). AF-lys levels in serum were measured to
conﬁrm aﬂatoxin as the cause of 125 deaths from 317 cases in Kenya in 2004 (Azziz-Baumgartner
et al., 2005). Based on three reported cases of acute aﬂatoxicosis in India and Kenya, Wild and Gong
(2010) calculated that an intake of more than 20 lg/kg bw per day was associated with acute
aﬂatoxicosis in adults. This required maize aﬂatoxin contamination levels of more than 1,000 lg/kg. It
is not clear whether repeated exposure is required, but symptoms of hepatitis may occur up to 3
weeks following acute symptoms such as vomiting (Kamala et al., 2018). In this more recent acute
aﬂatoxicosis outbreak in Tanzania (Kamala et al., 2018), AF-alb levels of > 1,000 pg/mg albumin in
cases versus controls (OR = 13.5, 95% CI: 1.5–165.3) were associated with acute aﬂatoxicosis. In this
outbreak, there were 20 deaths among 68 cases. Maize samples collected about 5 weeks after the
outbreak began showed higher levels of contamination from case households versus controls
(geometric mean 354.5 lg/kg vs 44.1 lg/kg; p = 0.04). Such contamination levels are far higher than
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any seen in the EU, and the CONTAM Panel therefore considers the risk of acute aﬂatoxicosis to be
highly unlikely in the EU.
In summary, high AFB1 exposure causes acute aﬂatoxicosis with a high mortality rate. Lower levels
of chronic exposure to AFB1 are associated with cirrhosis and indicators of liver dysfunction. There
appears to be an interaction between AFB1 exposure and HBV or HCV infection and consequently the
risk of non-HCC liver disease.
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Table 5: Overview of epidemiological studies on the association between exposure to aﬂatoxin and liver disease
Reference
country
Study type
(duration)
N
Age (years)
(mean  SD)
Biomarker
(matrix)
Method
(LOD/LOQ)
Levels of exposure Outcome
Afum et al.
(2016)
Ghana
Case–control 38 cases; 102 HBV/
HCV +ve controls;
136 –ve controls
> 18 Urinary AFM1 HPLC-FD (LOD =
0.5 pg/mg
creatinine)
68.5 pg/mg creatinine (cases)
67 pg/mg (ve con)
65.3 pg/mg (+ve con)
Liver disease
Anitha et al.
(2014) India
Case–control 138 cases
108 controls
> 18 AF-alb (s) ELISA (LOD ?) Con 19.25 pg/mg albumin
Child’s class A 18.1 pg/mg
Child’s class B 71.25 pg/mg
Child’s class C 575
pg/mg
Decompensated
liver disease
Chen et al.
(2007)
Taiwan
Case–control 72 cirrhosis, 13 HCC,
229 controls
66.9  9.7 AF-alb (s) ELISA (LOD
39.8 ng/mL)
10.5 (ALD) vs. 5.5 (CON) ng/mg
alb
ALD
Chu et al.,
(2017)
Taiwan
Nested case–
control
232 cirrhosis cases
262 HCC cases
577 controls
R: 30–65 AF-alb (s) ELISA (LOD 2
fmol/mg albumin)
Median of 21.5 fmol/mg
(equivalent to about 9.8 pg/mg)
in controls
Median for cases not given
Cirrhosis and
HCC in HBV
carriers
Chu et al.
(2018), Taiwan
Nested case–
control
506 cases
2,636 controls
R: 30–65 AF-alb (s) ELISA (LOD 2
fmol/mg albumin)
Median of 21.5 fmol/mg
(equivalent to about 9.8 pg/mg)
in controls
HCC in HCV
carriers
Habibi et al.
(2018)
Iran
Case–control 41 cases
41 controls
57.5  10.8 (cases)
44.8  15.1 (controls)
AF-alb (s) ELISA (LOD 0.054
pg/mL serum)
Cases: Median 3.87 pg/mL, IQR
3.46
Controls: Median 2.63
pg/mL, IQR 3.14(c)
HCC
Jolly et al.
(2007)
Ghana
Cross-
sectional
162 40.8 (R: 19–86) AF-alb (s) Radioimmunoassay Mean 0.89  0.46 pmol/mg
albumin (equivalent to 407 
211 pg/mg albumin)
Liver disease
Kuniholm et al.
(2008)
Gambia
Case–control 97 cases
397 controls
Controls 44.8  15.2
Cases 42.5  14.1
TP53 249ser FFQ for aﬂatoxin
exposure
NA Cirrhosis
Liu et al. (2008)
China
Case–control 71 cases
695 controls
36.6  15.6
(controls). Not given
for cases
AF-alb (p) ELISA (LOQ 10
fmol/mg albumin)
Cases: mean 15.11
pmol/mL plasma
Control: mean 10.02
pmol/mL plasma(d)
HCC
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Reference
country
Study type
(duration)
N
Age (years)
(mean  SD)
Biomarker
(matrix)
Method
(LOD/LOQ)
Levels of exposure Outcome
Lu et al. (2010)
China
Longitudinal
(21 years)
515 HBV +ve (123
went on to develop
HCC)
R: 20–60 at
recruitment
AFM1 (24 h u)
Collected monthly
for 8 months at
outset
HPLC(b) following
immunoafﬁnity
column
concentration
(LOD 0.5 ng/mL)
Mean of 48.46 ng/mL and a
median of 24.90 ng/mL, range
5.7–243 ng/mL among AFM1 +ve
samples
Association with HCC based on
+ve vs. ve AFM1 results
HCC
Lu et al. (2012)
China
Longitudinal
(23 years)
148
Absolute number of
cases not given
R: 20–60 at
recruitment
AFM1 (24 h u)
Collected monthly
for 8 months at
outset
HPLC(b) following
immunoafﬁnity
column
concentration
(LOD 0.5 ng/mL)
Mean of 48.46 ng/mL and a
median of 24.90 ng/mL, range
5.7–243 ng/mL among AFM1 +ve
samples
Association with HCC based on
+ve vs ve AFM1 results
HCC
Manda et al.
(2018)
Co^te d’Ivoire
Case–control 33 HCC
66 controls (33 HBV
+ve & 33 HBV ve)
49.84  15.34
(R: 24–77)
AFB1-lys (s) HPLC-FD (LOQ
2.3 pg/mg
albumin)
Mean of 36.57 pg/mg albumin in
HCC patients, 34.95 pg/mg
albumin in HBV patients and
25.63 pg/mg albumin in blood
donors
Liver disease
Mohd-Redzwan
et al. (2014)
Malaysia
Cross-
sectional
71 aﬂatoxin exposed
subjects(a)
34.34  9.7
(R: 23–57)
AFB1-lys (s)
AF metabolites (u)
HPLC-FD (LOQ
0.17 ng/mL)
Mean 6.85 +/3.2 pg/mg Liver disease
Wu et al.
(2009a)
Taiwan
Nested case–
control
241 cases and 1,052
controls from an
initial cohort of
24,000
53.8  7.9 AF-alb (s)
AF metabolites (u)
ELISA (LOD
0.01 fmol/lg)
ELISA (LOD
1 fmol/mL urine)
Mean 59.8 fmol/mg albumin
(equivalent to about 27 pg/mg)
Mean 55.2 fmol/mL urine
HCC
Zheng et al.
(2017)
China
Case–control 214 cases
214 controls
50.7  9.7 (cases)
51.2  9.9 (controls)
AF-alb (s)
AF-N7-gua (u)
ELISA (LOD
0.1 ng/mL)
ELISA (LOD
0.1 ng/mL)
Median; Cases 146.23 pg/mg
albumin, controls 74.42 pg/mg
albumin
Median; cases 0.17 ng/mg
creatinine controls 0.14 ng/mg
creatinine
HCC
+ve: positive; ve: negative; AF-alb: aﬂatoxin albumin adduct; AFB1-lys: aﬂatoxin B1 lysine adduct; AF-N7-gua: aﬂatoxin-N7-guanine; ALD: advanced liver disease; ELISA: enzyme-linked
immunosorbent assay; FD: ﬂuorescence detection; FFQ: food frequency questionnaire; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HPLC: high-performance liquid
chromatography; LOD: limit of detection; LOQ: limit of quantiﬁcation; IQR: interquartile range; p: plasma; R: range; s: serum; SD: standard deviation; u: urine.
(a): Identiﬁed by screening for AFM1 in urine.
(b): Detector not reported.
(c): Concentration reported as pg/mL serum without correcting for albumin levels which may be different depending on health status.
(d): No correction by the authors for the albumin level which was about 10% higher in controls than in cases. Consequently, the CONTAM Panel could not convert the concentration into pg/mg
albumin.
Aﬂatoxins in food
www.efsa.europa.eu/efsajournal 39 EFSA Journal 2020;18(3):6040
3.1.3.3. Other cancers
There are two case–control studies showing an association between aﬂatoxin and other cancers. In
a case–control study in a Shanghai population of gall bladder cancer (GBC) patients and controls
(gallstones) (Koshiol et al., 2017), an association with GBC was found for the presence of AFB1-lys
adducts assessed in serum taken after diagnosis (AFB1-lys detected in 32% of the cases vs 15% of
the controls), as well as the level of AFB1-lys and GBC (5.4 vs. 1.2 pg/mg alb in cases vs controls).
The authors acknowledged weaknesses in the study design.
In a case–control study in Korea (n = 477), Eom et al. (2013) used a structured interview to
estimate aﬂatoxin intake in relation to stomach cancer risk. There were no direct measurements of
aﬂatoxin levels. They observed an elevated risk of stomach cancer associated with higher aﬂatoxin
intake; OR = 1.94, 95% CI: 1.43–2.63.
There is currently insufﬁcient evidence to associate aﬂatoxin exposure with GBC and stomach cancer.
3.1.3.4. Kidney disease
In a pilot study investigating the possible impact of aﬂatoxin exposure on kidney disease in
indigenous Mexican women (n = 34), de Leon Martinez et al. (2019) reported a geometric mean of
3.48 (95% CI: 2.4–5.0) pg/mg albumin. Statistically signiﬁcant correlations were reported between
AFB1-lys and both kidney injury molecule 1 (Rho = 0.498, p = 0.007) and cystatin-C (Rho = 0.431,
p = 0.014), suggesting a possible role for aﬂatoxin exposure in kidney damage.
3.1.3.5. Anaemia in pregnancy
Only one study was identiﬁed that assessed in a cross-sectional fashion the correlation between
aﬂatoxin exposure (AF-alb) and anaemia in 755 pregnant women in Ghana (Shuaib et al., 2010b).
Although the odds of being anaemic increased statistically signiﬁcantly with each quartile of AF-alb, the
study design per se and the lack of replication do not support anaemia in pregnancy as an endpoint of
interest for the risk assessment at present.
3.1.3.6. HIV-related outcomes
There is a growing body of evidence assessing how aﬂatoxin exposure affects biomarkers and
health-related outcomes in populations infected with HIV. As far as observational studies are
concerned, ﬁve publications were identiﬁed spanning 2007 to 2013 and all recruiting populations from
Ghana. Only one cohort study was identiﬁed (Keenan et al., 2011); 141 HIV-positive Ghanaians were
assessed for aﬂatoxin exposure (AF-alb, median 0.94 pmoL/mg albumin equivalent to 430 pg/mg
albumin) and followed up for a median of 208 days for the development of symptomatic opportunistic
infections. At each visit, a maximum of four symptomatic diseases were recorded in the patient
records and the ﬁve most frequent diseases were chosen for outcomes (malaria, herpes, tuberculosis,
pneumonia and hepatitis). A statistically signiﬁcant increased hazard ratio was observed for
symptomatic tuberculosis (hazard ratio 3.30, 95% CI: 1.34–8.11) for those in the highest AF-alb
quartile compared with the lowest. The remaining four observational studies were cross-sectional with
various degrees of overlap (Jiang et al., 2008; Jolly et al., 2011, 2013; Obuseh et al., 2011).
The presence of only one small longitudinal study pertaining to this group of endpoints does not
justify the use of HIV-related endpoints in the risk assessment at present.
3.1.3.7. Child health
Nineteen studies assessed 31 associations between aﬂatoxin exposure and outcomes related to
mother and child health (Table 6; stillbirth, n = 2; prematurity, n = 1; growth, n = 18; autism, n = 1;
nodding syndrome, n = 1; organomegaly, n = 1; hepatitis B surface antibodies, n = 1). Only one study
assessed a European population (Italy, autism) while the remaining studies assessed African
populations (n = 15), South American populations (n = 2) and Asian populations (n = 1) in settings of
higher exposure than European populations.
3.1.3.7.1. Pre- and postnatal growth
A total of 15 studies published from 2007 to 2019 assessed the association between aﬂatoxin
exposure and indices of child growth (Table 6). One cluster randomised controlled trial in Kenya was
identiﬁed. Of the remaining 14 observational studies, 5 studies were birth cohorts with a follow-up
for 18 months after birth, 3 were prospective cohorts with a follow-up ranging from 6 to 36
months, 1 was a case–control study, 5 were cross-sectional studies and 1 study implemented both a
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cross-sectional and cohort study design. The sample sizes of the included observational studies
ranged from 46 to 785 participants. All the evaluated populations came from non-European, low-
and middle-income countries: Mexico (n = 2), Guatemala (n = 1), Nepal (n = 1), Egypt (n = 1),
Ghana (n = 1), Gambia (n = 2), Kenya (n = 2), Nigeria (n = 1), Uganda (n = 1) and Tanzania (n =
3). All but one of the assessed studies evaluated children younger than 3 years, while Castelino
et al. (2015) evaluated schoolchildren.
Most of the studies (80%, n = 12) used biomarkers for exposure assessment; AFB1-lys was
measured in six studies, AF-alb was measured in four studies, and AFB1 and AFM1 were measured in
one study each. The remaining two studies estimated aﬂatoxin exposure by using a food frequency
questionnaire including food items prone to aﬂatoxin contamination (Carlos et al., 2014) or estimated
the putative aﬂatoxin exposure level deﬁned as the estimate of the average amount of aﬂatoxins
consumed in a single day by a child (Voth-Gaeddert et al., 2018). All the included studies pertained to
populations with considerably higher exposures than those found in European populations.
Child growth was measured using the same indices but with a range of statistical analyses. Intra-
uterine growth was assessed either as a continuous trait using birth weight and length at birth (Turner
et al., 2007) or as a dichotomous variable using the small for gestational age (Shuaib et al., 2010a) or
low birth weight categorisation (Carlos et al., 2014; Shuaib et al., 2010a). Child growth was measured
in most cases using the well-established weight-for-age z-scores (WAZ) and height-for-age z-scores
(HAZ). Stunting or wasting was captured as a baseline characteristic or as a covariate but not
commonly used as a study outcome, possibly due to the high prevalence of these conditions in the
populations under study. Due to the known complex nature of child growth and its dependence on
numerous parameters (Bundy et al., 2017) the included studies used a wide variety of adjustments in
the ﬁnal statistical analyses.
Height or HAZ were statistically signiﬁcantly and negatively associated or correlated with aﬂatoxin
exposure in six publications (7 studies: 1 birth cohort, 1 cohort, 5 cross-sectional studies) using various
biomarkers. WAZ and birth WAZ were statistically signiﬁcantly and negatively associated with aﬂatoxin
exposure in 3 and 1 birth cohorts, respectively, again using various biomarkers.
In summary, child growth appears to be an emerging area of research in the ﬁeld of adverse events
related to aﬂatoxin exposure. However, the currently available body of evidence is characterised by small
sample sizes, considerable heterogeneity in the assessed populations and biomarkers, varying
methodological quality, and effect inconsistency. Thus, the potential for using these studies for risk
assessment is limited. In the following section, prospective studies using a biomarker are reported in
detail by study design (RCT, cohort), continent, country, biomarker and year of publication. Information
about all assessed studies, including case–control and cross-sectional studies, is provided in Table 6.
Hoffmann et al. (2018) conducted the only cluster randomised trial in rural Kenya to assess the
effectiveness of an intervention that reduced aﬂatoxin exposure on child linear growth. They enrolled
women in the ﬁfth to ﬁnal month of pregnancy (1,230 unborn children). The intervention consisted of
swapping contaminated maize with safe maize and encouraging household purchases from a stock list
supplied with clean maize. The primary outcomes were child length-for-age z-score (LAZ), the
prevalence of stunting and child serum AFB1-lys level after 24 months (endline follow-up); the
secondary outcomes included child LAZ, the prevalence of stunting and child serum AFB1-lys levels at
11 to 19 months (midline follow-up). At baseline, the observed aﬂatoxin exposure in the mothers
corresponded to 14.7 and 15.5 pg/mg albumin in the intervention and control groups, respectively.
Attrition was 28% for LAZ and 35% for the serum AFB1-lys levels at 24 months with comparable
attrition rates between the intervention and control groups. Interestingly, aﬂatoxin exposure showed a
decreasing trend in both groups over the course of the study. At 24 months, the intervention
signiﬁcantly reduced serum AFB1-lys levels (5.9 vs. 7.5 pg/mg albumin), but had no effect on LAZ or
stunting. Conversely, at the intermediate follow-up points, the intervention statistically signiﬁcantly
increased LAZ and reduced stunting without affecting serum AFB1 levels (4.7 vs. 5 pg/mg albumin).
The authors note that this could be due to seasonal variation or differences in response to the
intervention and avoid proposing an association between reductions in exposure and improvements in
linear growth.
Cohort studies
Lauer et al. (2019) assessed in a birth cohort the association between maternal aﬂatoxin exposure
during pregnancy and birth-related outcomes in 220 mother–infant pairs in Uganda. AFB1-lys was
measured using HPLC-FD and the median AFB1-lys levels in the mothers were 5.83 pg/mg albumin
(range: 0.71–95.60 pg/mg albumin, interquartile range: 3.53–9.62 pg/mg albumin). In the adjusted
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analysis, higher maternal AFB-lys levels were signiﬁcantly associated with lower birth weight, lower
birth WAZ, and lower head circumference-for-age z-score at birth.
Leroy et al. (2018) report on a cohort study nested within a cluster randomised controlled trial on
the efﬁcacy of three micronutrient supplements in Mexico. The cohort study population comprised 347
children with archived samples collected at the trial 4-month follow-up and corresponding to about one
third of children who participated in the efﬁcacy trial. Aﬂatoxin exposure was assessed using AFB1-lys
adduct and the baseline exposure was 0.82 (SD 0.72) pg/mg alb, which is lower compared with other
studies looking at child growth. Higher serum AFB1-lys adduct levels at baseline were statistically
signiﬁcantly associated with greater children’s linear growth from the trial’s baseline. The CONTAM
Panel notes that this is an effect in the opposite direction to previous reports. At the 10-month trial
follow-up point (6-month cohort follow-up period, 12% attrition), there was no statistically signiﬁcant
association between aﬂatoxin exposure and height-for-age difference (HAD).
Chen et al. (2018b) assessed the association between aﬂatoxin exposure and weight and length in
a Tanzanian setting with a high reported prevalence of growth impairment. Using a cohort study
design, they included a subsample (53%) of 60 children who were assessed for aﬂatoxin exposure at
the age of 24 months (AFB1-lys) and were followed up for 12 months. At baseline, 17% of the
children were underweight, 72% had detectable AFB1-lys exposure, and the mean level of AFB1-lys
was 5.1 (95% CI: 3.5–6.6) pg/mg alb. There were no statistically signiﬁcant associations observed
between aﬂatoxin exposure and WAZ or weight-for-height z-score (WHZ).
Mitchell et al. (2017) conducted an extension of the Chen et al. (2018b) study in Nepal. This cohort
study included 85 children followed up for 36 months and assessed aﬂatoxin exposure at 15, 24, and
36 months of age (AFB1-lys). There were no associations found between AFB1-lys and WAZ and
weight-for-length z-score (WLZ).
Watson et al. (2018) using a birth cohort in Gambia (n = 374) assessed the association between
aﬂatoxin exposure (AF-alb) at 6 months and growth indices (WAZ, WLZ, length, LAZ) at 6, 12, and 18
months. At 6, 12 and 18 months of age, 48%, 98%, and 99% of available plasma samples had
detectable AF-alb concentrations, respectively. After adjustment for covariates (season, mother’s
household quality, supplementation group, and age of introduction of non-breastmilk food), higher
average AF-alb levels were statistically signiﬁcantly associated with decreased LAZ, WAZ and WLZ
scores during follow-up. Aﬂatoxin exposure was also statistically signiﬁcantly associated with change in
length, LAZ and WLZ. Moreover, aﬂatoxin exposure was statistically signiﬁcantly correlated with insulin-
like growth factor-binding protein 3 (IGFBP3). Statistically signiﬁcant associations were not reported for
change in WAZ and no statistically signiﬁcant correlation was reported between aﬂatoxin exposure and
insulin-like growth factor 1 (IGF-1).
Turner et al. (2007) reported on a birth cohort with 138 mother–infant pairs in Gambia. The assessed
association pertained to in utero aﬂatoxin exposure (AF-alb) and birth weight as well as weight and length
with a 52-week follow-up. The geometric means of AF-alb levels were 40.4 pg/mg (range
4.8–260.8 pg/mg), 10.1 pg/mg (range 5.0–189.6 pg/mg) and 8.7 pg/mg (range 5.0–30.2 pg/mg) in
maternal, cord and infant blood, respectively, with a seasonal variation present for maternal and cord blood
measurements. Neither maternal nor cord blood AF-alb was signiﬁcantly associated with lower birth weight
or birth length. After adjustment for covariates (gender, age, placental weight, maternal weight, gestation
time, season) a higher average maternal AF-alb was signiﬁcantly related to lighter WAZ (-0.249 SD;
p=0.012). In contrast, cord AF-alb was not associated with WAZ. No statistically signiﬁcant associations
were reported for HAZ. Besides assessing intra-uterine exposure through measurements in maternal and
cord blood, Turner et al. (2007) also assessed the association between aﬂatoxin exposure at 16 weeks and
WLZ at the 52-week follow-up (4% attrition). There were no statistically signiﬁcant results observed for
weight but a statistically signiﬁcant association was found for length.
Shirima et al. (2015) conducted a multi-site cohort study on the association between aﬂatoxin
exposure and weight and length in infants in Tanzania (three sites) in settings with a high prevalence
of growth impairment. They recruited 166 infants (6–14 months old) and followed them for 12 months
(interim assessment at 6 months, 12% attrition). The proportion of underweight children was 8% at
baseline. Aﬂatoxin exposure was measured using plasma AF-alb adducts. Statistically signiﬁcant
differences were observed between sites at baseline for both the percentage of positive samples and
the mean concentrations. Although the results between mean AF-alb levels and WAZ and WHZ at 12
months were not reported in the published report of the study, communication with the authors
conﬁrmed that there were no statistically signiﬁcant associations observed (Routledge, 2019b).
Magoha et al. (2014) studied the association between AFM1 exposure and growth for 143 mother–
infant pairs in a high-exposure setting in Tanzania using a cohort study design. AFM1 exposure was
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estimated through AFM1 levels measured in breast milk (age 1, 3 and 5 months), the breast milk
intake recorded by the United States Environmental Protection Agency for infants of his/her age, and
the infant’s body weight. All the breast milk samples were contaminated by AFM1 at levels ranging
from 0.01 to 0.55 ng/mL (> 90% of samples above the EU limit for infant food; > 76% above the EU
limit for dairy milk and milk products). Exclusive breastfeeding decreased considerably during the
follow-up (19% at month 3, 3% at month 5). The mean estimated AFM1 exposure was 11.08
( 10.13) ng/kg bw per day) and ranged from 1.13 to 66.79 ng/kg bw per day. Due to the observed
decrease in exclusive breastfeeding, the highest exposure levels were observed at baseline. A small
but signiﬁcant inverse association was observed between AFM1 exposure levels and WAZ (adjusted
beta 0.009; CI: 0.016 to 0.001) and HAZ (beta 0.013; 95% CI: 0.024 to -0.002), but not for
WHZ (adjusted beta 0.020; CI: 0.028 to 0.068).
3.1.3.7.2. Effects other than growth
A small number of studies assessed a diverse group of outcomes in children including stillbirth,
prematurity, autism, nodding syndrome, anti-HBs titres and organomegaly. All were of small to
moderate sample size and none was longitudinal. Due to the small number and the limitations of the
assessed studies, the available evidence does not support any of these endpoints as eligible for the
risk assessment. Detailed information on study characteristics for this group is provided in Table 6. In
addition, other symptoms have been reported by Voth-Gaeddert et al. (2018) but these were not
speciﬁc for aﬂatoxin exposure.
3.1.3.7.3. Summary
Child health is an emerging area of interest for the ﬁeld of aﬂatoxin-related health outcomes but not
yet suitable for use in risk assessment. Child growth is assessed in a growing body of evidence outside
European populations with limited replicability in the observed associations. The evidence related to the
remaining child health outcomes is sparse, heterogeneous and with methodological limitations.
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Table 6: Overview of epidemiological studies on the association between exposure to aﬂatoxin and child health
Reference
Country
Study type
(months)
N
Age
(months)
Biomarker
(matrix)
Method (LOD/LOQ)
Levels of exposure
(mean  SD) Outcome
Hoffmann et al. (2018)
Kenya
Cluster RCT (24) 1,230 NA AFB1-lys (s) HPLC-FD (0.2 pg/mg
alb)
LAZ, stunting
Lauer et al. (2019)
Uganda
Birth cohort 220 < 2 days AFB1-lys (s) HPLC-FD (0.2 pg/mg
alb)
5.83 (IQR 3.53–9.62) Birth weight, birth
length, bLAZ, bWAZ,
bWLZ, bHC, bHCAZ
Voth-Gaeddert et al.
(2018)
Gambia
Birth cohort, Cross-
Sectional (5)
320 30.2 years
(mothers)
Putative aﬂatoxin
exposure (maize)
ELISA kit for AFT
(2 lg/kg)
48.1 (95% CI: 30.6–65.7) HAZ
Watson et al. (2018)
Routledge (2019a)
Gambia
Birth cohort (12) 374 NA AF-alb (s) ELISA (3 pg/mg alb) NR WAZ, LAZ, WLZ, IGFBP-
3, IGF-1
Mitchell et al. (2017)
Nepal
Birth cohort (36) 85 15 AFB1-lys (p) LC–MS (0.4 pg/mg alb) 3.85 (15.75)(c) WAZ, HAZ, WHZ
Magoha et al. (2014)
Tanzania
Birth cohort (5) 143 < 5 AFM1 (bm) LC-FD (0.005 ng/mL) 11.08 (10.13)(b) WAZ, HAZ, WHZ
Turner et al. (2007)
Gambia
Birth cohort (12) 138 NR AF-alb (s) ELISA (5 pg/mg alb) 40.4 (4.8–260.8)(c) WAZ, HAZ, birth weight,
birth length
Chen et al. (2018b)
Tanzania
Cohort (12) 60 24–36 AFB1-lys (p) LC–MS (0.4 pg/mg alb) 5.1 (95% CI: 3.5–6.6) WAZ, HAZ, WHZ
Leroy et al. (2019)
Mexico
Cohort (6) 347 12 AFB1-lys (s) LC-FD (0.2 pg/mg alb) 0.82  0.72 Height, HAD
Shirima et al. (2015)
Tanzania
Cohort (12) 166 6–14 AF-alb (p) ELISA (3 pg/mg of alb) 4.7 (95% CI: 3.9–5.6) WAZ, HAZ, WHZ,
growth velocity
Carlos et al. (2014)
Mexico
Case–control (NA) 342 >30 Aﬂatoxigenic food
intake
FFQ NA Stillbirth, LBW
Echodu et al. (2018)
Uganda
Cross-sectional (NA) 84(d) NR Total aﬂatoxin
(food)
ELISA (NR) 3.8 (0–7.8)(a),(e) Nodding syndrome
Githanga et al. (2019)
Kenya
Cross-sectional (NA) 205 1–14 years AFB1-lys (s) HPLC-FD (0.4 pg/mg
alb)
45.38 (87.03); g.mean,
20.4
Low hepatitis B surface
antibody titre
McMillan et al. (2018)
Nigeria
Cross-sectional (NA) 58 0.5–2 AFB1-lys (p) LC–MS/MS, IDMS
(22 pg/mL)
2.6 (0.2–59.2)(a) Severe acute
malnutrition, stunting,
HAZ, WHZ
De Santis et al. (2017)
Italy
Cross-sectional (NA) 233 24–144 AFB1 (s, u) LC–MS/MS (LOQ
0.03 ng/mL)
s, 0.01  0.05; u, 0.12 
0.12
Autism
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Reference
Country
Study type
(months)
N
Age
(months)
Biomarker
(matrix)
Method (LOD/LOQ)
Levels of exposure
(mean  SD) Outcome
Castelino et al. (2015)
Kenya
Cross-sectional (NA) 199 144 AF-alb (s) ELISA (LOD 3 pg/mg
alb)
110.5 (95.4–127.9)(c) Height
Shouman et al. (2012)
Egypt
Cross-sectional (NA) 46 < 52 AFB1 (s) TLC (NR) 51.6 (30.6–62.8)(a) WAZ, HAZ
Shuaib et al. (2010a)
Ghana
Cross-sectional (NA) 785 26.8 years
(mother)
AFB1-lys (s) LC-FD (0.5 pg/mL) 10.9  19.0 Stillbirth, prematurity,
SGA, LBW
Gong et al. (2012)
Kenya
Cross-sectional 249 6–17 years AF-alb (s) ELISA (3 pg/mg alb) 114.5 (99.7, 131.4)(c) Hepatomegaly,
splenomegaly,
hepatosplenomegaly
AFB1: aﬂatoxin B1; bm: breast milk; FFQ: food frequency questionnaire; g. mean: geometric mean; HAD: height-for-age difference; HAZ: height-for-age z-score; HPLC: high-performance liquid
chromatography; LC–MS: liquid chromatography coupled to mass spectrometry; LC–MS/MS: liquid chromatography coupled to tandem mass spectrometry; LBW: low birth weight; LOD: level of
detection; LOQ: level of quantiﬁcation; NA: not applicable; NR: not reported; p: plasma; s: serum; SD: standard deviation; SGA: small for gestational age; u: urine; WAZ: weight-for-age
z-score; WHZ: weight-for-height z-score; y: year.
(a): Median, range/IQR.
(b): Estimated.
(c): Geometric mean (SD or range or 95% CI).
(d): Households.
(e): In food.
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3.1.4. Mode of action
There is convincing evidence from numerous publications that AFB1 has a genotoxic mode of
action. Thereby the formation of pro-mutagenic DNA adducts can be regarded as a molecular initiating
event (Moore et al., 2018). Subsequently, misreplication or mis-repair of adducted DNA might result in
mutations of critical genes. In addition to DNA adduct formation, a broad spectrum of cellular effects
have been reported in response to AFB1 exposure.
3.1.4.1. DNA adduct formation
The reactive AFB1-exo-8,9-epoxide can covalently bind to N7 of guanine in DNA, yielding the AFB1-
N7-gua. DNA adduct formation is > 2,000 times greater in DNA than in aqueous solution with free
20dG, presumably due to intercalation (Bren et al., 2007; Brown et al., 2009). Under physiological
conditions, spontaneous depurination or rearrangement to the more persistent ring-opened AFB1-FAPY
adduct might occur. In DNA, AFB1-N7-gua and AFB1-FAPY intercalate above the 50-face of the
respective guanine. In vitro studies indicate sequence speciﬁcity with preferential formation of DNA
adducts in guanine-containing sequences (Besaratinia et al., 2009). Both AFB1-N7-gua and AFB1-FAPY
produce G-to-T transversions in E. coli, with the AFB1-FAPY being more mutagenic (Banerjee et al.,
2011; Stone et al., 2011). A site-speciﬁc mutagenesis assay in mammalian cells (COS-7) showed a
replication error frequency of the AFB1-FAPY adduct of 97% with G-to-T transversions as the
predominant effect (Lin et al., 2014, 2016).
Recent studies identiﬁed the translesion synthesis DNA polymerase polf to be able to bypass the
AFB1-FAPY lesion and might account for the commonly occurring G-to-T transversions (Lin et al., 2013,
2014; McCullough and Lloyd, 2019).
3.1.4.2. Factors affecting DNA damage and repair
DNA adduct formation depends on the production rate of AFB1-exo-8,9-epoxide and its
detoxiﬁcation by three main pathways: (i) spontaneous or epoxide hydrolase-mediated hydrolysis; (ii)
GSH conjugation; (iii) further oxidation by CYPs. Several of the involved enzymes, particularly GSTs
and CYP3A4, are known potential sources of interindividual variation in susceptibility to aﬂatoxins
(EFSA, 2007a; see Sections 3.1.1 and 3.1.4.6).
Hydrolysis of the 8,9-epoxides leads to the unstable AFB1-8,9-dihydrodiol, which is prone to base-
catalysed rearrangement, thus generating AFB1 dialdehyde (Figure 1) that may react with proteins
(Guengerich, 2005). Members of the NADPH-dependent AKR play a key role in the reduction of the
reactive AFB1 dialdehyde to the less reactive AFB1-dialcohol. Expression of the human isoform AKR7A3
in mammalian cells was found to decrease the cytotoxicity of AFB1 and its dialdehyde (Bodreddigari
et al., 2008), supporting the role of AKR in detoxiﬁcation.
In Fischer F344 rats, application of a potent nuclear factor erythroid 2-related factor 2 (Nrf2)
activator (CDDO-Im) for 5 weeks (three doses of 30 lmol/L by oral gavage every other day) before
administration of AFB1 (daily 200 lg/kg by gavage for 4 weeks) was found to suppress the level of
AFB-FAPY-adducts and prolonged the mean life span of the animals from 74 to 90 weeks (Johnson
et al., 2014). Among others, the Nrf2 pathway regulates the expression of GSTs and key enzymes of
GSH biosynthesis, which might at least contribute to the reported effects. Furthermore, Nrf2 knockout
rats display higher sensitivity to AFB1 toxicity (Taguchi et al., 2016). The effect of AFB1 on antioxidant
key enzymes regulated by the Nrf2 pathway is not only limited to the liver but has also been described
in the kidney (Wojtowicz-Chomicz et al., 2013). Taken together, the available studies indicate an
important role for the Nrf2 pathway in the suppression of AFB1 adduct formation via regulation of GSH
biosynthesis and GST expression.
Base excision repair (BER) was investigated in a study in male mice (heterozygous p53 knock out
and control wild-type) exposed to 0, 0.2 and 1.0 mg/kg AFB1 in the diet for 26 weeks (Mulder et al.,
2015). Exposure to AFB1 did not alter BER either in the liver or lungs of p53 knock out (+/) mice. In
p53 (+/+) control livers repair activity was decreased in the 1.0 mg/kg AFB1 treatment group
(compared to 0.2 mg/kg), an effect that was not seen in the p53 (+/) knock out livers. A previous
study from the same group using the same dosing protocol, observed the opposite effect on
nucleotide excision repair. In that study AFB1 treatment increased global nucleotide excision repair in
p53 (+/+) tissues, and this effect was attenuated in p53 (+/) tissues (Mulder et al., 2014).
In an attempt to induce liver carcinomas in Wistar rats upon i.p. treatment with AFB1, differentially
expressed genes were predominately observed for cell proliferation, cell adhesion and vasculature
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development, thus reﬂecting tumour development. Downregulation was observed in the gene group
involved in apoptosis regulation and DNA repair (Shi et al., 2016).
3.1.4.3. Induction of oxidative stress
There is increasing evidence that AFB1 is not only able to generate DNA adducts, but also induce
oxidative stress (da Silva et al., 2018). Imbalance in cellular redox systems might arise from: a) direct
pro-oxidative chemical features of a compound; or b) impact on antioxidative defence systems on the
transcriptional (gene expression) or posttranscriptional level (e.g. protein adduct formation; enzyme
inhibition).
Recent studies demonstrate that AFB1 enhances reactive oxygen species (ROS) formation and
causes oxidative damage (Marin and Taranu, 2012; Zhou et al., 2019). In several animal models, AFB1
was found, among others, to uncouple mitochondrial oxidative phosphorylation, induce mitochondrial
permeability, enhance lipid peroxidation and decrease the level of GSH (Liu and Wang, 2016; Shi et al.,
2015; da Silva et al., 2018). However, it remains to be clariﬁed whether this is due to interactions on
the protein level or impact on gene expression.
Direct impact on cellular proteins has been shown in vitro. Under cell-free conditions as well as in
cell culture (HepG2) AFB1 inhibits the activity of the 20S proteasome, which is involved in the cellular
defence against oxidative stress (Amici et al., 2007). Moreover, in the low micromolar range, AFB1 was
reported to act as a moderate competitive inhibitor of serine proteases, thus potentially interfering
with the removal of damaged proteins (Cuccioloni et al., 2009). AFB1 was reported to induce
autophagy in macrophages (An et al., 2017). Autophagy is a central intracellular process, delivering
cytoplasmic components to the autophagosomes and lysosomes for degradation. Present studies
indicate that autophagy induction by AFB1 occurs downstream of ROS production (An et al., 2017). In
3D4/21 cells18 incubation with AFB1 induced oxidative stress, enhanced the expression levels of the
DNA methyltransferases DNMT1 and 3a and activated the JAK2/STAT3 signalling pathway (Zhou et al.,
2019). These results might provide an additional link between the induction of oxidative stress by
AFB1 and its immunological properties.
Studies in vitro and in vivo argue that AFB1 has an impact on enzymes of the antioxidant defence.
Prolonged incubation of HepG2 cells (24 or 48 h) with AFB1 resulted in a decrease of glutathione
reductase and catalase activity, whereas an increase in GST activity was apparent (Amici et al., 2007).
Male albino Charles Foster rats showed signiﬁcantly enhanced ROS levels in the liver 4 weeks after
AFB1 application (i.p., 1 mg/kg bw, twice on consecutive days) together with declining immunostaining
for superoxide dismutase, indicative of a decrease in the antioxidant defence (Singh et al., 2015).
These data are in line with reports on the importance of the Nrf2 pathway to suppress AFB1 toxicity
(see Section 3.1.4.2).
Recent studies demonstrate that the onset of oxidative stress by AFB1 leads to oxidative DNA
damage. In HepG2 human HCC cells, incubation with AFB1 resulted not only in the formation of
respective DNA adducts but also > 30-fold higher amounts of cyclic a-methyl-c-hydroxy-1,N2-propano-
dG arising from lipid peroxidation (Weng et al., 2017). In adolescents (n = 84) from an area in China
at high risk for HCC, urinary AFB1 levels were positively associated with the urinary excretion of 8-
hydroxydeoxyguanosine (8-OHdG) as well as 8-OHdG and hOGG1 levels in peripheral lymphocytes
indicative for the presence of oxidative stress (Peng et al., 2007). In a case–control study in Taiwan,
(74 HCC cases, 290 matched controls) an association between urinary AFB1 metabolites and 8-oxo-dG
with urinary 15-F2t-isoprostan, a lipid oxidation marker, was observed (Wu et al., 2007, 2008).
Furthermore, it has to be taken into account that HBV infection has also been shown to induce
oxidative stress (Liu et al., 2008).
In summary, besides DNA adduct formation, AFB1 induces oxidative stress including modulation of
antioxidant defence systems. Considering the potential sequence of events towards HCC, oxidative
stress might compromise critical AFB1 detoxiﬁcation pathways (e.g. GSH conjugation) and/or induce
additional DNA lesions.
3.1.4.4. Gene transcription and epigenetic mechanisms
Toxicogenomic in vitro studies show the clear impact of AFB1 exposure at the transcription level. A
spectrum of cellular transcriptional response results from the DNA adduct formation of AFB1.
Nevertheless, several studies also argue for non-genotoxic mechanisms such as the binding of AFB1 to
nuclear receptors as a modulating factor for gene regulation. In cultured primary human hepatocytes,
18 Porcine alveolar macrophages immortalised with SV40 large T antigen transformed with pSV3-neo.
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a 24 h treatment with AFB1 at non-cytotoxic concentrations (0.001 lM) upregulates the gene
transcription of several nuclear receptors: the aryl hydrocarbon receptor (AhR), the pregnane X
receptor (PXR) and the constitutive androstane receptor (CAR). Furthermore, in concentrations up to 1
lM, enhanced transcript levels of the CYP1A1, 1A2, 2B6, 3A5, 3A4 and 2C9 were observed (Ayed-
Boussema et al., 2012), indicating the activation of respective nuclear receptors. In lymphocytes and
monocytes from healthy volunteers (n = 10, male), CYP1A1, CYP1B1, CYP3A4, CYP3A5 and CYP3A7
were found to be expressed. In monocytes AFB1 treatment highly induced CYP1A1, CYP1B1 and
CYP3A4, but only CYP1A1 was induced in lymphocytes, arguing for a different response in myeloid and
lymphoid lineage cells (Bahari et al., 2014, 2015). The partly planar and bulky structure of AFB1 might
indeed favour binding to nuclear receptors, thus affecting gene expression.
Several epigenetic mechanisms have been associated with AFB1 exposure and the development of
HCC. Overall, a decline of global DNA methylation together with hypermethylation of several tumour
suppressor genes has been observed in vitro and in vivo (Zhang et al., 2006, 2012; Wu et al., 2013;
Dai et al., 2017; Martin and Fry, 2018). In primary human hepatocytes AFB1 treatment (0.3 lM,
repetitive daily treatment for 5 days, followed by 3 days washout) has been reported to affect the DNA
methylation pattern (Rieswijk et al., 2016). Upregulation of TXNRD1 diminishes the expression of
AFB1-aldehyde reductase and GST which play an important role in the detoxiﬁcation of the genotoxic
AFB1-8,9-epoxide. Feng et al. (2012) reported a statistically signiﬁcant association between AFB1-DNA
adducts and RASSF1A methylation in human HCC.
Human immortal hepatocytes expressing one oncogenic H-Ras allele, L02R cells, were treated
weekly with 0.3 lM AFB1, leading to a malignant phenotype showing anchorage-independent grow
and the formation of tumours in immunodeﬁcient mice at week 17 post-treatment. Seven genes were
identiﬁed as downregulated by DNA hypermethylation (Wang et al., 2017). Among others,
transformation was associated with hypermethylation of the RUNX3 gene. In 20 pairs of HCC and their
adjacent tissues, hypermethylation of RUNX3 was found in 70% of the HCC samples, downregulation
of respective mRNA in 95% (19/20) (Wang et al., 2017).
Furthermore, in utero exposure to AFB1 has been associated with a modiﬁed DNA methylation
pattern in the offspring (2–8 months), measured in white blood cells of the infants (Hernandez-Vargas
et al., 2015).
A recent study using skin- (HaCaT) and lung-derived cells (L-132), reported upregulation of both the
maintenance (DNMT1) and de novo DNA methyltransferases (DNMT3a and DNMT3b) after incubation
with AFB1 (24 h, 1 lM) on the transcription and on the protein level. AFB1-treatment was found to
decrease HAT activity and increases HDAC expression and activity (Soni et al., 2018). However, the
underlying mechanism for this impact on epigenetic key enzymes remains to be elucidated.
In Balb/c mice exposure to AFM1 was found to decrease the expression of the microRNA (miRNA)
miR-155 in T cells, which is discussed to contribute to immunotoxicity (Shirani et al., 2019). So far,
modulation of the expression levels of several microRNAs (miRNA) have been associated with effects
caused by AFB1 exposure including liver carcinogenesis (Zeng et al., 2010; Herceg and Paliwal, 2011;
Fang et al., 2013; Liu et al., 2014; Marrone et al., 2016; Dai et al., 2017). In patients with HCC related
to AFB1 exposure, differences in expression of several miRNA either in tumour tissue (e.g. miRNA-24,
Liu et al., 2014) or serum (e.g. miRNA-4651, Wu et al., 2017), have been identiﬁed as potentially
relevant. However, it is unclear whether AFB1 directly affects miRNA expression (e.g. via binding to
CpG-rich promoters) or whether changes in miRNA expression arise from secondary cellular responses
to the genotoxicity of AFB1.
3.1.4.5. Other potential targets
Lung
In air–liquid interface cultures of primary human sinonasal and bronchial cells, AFB1 and AFB2 were
found to reduce ciliary beat frequency, a mechanism involved in mucociliary immunity (Lee et al.,
2016). In lung cancer cells AFB1 affects several signalling pathways involved in carcinogenesis and
tumour cell migration (Cui et al., 2015). In human bronchial epithelial cells (BEAS-2B), incubation with
AFB1 (1.5 lM, 30 min) resulted in a decrease of the p53 level, persisting for 12 h (Van Vleet et al.,
2006). In the respiratory tract CYP2A13 is discussed to play a central role for metabolic activation of
AFB1 (Yang et al., 2013). But AFB1 also appears to play a role for the onset of oxidative stress in the
lung. Treatment of female A/J mice with a single i.p. dose of 50 mg/kg bw AFB1 resulted in an
increase of 8-OHdG formation in alveolar macrophages and Clara cells (Guindon et al., 2007; Guindon-
Kezis et al., 2014).
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For AFG1, the presence of TNF-a as a proinﬂammatory stimulus was associated with an
upregulation of CYP2A13 and enhanced oxidative DNA damage in murine AT-II cells and human AT-II
like cells (A549) (Shao et al., 2019).
Development and reproduction
In Leydig cells, isolated from 35-day-old male Long–Evans rats, incubation with AFB1 decreased the
secretion of testosterone in a dose-dependent manner. Signiﬁcant effects were observed after 3 h at a
concentration of ≥ 1 lM. After 18 h of incubation a signiﬁcant decrease of testosterone secretion was
already measured with 0.01 lM of AFB1. Furthermore, the expression of cholesterol transporter
steroidogenic acute regulatory protein (StAR), 3b-hydroxysteroid dehydrogenase (HSD3B) and 17b-
hydroxysteroid dehydrogenase enzyme (HSD17B3) was suppressed (Adedara et al., 2014). In Sprague
Dawley rats, treatment with AFB1 (gavage postnatal days 49–70) at 15 and 150 lg/kg bw per day
resulted in a decrease of serum testosterone, luteinising hormone and FSH levels together with a
downregulation of testosterone biosynthesis-related genes and a decrease of the Leydig cell number. In
vitro, treatment of isolated adult Leydig cells with AFB1 inhibited the expression of testosterone
biosynthesis genes, enhanced ROS production and induced apoptosis. Apoptosis induction was
associated with the suppression of the AMPK/mTOR-mediated autophagy ﬂux pathway (Chen et al.,
2019).
In studies with trophoblastic JEG-3 cells, the placental transporters ABCC2 and OAT4 were
increased about ﬁvefold at 2 and 6 lM AFB1, whereas the expression of ABCG2 was suppressed.
Several enzymes involved in steroid homeostasis were upregulated including CYP19A1, HSD3B1,
HSD17B1 and members of the UGT1A-family (Huuskonen et al., 2013).
In porcine parthenotes, ex vivo treatment with AFB1 impaired the development of blastocytes at
concentrations ≥ 1 nM indicative for impact on early embryonic development (Shin et al., 2018).
Mature male Swiss albino mice were treated i.p. for 7, 14 and 21 days, receiving a daily dose of 20
lg/kg bw AFB1. In addition to the impact on cell cycle regulation by downregulation of CDK1, cyclin
D4 and induction of p21, a decrease of estrogen receptor alpha (ERa) expression was observed
(Zamir-Nasta et al., 2018). Male mice (4 weeks of age) receiving a daily dose of 50 lg/kg bw AFB1 i.p.
for 45 days prior to potential mating, showed no signiﬁcant differences in the number and viability of
the offspring. The relevance of an apparent increase in transcripts for Renin in the AFB1-treated males
remains to be clariﬁed (Austin et al., 2012).
Taken together, the results argue for impact of AFB1 on key enzymes in hormone homeostasis
which may lead to the disturbance of regulatory mechanisms in fertility. Transport processes across the
placenta may also be affected.
3.1.4.6. Factors inﬂuencing susceptibility in humans
This section focuses on factors inﬂuencing susceptibility of humans. The CONTAM Panel notes that
in animal studies at high doses, substances that causes regenerative hyperplasia may exacerbate the
incidence of tumours.
3.1.4.6.1. Co-occurrence with viral infections
Hepatitis B virus
It is well-established that co-exposure to HBV has a strong inﬂuence on the carcinogenic risk of
aﬂatoxins to humans (see Sections 1.3.3 and 3.1.3.2.1). In epidemiological studies, there is an
interaction between aﬂatoxin exposure and hepatitis B infection, and subjects positive for HBsAg show
a multiplicative risk for liver cancer when present together with aﬂatoxin exposure (FAO/WHO, 2018).
At the molecular level, some data suggest that HBV infection of the liver alters the expression of
the genes coding for the enzymes which metabolise/detoxify aﬂatoxins such as an induction of CYP
enzymes or decrease in GST activity. This may provide one mechanistic basis for the higher risk of liver
cancer among HBV-infected individuals exposed to aﬂatoxins (EFSA, 2007a).
Hepatitis C virus
Aﬂatoxin B1 exposure has also been shown to increases the risk of HCC in patients with HCV
infection (see Section 3.1.3.2.1). In a nested case–control study in Taiwan, high serum AF-alb levels
were associated with HCC risk in HCV–infected participants (Chu et al., 2018).
Jeannot et al. (2012) also demonstrated that transgenic mice expressing several HCV proteins
(core, E1, E2 and p7, nucleotides 342–2771) were prone to hepatocarcinogenesis when exposed to
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AFB1. No liver lesions were observed in 7-day-old mice (wild-type or HCV-transgenic) treated. with a
single dose of tricaprylin administered i.p, used as vehicle. Upon treatment with 6 lg/g bw AFB1, tumours
(adenomas or carcinomas) and preneoplastic lesions (hyperplasia or foci) were observed in 22.5% (9 of
40) and 50% (18 of 36) of wild-type and HCV-transgenic mice, respectively; the difference being largely
due to the incidence of adenomas (30.5 vs 12.5%). Although oxidative stress and steatohepatitis were
observed in both AFB1-treated groups, molecular changes indicative of the enhanced inﬂammatory
response and altered lipid metabolism were more pronounced in HCV-transgenic mice.
Epstein–Barr virus
Epstein–Barr virus (EBV) is a member of the gamma herpes virus family. Although mostly
asymptomatic, EBV infection has been associated with several human B-cell malignancies, e.g.
endemic Burkitt’s lymphoma in children in sub-Saharan Africa. The EBV life cycle in B cells comprises
latent stages, where only a few viral genes are expressed, and the lytic stage, characterised by
expression of all viral genes and rapid replication until lysis of the host cell occurs. In vitro and in
animal models, exposure of B cells to AFB1 leads to the alteration of cellular gene expression that in
turn reactivates EBV towards the lytic cycle. AFB1 is considered to be a cofactor in EBV-mediated
carcinogenesis (Accardi et al., 2015).
3.1.4.6.2. Genetic polymorphisms
Some genetic polymorphisms have previously been identiﬁed as being associated with increased
risk of aﬂatoxin-related liver cancer, including the GSTM1 null polymorphism and the XRCC1 gene
codon 399 AG/GG variants (Kirk et al., 2005).
So far, a spectrum of genetic polymorphisms has been identiﬁed affecting the susceptibility of
individuals to AFB1-mediated liver carcinogenesis. A study involving 966 healthy adults (Guangxi,
China) reported an association of the GSTM1-null genotype and XRCC3 genotypes (i.e. threonine/
methionine and methionine-methionine variants) with higher levels of AFB1-DNA adducts in peripheric
blood lymphocytes (measured by ELISA) (Long et al., 2009b). In a case–control study based in the
same region with 1,499 liver cancer cases and 2,045 controls, an association between genetic
polymorphisms in the DNA repair gene XRCC4 (codon 247 alanine>serine), higher AFB1-DNA adduct
levels and increased risk for HCC (Long et al., 2013). A study with 2,558 healthy adults of the Guangxi
Region found XPC genotypes with codon 939 glutamine alleles (XPC-lysine-glutamine and XPC-
glutamine-glutamine variants) to be associated with higher levels of AFB1-DNA adducts in leucocytes
(ELISA) (Long et al., 2015).
Eight single nucleotide polymorphisms (SNPs), including SLCO1B1, SLCO1B3, GSTT1, GSTM1,
GSTA1, GSTP1, CYP2E1 and CYP3A4, were determined in a case–control study in a rural Chinese area
with 475 patients with liver damage and 475 controls. For SLCO1B1 (T521C), a member of the solute
carrier transporter family, the OR of genotype TC vs TT was 0.743, indicating a reduced risk. No clear
associations were observed for the other SNPs (Yang et al., 2017b). A study located in the Guangxi
region (China), comprising 181 cases of HCC and 641 probands without carcinoma, found an increased
risk for HCC in individuals with the GSTM1-null or GSTT1-null genotype (Wei et al., 2012).
Between 2006 and 2018 there have been several reports on the role of genetic polymorphisms in
DNA repair genes in aﬂatoxin-associated HCC from the Guangxi Zhang Autonomous Region of China, a
high-risk region for aﬂatoxin exposure and HCC. In a case–control study on 491 HCC cases and 862
controls, Long et al. (2008) reported an increased risk of HCC in individuals with the XRCC3 codon 241
methionine/threonine or methionine/methionine variants compared with those homozygous for
threonine at codon 241. The adjusted OR for HCC among met homozygotes versus threonine
homozygotes was 7.19 (95% CI: 4.52–11.42). Having high levels of AFB1 DNA adducts was also a risk
factor for HCC (OR 5.58, 95% CI: 4.19–7.44). In a separate case–control study in the same region,
Long et al. (2009a) reported an increased risk of HCC associated with the codon 751 glutamine
heterozygous and homozygous variants of XPD compared with the lysine homozygotes, with a higher
risk in women than men. No association with HCC risk was observed for the XPD codon 312
polymorphism in this population. In a separate investigation with 1,156 HCC cases and 1,402 controls,
the same group (Long et al., 2010) found an association between HCC risk and the glutamine variants
of XPC codon 939 versus the lysine homozygotes, although the effect was not large, with an OR of
1.25 (95% CI: 1.03–1.92) for the heterozygotes and 1.81 (95% CI: 1.36–2.40) for the glutamine
homozygotes. The XRCC7 rs#7003908 polymorphism was also found to modify HCC risk in the region
(Long et al., 2011), with increased risk associated with -TG or -GG variants compared with -TT; OR
3.45 (95% CI: 2.40–4.94) and OR 5.04 (95% CI: 3.28–7.76), respectively.
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3.1.4.6.3. Others
A nested case–control study in Taiwan investigated the risk of HCC in relation to aﬂatoxin exposure
and alcohol consumption; high versus low serum AF-alb levels were associated with HCC risk in
habitual alcohol consumers (OR 4.22, 95% CI: 1.16–15.37). It was suggested that alcohol
consumption modiﬁes the hepatocarcinogenic effect of AFB1 via the increased hepatocyte vulnerability
to AFB1-induced DNA damage and mutations (Chu et al., 2018).
3.1.5. Considerations of critical effects and dose–response analysis
3.1.5.1. Considerations of critical effects
It is clear from in vitro and animal studies that AFB1, AFB2, AFG1 and AFM1 are mutagenic and
also AFB1, AFG1 and AFM1 are carcinogenic when delivered orally via the diet or by gavage with the
evidence being most abundant for AFB1. There is limited evidence for the carcinogenicity of AFB2 and
inadequate evidence for carcinogenicity of AFG2. Based on evidence for AFB1, it can be concluded that
absorption occurs in the small intestine with as much as 50% of the dose reaching the liver where it is
activated. A critical step in the activation is the formation of AFB1-exo-8,9-epoxide which is known to
form adducts with DNA and proteins. Studies have shown that DNA lesions and DNA adducts such as
AFB1-N7-gua and AFB1-FAPY are formed and that these can lead to G-to-T transversions.
Effects in experimental animals
A clear dose–response relationship was observed between AFB1 and the incidence of HCC in
experimental animals, with the dose–response being linear over a wide concentration range, at least,
in rainbow trout. While AFG1 produces fewer liver tumours than AFB1, it induces more kidney tumours
in animal models. Studies in vitro have shown a difference in genotoxic potency between AFB1 and
AFG1 with the indication that AFG1 is less toxic than AFB1 by about a factor of 10 in liver cells (see
Section 3.1.2.3). While the absolute potency of AFB2 and AFG2 is not known, the literature suggests
that they are less potent than AFB1. AFM1 is known to be less effective, with a potency 0.1 times that
of AFB1 based on carcinogenicity in rats (see Section 1.3.3).
The liver is also the most sensitive organ, with AFB1 causing acute hepatotoxicity in experimental
animals. Several indicators of liver damage are altered after AFB1 exposure including biochemical
changes (upregulation of enzymes known to indicate damage), histological changes (bile duct
proliferation), increases in GST-P+, a marker of pre-neoplastic damage and formation of AFB1 adducts.
Short-term toxicity studies reported changes in liver function and gut morphology, and there is also
evidence of growth effects, with stunting and wasting being noted.
There is clear evidence for oxidative stress occurring in animals exposed to AFB1 but this was
considered secondary to the effects on the liver. Changes in the gut microbiota and immunotoxic
effects have been noted, but these occur at higher doses and are therefore not considered critical.
Exposure to AFB1 was shown to cause a number of effects on reproduction and development.
These included a shortened time to delivery and low birth weight in mice (NOAEL of 0.05 mg/kg bw
per day), effects on brain development in rats (NOAEL of 0.007–0.014 mg/kg bw per day) and adverse
effects on spermatogenesis at the lowest dose tested (0.004 mg/kg bw per day) and following a short-
term exposure. To evaluate whether these effects should be considered in the risk characterisation of
aﬂatoxins in humans, the CONTAM Panel compared the identiﬁed doses with a scenario of short-term
exposure and noted that calculated exposure is three orders of magnitude lower than the LOAEL of
4 lg/kg bw per day. Therefore, the CONTAM Panel concluded that reproductive and developmental
toxicity should not be considered further.
Effects in humans
AFB1 can cause acute aﬂatoxicosis with a high mortality rate. However, this effect is observed
following high AFB1 exposure and is not expected to occur in the EU population (see
Section 3.1.3.2.2).
There is clear evidence from the studies reported since the 1970s that aﬂatoxin exposure is
associated with a risk of HCC, with a higher risk for people infected with HBV. The studies on aﬂatoxin
and HCC published since 2006 have added to this evidence and a higher risk is now also reported for
HCV. However, there is currently insufﬁcient evidence to associate aﬂatoxin exposure with other
cancers such as gall bladder cancer and stomach cancer.
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Child health is an emerging area of interest among aﬂatoxin-related health outcomes in humans.
Adverse effects on child growth related to aﬂatoxin exposure have been reported from a growing body
of evidence from populations outside of Europe and this is supported by data from experimental animal
studies. However, the currently available evidence is weak, being characterised by small sample sizes,
heterogeneity in the assessed populations and biomarkers, varying methodological quality, and effect
inconsistency. Thus, at present, the potential for using these studies for risk assessment is limited.
Aﬂatoxin adducts, AF-alb (AFB1-lys), urinary AF-N7-gua and urinary AFM1 are all validated
biomarkers of dietary exposure to aﬂatoxin. However, these biomarkers cannot be converted reliably
into dietary exposures in individuals and can, therefore, presently not be used in dietary risk
assessments. Consequently, the new epidemiological studies which used biomarkers of exposure
cannot be used to identify a reference point.
Overall, the CONTAM Panel considers that liver carcinogenicity of aﬂatoxins remains the pivotal
effect for the risk assessment, both in experimental animals and in humans. The epidemiological study
by Yeh et al. (1989) on mortality from liver cancer in several provinces in China, and the two-year
carcinogenicity study by Wogan et al. (1974), are still considered the most suitable studies for
performing a dose–response analysis.
3.1.5.2. Dose–response analysis (including BMD modelling)
As described in Section 3.1.5.1, the CONTAM Panel considered liver carcinogenicity to be the critical
effect following oral exposure to aﬂatoxins. The CONTAM Panel selected the chronic study by Wogan
et al. (1974) in male rats for dose–response modelling of the incidence of HCC (see Table 2). A BMD
analysis was performed using the EFSA web tool, which is based on the R-package PROAST 66.38.
The BMD analysis performed followed the updated guidance of the Scientiﬁc Committee on BMD
modelling (EFSA Scientiﬁc Committee, 2017) and a detailed description of the BMD analysis performed
by the Panel can be found in Appendix III. The default benchmark response (BMR) for quantal data
was selected, i.e. an extra risk of 10%. Using model averaging, the resulting BMDL10 for the incidence
of HCC was 0.4 lg/kg bw per day (see Appendix III.1).
From the human studies, the CONTAM Panel selected the study by Yeh et al. (1989) as the pivotal
study. In 2018, the CONTAM Panel also used this study as the pivotal study and concluded, based on
wide BMD conﬁdence intervals, that it was not appropriate to use BMD analysis to identify a reference
point for risk assessment (see EFSA CONTAM Panel, 2018, for further details). Instead, the CONTAM
Panel decided to use the cancer potency estimates reported by JECFA (FAO/WHO, 2018; see
Section 1.3.3). No new information has become available that changes the previous conclusion and
the same approach was followed in the current assessment.
3.1.6. Possibilities for derivation of a health-based guidance value (HBGV)
In view of the genotoxic properties of aﬂatoxins, the CONTAM Panel considered that it was not
appropriate to establish a tolerable daily intake and considered the possibility of applying an MOE
approach. Based on studies in animals, the CONTAM Panel selected a BMDL10 of 0.4 lg/kg bw per day
for the incidence of HCC to be used in an MOE approach for the risk characterisation. The calculation
of a BMDL from the human data was not appropriate and no MOE approach could be used for these
data; instead, the cancer potency estimates reported by JECFA were used (see Section 1.3.3 for
further details).
Differences in carcinogenic potency are reported for AFB2 and AFG2 compared with AFB1 and
AFG1. However, in vivo there is insufﬁcient evidence to derive potency factors for AFB2 and AFG2.
There are indications of differences in the cancer potency between AFB1 and AFG1 in the liver with
AFB1 being more potent. In the kidney, AFG1 has a higher cancer potency than AFB1. Again, the
available data are not sufﬁcient to be able to derive an individual potency factor that can be used in
the risk assessment. Therefore, in the absence of new in vivo data to quantify differences between the
individual aﬂatoxins the CONTAM Panel applied equal potency factors for AFB1, AFB2, AFG1 and AFG2
as used in previous assessments. The CONTAM Panel considers that this conservative approach is
appropriate in this case, but notes the uncertainty arising from the insufﬁcient data available on AFB2
and AFG2. For AFM1, JECFA (FAO/WHO, 1999, 2001, 2018) concluded, based on a study in Fischer
rats, that AFM1 induces liver cancer with a potency one tenth that of AFB1. No new evidence has
become available that necessitates a change to this conclusion and a potency factor of 0.1 was used in
this assessment for AFM1.
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3.2. Occurrence data
3.2.1. Occurrence data on food as submitted to EFSA
An initial number of 533,953 analytical results (analysed from 153,091 samples) for food and
beverage samples on aﬂatoxins from 29 European countries were available in the EFSA database.
Analytical results were reported either as individual results for AFB1, AFB2, AFG1, AFG2, aﬂatoxin G5
(AFG5), AFM1 and AFM2 or as AFT (the sum of AFB1, AFB2, AFG1, AFG2). AFG5 and AFM2 were not
included in the present assessment due to the limited number of analytical results for them. In
addition, a part of the data was classiﬁed as ‘Aﬂatoxins’ without further speciﬁcation given (Annex B,
Table B.1). Data were reported on samples collected between the years 2003 and 2018 with most of
the data collected after 2007. However, in order to reﬂect the current contamination levels, only the
most recent data were used in the assessment (from 2013 onwards).
The occurrence data were carefully evaluated, and a list of validation steps was applied before
being used to estimate dietary exposure (see Annex B, Table B.2 for further details). The ﬁnal data set
comprised 209,802 analytical results (analysed from a total of 69,166 samples) on AFB1 (n = 57,983),
AFB2 (n = 49,093), AFG1 (n = 49,325), AFG2 (n = 45,534) and AFM1 (n = 7, 867).
An evaluation of the LOQs was performed. As a ﬁrst step, analytical results were excluded for
which the LOQ was higher than the ML in force. This concerned the data for AFB1, AFB2,19 AFG1 and
AFG2 reported for processed cereal-based foods and baby foods for infants and young children and
the data for AFM1 reported for infant formulae, while for other food categories the LOQs were lower
than MLs. Considering the large amount of left-censored data present in the data set (around 90%),
the presence of relatively high LODs/LOQs may have a signiﬁcant inﬂuence on the UB scenario. In
order to reduce this impact, but without compromising the number of analytical results available on
food categories mainly contributing to the exposure to aﬂatoxins, a careful evaluation of LOQs was
performed. This evaluation was based on the EFSA internal guidance on the application of LOD/LOQ
cut-offs (EFSA, 2018a). Special attention was paid to those food categories that are considered to be
potentially important contributors to the dietary exposure to aﬂatoxins and for which the difference
between the LB and UB mean concentration was larger than 30%. Four main food categories,
including ‘Grains and grain-based products’, ‘Vegetables and vegetable products’, ‘Legumes, nuts and
oilseeds’ and ‘Fruit and fruit products’ were identiﬁed for AFB1, AFB2, AFG1 and AFG2 and the food
category ‘Milk and dairy products’ for AFM1. To identify the most appropriate LOQ cut-off values, the
distributions of quantiﬁed values (values above LOQ) as well as the reported LOQs were evaluated. A
percentile (75th or 90th) derived from the quantiﬁed values was selected as a cut-off value and
subsequently applied to the LOQs reported (Annex B, Table B.3).
Approximately 95% of the data were obtained for samples collected within the ofﬁcial monitoring
programmes, while the remaining samples from unspeciﬁed surveys, surveillance and monitoring
programmes. Regarding the sampling strategy, a part of the analytical results (12%) was obtained by
suspect sampling. There were no differences observed between mean concentrations of samples
collected via different sampling strategies. Therefore, the CONTAM Panel decided not to exclude any
samples on the basis of the sampling strategy.
The analytical results included in the ﬁnal data set and considered for the dietary exposure to
aﬂatoxins were collected in 26 different European countries, most of them in Germany and the
Netherlands (27% of analytical results for each), followed by France (11% of analytical results).
Figure 3 shows the distribution of analytical results for AFB1, AFB2, AFG1, AFG2 and AFM1 collected.
It should be noted that the origin of the samples was not always the European country reporting the
data, i.e. the data set also contained samples originating from North and South America, Africa, Asia
and Australia. The samples were collected between 2013 and 2018 and the number of samples per
year is presented in Figure 4 for AFB1, AFB2, AFG1, AFG2 and AFM1.
19 Assuming the same ML for AFB2, AFG1 and AFG2 as for AFB1.
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Table 7 shows the number of analytical results and the percentage of left-censored data per
substance and food category at FoodEx level 1. Most of the analytical results were available for AFB1
(n = 57,983). About 50,000 analytical results were available for AFB2, AFG1 and AFG2 while results for
AFM1 were far fewer (n = 7,867). For each substance, a high proportion of left-censored data was
observed, ranging from 78% for AFM1 to 98% for AFG2 (Table 7).
The most frequently analysed food categories were ‘legumes, nuts and oilseeds’, ‘fruit and fruit
products’ and ‘grains and grain-based products’. A substantial amount of data was also available for
many other food categories, while some of them, e.g. ‘eggs and egg products’, ‘ﬁsh and other seafood’
and ‘non-alcoholic beverages’, were much less represented (Table 7).
Figure 4: Distribution of analytical results for AFB1, AFB2, AFG1, AFG2 and AFM1 by sampling year
(after excluding non-qualifying data)
AT: Austria; BE: Belgium; BG: Bulgaria; CY: Cyprus; CZ: Czech Republic; DE: Germany; DK: Denmark; EE: Estonia;
ES: Spain; FI: Finland; FR: France; HR: Croatia; HU: Hungary; IE: Ireland; IT: Italy; LT: Lithuania; LU: Luxembourg;
MT: Malta; NL: Netherlands; PO: Poland; PT: Portugal; RO: Romania; SE: Sweden; SI: Slovenia; SK: Slovakia; UK:
United Kingdom.
Figure 3: Distribution of analytical results for AFB1, AFB2, AFG1, AFG2 and AFM1 collected from
European countries (after excluding non-qualifying data)
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3.2.1.1. Analytical methods
As speciﬁed in Section 3.2.1 (for more detail see Annex B, Tables B.2 and B.3), some of the
analytical results obtained by analytical methods with high LOD/LOQ were not included in the ﬁnal
data set. Most results were obtained by LC-FD (34%) and LC–MS-based methods (33%). Gas
chromatography-based methods and immunochemical tests, particularly ELISAs, were also used. For
the remaining samples, no information on the analytical method was reported.
The distribution of the LOQs for the individual AFB1, AFB2, AFG1, AFG2 and AFM1 across the
FoodEx level 1 food categories is summarised in Annex B, Table B.4. No particular variability of LOQs
was observed across the food categories with the median LOQs being up to 1 lg/kg for AFB1 and
AFB2, up to 2 lg/kg for AFG1 and AFG2 and up to 0.02 lg/kg for AFM1.
3.2.1.2. Occurrence data considered for dietary exposure assessment
The text below describes the occurrence data for AFB1, AFM1 and AFT. Detailed statistical
description of the AFB1, AFB2, AFG1, AFG2, AFM1 and AFT occurrence data according to FoodEx levels
1, 2 and 3 are reported in Annex B, Tables B.5 (level 1), B.6 (level 2) and B.7 (level 3). In addition,
the summary of occurrence data including the number of results, percentage of left-censored data and
Table 7: Distribution of analytical results per toxin and food category
FoodEx level 1 food
category
AFB1 AFB2 AFG1 AFG2 AFM1
N LCD N LCD N LCD N LCD N LCD
Grains and grain-based
products
8,979 94% 6,617 98% 6,793 99% 4,868 99% 2 100%
Vegetables and
vegetable products
777 90% 867 97% 867 98% 395 98% – –
Starchy roots and
tubers
53 91% 50 96% 50 96% 50 96% – –
Legumes, nuts and
oilseeds
27,772 86% 24,839 94% 24,877 94% 24,870 98% 1 100%
Fruit and fruit products 9,577 88% 8,532 95% 8,554 91% 7,037 98% – –
Meat and meat
products
671 99% 121 98% 121 98% 121 98% – –
Fish and other seafood 89 94% 34 88% 34 94% 34 94% – –
Milk and dairy products 22 73% 17 76% 17 76% 17 76% 6,878 76%
Eggs and egg products – – – – – – – – 2 100%
Sugar and
confectionery
878 78% 779 94% 779 86% 781 95% 1 100%
Animal and vegetable
fats and oils
836 81% 807 94% 806 93% 806 98% 26 96%
Fruit and vegetable
juices
146 99% 145 100% 145 99% 145 100% – –
Non-alcoholic
beverages
41 98% 38 97% 38 100% 38 100% – –
Alcoholic beverages 383 100% 381 100% 381 100% 381 100% – –
Herbs, spices and
condiments
5,548 71% 4,712 92% 4,711 90% 4,838 95% – –
Food for infants and
small children
1,433 97% 443 99% 441 99% 442 99% 895 89%
Products for special
nutritional use
116 97% 101 100% 101 100% 101 100% 4 100%
Composite food 101 90% 93 94% 93 95% 93 95% 2 50%
Snacks, desserts, and
other foods
561 85% 517 96% 517 92% 517 99% 56 96%
Total 57,983 87% 49,093 95% v49,325 94% 45,534 98% 7,867 78%
N: number of analytical results; LCD: left-censored data; AFB1: aﬂatoxin B1; AFB2: aﬂatoxin B2; AFG1: aﬂatoxin G1; AFG2
aﬂatoxin G2; AFM1: aﬂatoxin M1.
Aﬂatoxins in food
www.efsa.europa.eu/efsajournal 55 EFSA Journal 2020;18(3):6040
the mean LB and UB concentrations for AFB1, AFM1, AFT and AFT+M1 according to the FoodEx food
categories as used for exposure assessment are reported in Annex B, Table B.8.
Occurrence data on AFB1
Table 8 provides a summary of occurrence data on AFB1 across the FoodEx level 1 food categories
including the number of results, percentage of left-censored data and statistical descriptors of the
results (mean, median, and 95th percentile). More detail on statistical description and according to
lower FoodEx levels are reported in Annex B, Tables B.5–B.7.
The occurrence data on AFB1 were available for 18 FoodEx level 1 food categories. The data set
was characterised by a high proportion of left-censored data. The highest number of available data
points corresponded to the food category ‘legumes, nuts and oilseeds’, in particular to different tree
nuts (e.g. pistachios, hazelnuts, walnuts, etc.) and to peanuts. The highest AFB1 mean concentrations
were obtained for the food category ‘legumes, nuts and oilseeds’, in particular for pistachios, peanuts
and ‘other seeds’ and for the food category ‘herbs, spices and condiments’, in particular for anise
pepper and ﬂavourings and essences.
Comparison of the occurrence of AFB1 in selected food categories over the sampling
years
The CONTAM Panel considered that it might be of interest to evaluate the contamination frequency
and concentrations of AFB1 over the last decade. For this purpose, the proportion of left-censored
data and the mean concentrations of the quantiﬁed analytical results of AFB1 for selected food
categories (i.e. pistachios, hazelnuts, other tree nuts, peanuts and dried ﬁgs) sampled between 2008
and 2017 were evaluated (Annex C and Figures C.1–C.5). A low variability of contamination frequency
over the years was observed for pistachios and peanuts, while for other food categories the proportion
of left-censored data showed wider ranges (e.g. for hazelnuts it ranged from 17% in 2014 to 42% in
2008). Generally, the proportion of left-censored data seems to have increased over the time period.
The mean AFB1 concentrations did not show a clear trend within any food category over the last
Table 8: Summary of the AFB1 occurrence data by food category (lg/kg)
Food category, FoodEx level 1 N %LCD
Mean Median(a) P95(b)
LB UB LB UB LB UB
Grains and grain-based products 8,979 94 0.15 0.57 0 0.42 0.17 1.00
Vegetables and vegetable products 777 90 0.34 0.95 0 1.00 1.26 1.26
Starchy roots and tubers 53 91 0.53 0.87 0 0.30 – –
Legumes, nuts and oilseeds 27,772 86 1.72 2.18 0 0.60 3.60 3.60
Fruit and fruit products 9,577 88 0.64 0.97 0 0.20 1.63 1.63
Meat and meat products 671 99 0.01 0.17 0 0.10 0.00 0.60
Fish and other seafood 89 94 0.05 0.22 0 0.10 0.28 1.50
Milk and dairy products 22 73 0.07 0.23 0 0.20 – –
Sugar and confectionery 878 78 0.25 0.47 0 0.20 0.90 1.00
Animal and vegetable fats and oils 836 81 0.80 1.02 0 0.20 2.10 2.10
Fruit and vegetable juices 146 99 0.02 1.00 0 1.00 0.00 1.00
Non-alcoholic beverages 41 98 0.02 0.78 0 1.00 – –
Alcoholic beverages 383 100 0.00 0.88 0 1.00 0.00 1.00
Herbs, spices and condiments 5,548 71 1.29 1.74 0 0.62 4.10 4.20
Food for infants and small children 1,433 97 0.00 0.06 0 0.03 0.00 1.00
Products for special nutritional use 116 97 0.07 0.48 0 0.20 0.00 1.00
Composite food 101 90 0.04 0.73 0 1.00 0.18 1.00
Snacks, desserts, and other foods 561 85 0.37 0.58 0 0.20 1.20 1.66
N: number of analytical results; % LCD: proportion of left-censored data; P95: 95th percentile; LB: lower bound; UB: upper
bound; AFB1: aﬂatoxin B1.
(a): Due to the high proportion of left-censored data, the distribution of the LB concentrations is right-skewed. Therefore, the LB
median results to be zero.
(b): The 95th percentiles obtained on occurrence data with fewer than 60 analytical results may not be statistically robust
(EFSA, 2011b) and are therefore not reported in the table.
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10 years. It should be noted that for some years only a limited number of data was available which
may have inﬂuenced the results.
Comparison of the occurrence of AFB1 in foods from conventional and organic farming
A total of 14,733 analytical results of AFB1 with a clear speciﬁcation of the production method were
available in the data set. The food categories with a sufﬁcient number of results (n ≥ 40) were
selected and a comparison of the AFB1 concentrations between conventional and organic farming was
carried out (Annex D, Table D.1). Using conventional farming, for several food categories, in particular
for peanuts, tree nuts and vegetable fat, higher mean LB AFB1 concentrations were observed, while
for other food categories the mean LB AFB1 concentrations were similar or lower (e.g. cereal-based
food for infants and young children). Since the number of samples of the organic food products was
considerably lower than for the conventional ones and the sampling countries and sampling years were
not the same, it was not possible to draw a ﬁrm conclusion.
Occurrence data on AFT
The occurrence data for AFT were calculated from the analytical results of the individual aﬂatoxins
(for more detail see Section 2.3.2). By this approach, a total of 44,327 samples were available for the
assessment of the AFT.
Table 9 provides a summary of occurrence data on AFT across the FoodEx level 1 food categories
including the number of results and statistical descriptors of the results (mean, median and 95th
percentile). More details on statistical description and according to lower FoodEx levels are reported in
Annex B, Tables B.5–B.7.
The occurrence data on AFT covered 18 FoodEx level 1 food categories with the majority of
samples available for ‘legumes, nuts and oilseeds’ (n = 24,507) belonging mostly to different tree nuts
(e.g. pistachios, hazelnuts, walnuts, etc.) and to peanuts. The highest AFT mean concentrations were
observed for the same FoodEx level 1 food category, in particular for pistachios, peanuts and ‘other
seeds’. High mean AFT levels were also measured for the food category ‘herbs, spices and condiments’
(i.e. anise pepper and ﬂavourings and essences) and ‘animal and vegetable fats and oils’ (i.e.
vegetable fat with the majority of samples being hazelnut and other unspeciﬁed nut pa^te/paste).
Table 9: Summary of the AFT occurrence data by food category (lg/kg)
Food category, FoodEx level 1 N
Mean Median(a) P95(b)
LB UB LB UB LB UB
Grains and grain-based products 4,860 0.10 0.65 0.00 0.40 0.50 2.00
Vegetables and vegetable products 389 0.40 1.21 0.00 0.40 1.60 2.00
Starchy roots and tubers 50 0.95 1.68 0.00 0.60 – –
Legumes, nuts and oilseeds 24,507 2.39 3.47 0.00 1.20 5.90 6.90
Fruit and fruit products 6,254 1.09 1.53 0.00 0.40 3.40 3.80
Meat and meat products 120 0.05 0.25 0.00 0.20 0.00 0.55
Fish and other seafood 34 0.20 0.43 0.00 0.20 – –
Milk and dairy products 17 0.35 0.65 0.00 0.40 – –
Sugar and confectionery 778 0.44 0.85 0.00 0.40 2.17 2.94
Animal and vegetable fats and oils 802 1.16 1.68 0.00 0.40 2.73 3.70
Fruit and vegetable juices 145 0.04 2.01 0.00 2.00 0.00 2.00
Non-alcoholic beverages 38 0.03 1.68 0.00 2.00 – –
Alcoholic beverages 381 0.00 1.76 0.00 2.00 0.00 2.00
Herbs, spices and condiments 4,809 1.74 2.77 0.00 1.40 5.30 6.66
Food for infants and small children 441 0.00 0.19 0.00 0.10 0.00 1.20
Products for special nutritional use 101 0.08 0.96 0.00 0.40 0.00 2.00
Composite food 93 0.12 1.58 0.00 2.00 0.77 2.00
Snacks, desserts, and other foods 508 0.52 0.89 0.00 0.40 1.70 2.20
N: number of samples; P95: 95th percentile; LB: lower bound; UB: upper bound; AFT: aﬂatoxin total.
(a): Due to the high proportion of left-censored data, the distribution of the LB concentrations is right-skewed. Therefore, the LB
median results to be zero.
(b): The 95th percentiles obtained on occurrence data with fewer than 60 analytical results may not be statistically robust
(EFSA, 2011b) and are therefore not reported in the table.
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The relative contribution of the individual AFB1, AFB2, AFG1 and AFG2 to the AFT MB concentration
was calculated for the food categories for which a sufﬁcient number of samples were available (i.e.
tree nuts, peanuts and dried ﬁgs). Only samples for which at least one aﬂatoxin was quantiﬁed were
included. Based on these individual contributions within each sample, the distribution of the
contributions, including the mean, median, 5th, 25th 75th and 95th percentiles, was calculated
(Table 10). On average, AFB1 contributed about 60% to the MB concentration of AFT and therefore
can be considered as the major contributor to the AFT MB concentration. However, it should be noted
that for some samples AFG1 contributed considerably as indicated by a relatively high contribution
observed at the 95th percentile (68% for tree nuts and 75% for dried ﬁgs) (Table 10).
Occurrence data on AFM1
Quantiﬁed analytical results on AFM1 were obtained only for milk-based foods. The highest AFM1
mean concentrations were reported for the food category ‘milk and dairy products’ and milk-based
food belonging to the category ‘food for infants and small children’. In particular, Parmigiano-Reggiano
cheese was the milk-based food with the highest reported mean AFM1 concentration.
Table 11 provides a summary of the occurrence data on AFM1 across the FoodEx level 1 and 2
food categories, including the number of results, percentage of left-censored data and statistical
descriptors of the results (mean, median and 95th percentile). More detail on the statistical description
and according to lower FoodEx levels are reported in Annex B, Tables B.5–B.7.
Table 10: Contribution (%) of the individual AFB1, AFB2, AFG1 and AFG2 to the AFT middle-bound
concentration in all samples of tree nuts, peanuts and dried ﬁgs where quantiﬁed
amounts of at least one aﬂatoxin were reported
Substance Food category N Mean
Percentile
5th 25th 50th 75th 95th
AFB1 Tree nuts 2,442 60 17 37 63 84 93
Peanuts 1,188 69 25 62 75 83 90
Dried ﬁgs 1,087 56 13 38 59 79 92
AFB2 Tree nuts 2,442 8 2 4 7 10 19
Peanuts 1,188 13 3 9 13 18 24
Dried ﬁgs 1,087 9 2 4 6 11 21
AFG1 Tree nuts 2,442 27 0 5 19 48 68
Peanuts 1,188 22 1 6 17 36 58
Dried ﬁgs 1,087 30 1 8 24 49 75
AFG2 Tree nuts 2,442 8 0 2 6 10 26
Peanuts 1,188 16 0 4 11 27 45
Dried ﬁgs 1,087 6 0 2 4 7 17
N: number of samples; AFB1: aﬂatoxin B1; AFB2: aﬂatoxin B2; AFG1: aﬂatoxin G1; AFG2 aﬂatoxin G2; AFT: aﬂatoxin total.
Table 11: Summary of the AFM1 occurrence data by food category (lg/kg)
Food category N %LCD
Mean Median(a),(b) P95(b)
LB UB LB UB LB UB
Milk and dairy products (Level 1) 6,878 76 0.023 0.035 0 0.014 0.092 0.092
Milk and dairy products 70 89 0.001 0.012 0 0.010 0.013 0.023
Liquid milk 6,020 76 0.018 0.031 0 0.015 0.087 0.087
Milk-based beverages 28 93 0.001 0.011 0 0.007 – –
Concentrated milk 168 81 0.037 0.044 0 0.005 0.018 0.036
Whey and whey products (excluding whey
cheese)
13 92 0.003 0.006 0 0.005 – –
Cream and cream products 114 96 0.000 0.009 0 0.010 0.000 0.020
Fermented milk products 96 94 0.052 0.069 0 0.011 1.000 1.000
Milk derivatives 8 25 0.044 0.045 0.028 0.028 – –
Aﬂatoxins in food
www.efsa.europa.eu/efsajournal 58 EFSA Journal 2020;18(3):6040
Comparison of the occurrence of AFM1 in foods from conventional and organic farming
A sufﬁcient number of samples for which the production method was reported was only available
for the food category ‘liquid milk’. In total, 76 and 143 analytical results coming from organic and
conventional farming, respectively, were retrieved from the data set. It should be noted that this sub-
data set comprised a large amount of left-censored data and the AFM1 concentrations are lower than
those in the data set as a whole of AFM1 concentrations in liquid milk (see Table 11). Bearing this
limitation in mind, the mean LB AFM1 level in liquid milk was much lower in samples obtained from
organic farming than from conventional farming (Annex D, Table D.2).
3.2.2. Levels of biomarkers of exposure in the European population
A limited number of studies have been published that measure the presence of aﬂatoxin biomarkers
in urine and serum for the European population. However, only results on validated biomarkers (see
Section 3.1.3.1) are reported in this Scientiﬁc Opinion (Appendix IV, Table IV.1).
Although AFM1 in human milk is not a validated biomarker against dietary exposure, it is a useful
indicator of exposure of infants. Globally, large regional differences in AFM1 levels in human milk have
been reported (Degen et al., 2013; Cherkani-Hassani et al., 2016) and therefore the CONTAM
Panel only reports detailed information for European countries. Appendix IV, Table IV.2, gives an
overview of the concentrations of AFM1 in human milk reported in scientiﬁc literature for the European
population. Concentrations are highly variable and range from < LOD to 570 ng/L. The percentage of
samples that contained detectable AFM1 concentrations also varied widely (from 5% to 100%) among
the studies.
3.2.3. Processing
Food processing may inﬂuence the concentration of aﬂatoxins in food products. Milling of cereals
distributes the aﬂatoxins among the different milling products but does not destroy them. Grain sorting
and cleaning, on the other hand, may lead to a reduction by the removal of contaminated kernels.
Heat treatments such as roasting and baking can reduce the concentration of aﬂatoxins, but a
complete reduction is not achieved (FAO/WHO, 2018).
Food category N %LCD
Mean Median(a),(b) P95(b)
LB UB LB UB LB UB
Cheese 359 53 0.097 0.107 0 0.050 0.415 0.415
Milk and milk product imitates 2 100 0.000 0.007 – – – –
Food for infants and small children
(Level 1)
895 89 0.036 0.053 0 0.010 0.023 0.050
Food for infants and small children 85 53 0.124 0.204 0 0.018 1.000 1.000
Infant formula, powder 354 90 0.060 0.071 0 0.010 1.000 1.000
Follow-on formula, powder 243 100 0 0.010 0 0.010 0 0.025
Cereal-based food for infants and young
children
43 100 0 0.010 0 0.012 – –
Ready-to-eat meal for infants and young
children
7 86 0.003 0.018 0 0.020 – –
Yoghurt, cheese and milk-based dessert for
infants and young children
3 100 0.000 0.040 – – – –
Fruit juice and herbal tea for infants and
young children
1 100 0.000 0.013 – – – –
Infant formula, liquid 54 78 0.005 0.015 0 0.018 – –
Follow-on formula, liquid 105 92 0.002 0.007 0 0.003 0.023 0.023
N: number of analytical results; % LCD: proportion of left-censored data; P95: 95th percentile; LB: lower bound; UB: upper
bound; AFM1: aﬂatoxin M1.
(a): Due to the high proportion of left-censored data, the distribution of the LB concentrations is right-skewed. Therefore, the LB
median results to be zero.
(b): The 95th percentiles obtained on occurrence data with fewer than 60 analytical results and the median obtained on
occurrence data with fewer than six analytical results may not be statistically robust (EFSA, 2011b) and are therefore not
reported in the table.
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Levels of aﬂatoxins in nuts are reduced during roasting and the effect increases with increased
duration and temperature. Yazdanpanah et al. (2005) reported a reduction of the AFB1 concentration in
pistachios of more than 95% following a roasting step of 120 min at 150°C. However, the product was
no longer edible. Ari~no et al. (2009) on the other hand applied a commercial roasting process of 20 min
at 120°C to naturally contaminated raw pistachios but no reduction was noted. It should be noted that
the initial AFB1 concentration was low (< 0.2 lg/kg). Martins et al. (2017) applied different time–
temperature combinations for the roasting of peanuts and achieved reductions of up to 90%. However,
colour analysis with roasted peanut samples available on the market showed that only roasting at 160°C
for 5 min gave a similar darkness and this roasting process only led to a reduction of 15%.
In addition, some authors report that the percentage of aﬂatoxin reduction during roasting of nuts
also depends on the initial aﬂatoxin concentration, with a higher reduction percentage for more
contaminated samples (Yazdanpanah et al., 2005; Zivoli et al., 2014; Martins et al., 2017). For
example, Martins et al. (2017) reported reductions of 55, 64 and 81% for initial aﬂatoxin
concentrations of 35, 332 and 695 lg/kg, respectively, following 20 min roasting at 180°C. However,
this observation was not conﬁrmed by Arzandeh and Jinap (2011). They noted a decrease in the
aﬂatoxin reduction when the initial aﬂatoxin concentration exceeded 200 lg/kg.
3.3. Dietary exposure assessment for humans
3.3.1. Current dietary exposure assessment
The CONTAM Panel assessed the dietary chronic exposure (following the methodology described in
Section 2.6) to the individual AFB1 and AFM1, and the overall AFT and AFT+AFM1 exposure. Analytical
results for AFT were generated by summing up the available individual concentrations of all four
aﬂatoxin forms (AFB1, AFB2, AFG1 and AFG2) for each sample as explained in Section 2.3.2. Analytical
results for AFT+AFM1 were generated by combining AFT concentrations and AFM1 concentrations
multiplied by a factor of 0.1 based on differences in carcinogenic potency (for more detail see
Section 3.1.6).
A summary of the occurrence data on AFB1, AFM1, AFT and AFT + AFM1 including the number of
results, percentage of left-censored data and mean concentrations across the FoodEx Level food
categories as used for exposure assessment is presented in Annex B, Table B.8.
Overall, it should be kept in mind that a high proportion of left-censored data has a major impact
on the exposure estimates; the exposure is likely to be underestimated with the LB approach and
overestimated with the UB approach.
3.3.1.1. Mean and high chronic dietary exposure
Mean and high dietary chronic exposure to AFB1
Table 12 shows summary statistics for the assessment of chronic dietary exposure to AFB1.
Detailed mean and 95th percentile dietary exposure estimates calculated for each of the 38 dietary
surveys are presented in Annex E, Table E.1.
Table 12: Summary statistics for the chronic dietary exposure to AFB1 (ng/kg bw per day) across
European countries
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)
Infants 0.08 0.58 0.18 2.01 0.60 4.87
Toddlers 0.43 3.15 0.64 5.35 1.05 6.95
Other children 0.47 3.46 0.76 4.93 1.78 6.12
Adolescents 0.27 1.99 0.40 2.98 1.24 4.27
Adults 0.22 1.35 0.33 2.15 0.49 3.25
Elderly 0.19 1.32 0.26 1.90 0.31 2.91
Very elderly 0.18 1.41 0.26 2.07 0.41 2.93
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The highest estimated chronic dietary exposure to AFB1 was in the young population groups.
Concerning the mean dietary exposure, the highest estimated LB exposure levels were in other
children with a maximum exposure of 1.78 ng/kg bw per day, while the highest UB exposure was
observed for toddlers (6.95 ng/kg bw per day). The highest LB 95th percentile exposure was for other
children with estimates of 6.22 ng/kg bw per day and the highest UB 95th percentile exposure was
estimated for toddlers (14.01 ng/kg bw per day).
Dietary exposure in speciﬁc groups of the population, namely ‘Pregnant women’ and ‘Lactating
women’, were within the range of exposure estimates for the adult population.
Mean and high chronic dietary exposure to AFM1
Table 13 shows summary statistics for the assessment of chronic dietary exposure to AFM1.
Detailed mean and 95th percentile dietary exposure estimates calculated for each of the 38 dietary
surveys are presented in Annex E, Table E.2.
Age group
Minimum Median Maximum
LB UB LB UB LB UB
95th percentile dietary exposure in total population (ng/kg bw per day)
Infants(a) 0.35 2.79 0.74 5.18 1.84 13.03
Toddlers(a) 0.77 6.80 1.46 9.69 2.88 14.01
Other children 1.17 6.03 1.58 8.71 6.22 11.88
Adolescents(a) 0.70 3.25 0.98 5.61 4.62 8.62
Adults 0.62 2.76 0.87 4.24 1.36 6.78
Elderly 0.47 2.76 0.62 3.72 1.10 5.26
Very elderly(a) 0.42 2.81 0.56 3.86 0.93 5.05
AFB1: aﬂatoxin B1; bw: body weight; LB: lower bound; UB: upper bound.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with fewer than 60 observations may not be
statistically robust (EFSA, 2011b) and are therefore not included in this table.
Table 13: Summary statistics for the chronic dietary exposure to AFM1 (ng/kg bw per day) across
European countries
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)
Infants 0.14 0.21 0.57 0.81 1.56 1.98
Toddlers 0.45 0.64 0.68 1.05 1.42 1.81
Other children 0.18 0.28 0.35 0.52 0.78 1.00
Adolescents 0.08 0.12 0.15 0.23 0.25 0.37
Adults 0.05 0.06 0.08 0.12 0.14 0.20
Elderly 0.04 0.06 0.08 0.12 0.14 0.18
Very elderly 0.04 0.06 0.08 0.11 0.15 0.22
Pregnant women 0.09 0.11 0.11 0.15 0.13 0.20
Lactating women 0.14 0.20 0.18 0.25 0.22 0.29
95th percentile dietary exposure in total population (ng/kg bw per day)
Infants(a) 0.66 0.98 1.48 2.06 6.23 7.88
Toddlers(a) 1.05 1.49 1.47 2.18 3.80 4.85
Other children 0.43 0.62 0.80 1.26 2.16 2.73
Adolescents(a) 0.22 0.31 0.37 0.58 0.48 0.69
Adults 0.13 0.16 0.25 0.32 0.39 0.54
Elderly 0.12 0.16 0.24 0.32 0.38 0.48
Very elderly(a) 0.17 0.25 0.25 0.31 0.34 0.45
Pregnant women 0.21 0.27 0.28 0.38 0.34 0.49
Lactating women 0.34 0.46 0.38 0.51 0.41 0.56
AFM1: aﬂatoxin M1; bw: body weight; LB: lower bound; UB: upper bound.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with fewer than 60 observations may not be
statistically robust (EFSA, 2011b) and are therefore not included in this table.
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The highest estimated chronic dietary exposure to AFM1 was in infants and toddlers, which can be
explained by their speciﬁc consumption patterns that are mostly based on milk and milk products.
Concerning the mean dietary exposure, the highest estimated LB and UB exposure levels were in
infants with a maximum LB/UB exposure of 1.56/1.98 ng/kg bw per day. The highest LB/UB 95th
percentile exposure was also observed for infants, with estimates of 6.23/7.88 ng/kg bw per day.
Dietary exposure in the speciﬁc population group ‘Pregnant women’ was within the range of
exposure estimates observed for the adult population. ‘Lactating women’ showed higher exposure
levels than those estimated for the adult population, with the median mean exposure levels being
twice as high. This outcome is driven by an increased consumption of milk and milk products during
the lactating period.
Mean and high chronic dietary exposure to AFT+AFM1
Table 14 shows summary statistics for the assessment of chronic dietary exposure to AFT+AFM1.
Detailed mean and 95th percentile dietary exposure estimates calculated for each of the 38 dietary
surveys are presented in Annex E, Table E.3.
The highest estimated chronic dietary exposure to AFT+AFM1 was in the young population groups.
Among the mean dietary exposures calculated for toddlers, the highest LB estimate amounted to
2.05 ng/kg bw per day while the highest UB estimate amounted to 12.54 ng/kg bw per day in other
children. The highest LB 95th percentile exposure was for toddlers with estimates of 4.45 ng/kg bw
per day and the highest UB 95th percentile exposure was estimated for infants (29.56 ng/kg bw per
day). Overall, the chronic dietary exposure estimates for AFT+AFM1 are higher than those calculated
for the individual AFB1, with the exception of the highest LB 95th percentile in other children and
adolescents. This is explained by the high consumption of candy recorded in several dietary surveys
and for which an AFB1 mean occurrence level was higher than the mean occurrence level obtained by
summing the individual aﬂatoxins (due to the loss of one sample not being analysed for all four
aﬂatoxins). Moreover, the food category ‘candies with sugar’ was considered as a separate food
category in the exposure assessment for AFB1 while for the AFT+AFM1 exposure it was merged with
the upper level food category ‘confectionery (non-chocolate)’ due to the limited amount of data.
Table 14: Summary statistics for the chronic dietary exposure to AFT+AFM1(b) (ng/kg bw per day)
across European countries
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)
Infants 0.18 0.88 0.42 2.58 1.01 9.92
Toddlers 0.74 5.09 1.23 9.14 2.05 12.51
Other children 0.87 5.32 1.22 8.63 1.92 12.54
Adolescents 0.43 2.87 0.64 5.19 1.05 6.98
Adults 0.35 2.29 0.55 4.00 0.80 6.60
Elderly 0.28 2.11 0.46 3.68 0.58 6.51
Very elderly 0.31 2.53 0.43 3.75 0.60 6.61
95th percentile dietary exposure in total population (ng/kg bw per day)
Infants(a) 0.65 4.03 1.16 7.43 3.27 29.56
Toddlers(a) 1.29 8.25 2.33 15.33 4.45 27.05
Other children 1.70 7.50 2.30 16.08 4.40 22.92
Adolescents(a) 1.06 4.81 1.41 11.54 2.56 13.15
Adults 0.83 4.36 1.25 9.16 2.30 14.20
Elderly 0.65 4.40 1.01 7.58 1.59 12.34
Very elderly(a) 0.73 5.11 0.95 8.85 1.44 13.34
AFT: aﬂatoxin total; AFM1: aﬂatoxin M1; bw: body weight; LB: lower bound; UB: upper bound.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with fewer than 60 observations may not be
statistically robust (EFSA, 2011b) and are therefore not included in this table.
(b): Dietary exposure to AFT+AFM1 was calculated by applying the potency factor of 0.1 to the concentrations of AFM1 (see
Section 3.1.6).
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For AFT, detailed mean and 95th percentile dietary exposure estimates calculated for each of the
38 dietary surveys are presented in Annex E, Table E4. The exposure estimates for AFT showed, in
general, lower levels than the exposure levels estimated for AFT+AFM1, particularly for population
groups of small children.
3.3.1.2. Contributions of different food groups
The contribution (%) of each of the FoodEx level 1 food categories to total mean exposure of
AFB1, AFM1, AFT and AFT+M1 was calculated for each age group and dietary survey. Estimations of
exposure using the LB approach, which is considered to be less inﬂuenced by the value of the LOD/
LOQ, were used to explain the contribution of the different food categories. The contribution of
individual food categories to the LB mean chronic dietary exposure to AFB1, AFM1, AFT and AFT+M1
varied between the dietary surveys. This is explained by the speciﬁc food consumption patterns in the
individual European countries and even in different regions of one country.
Contribution of individual food categories to the LB mean chronic dietary exposure to
AFB1
The food category ‘grains and grain-based products’ was the most important contributor to the
overall LB mean chronic dietary exposure to AFB1 across all age groups. The LB median contribution
among surveys ranges from 38% for adults to 50% for the very elderly, with contributions reaching up
to 75% in one survey of toddlers. Grains for human consumption, in particular corn grain, bread and
rolls and ﬁne bakery wares had the highest contribution among the food subcategories. The AFB1
concentrations for ‘bread and rolls’ were low; therefore the contribution is driven by high consumption
rather than the presence of AFB1. It should be noted that the majority of quantiﬁed results (i.e. above
the LOQ) of ‘ﬁne bakery wares’ contained nut-based ﬁllings and therefore it is likely that the high
contribution to the exposure to AFB1 is inﬂuenced by ingredients other than cereals.
Another very important contributor to the overall LB mean chronic dietary exposure to AFB1 was
the food category ‘legumes, nuts and oilseeds’ (contributing up to 29% for adults). In most surveys,
this high contribution was driven by peanuts (up to 24% in adults). Despite relatively high AFB1
concentrations measured in almonds, pistachios and other seeds, the exposure to AFB1 from these
foods was small, which is explained by low consumption. Similarly, different products within the food
category ‘herbs, spices and condiments’ reported with a high AFB1 level (e.g. ﬂavourings or essences)
did not make a major contribution to the overall AFB1 LB mean exposure because of the low
consumption recorded within the dietary surveys.
Speciﬁcally, in other children and adolescents, ‘sugar and confectionary’ made an important
contribution to the overall AFB1 LB mean exposure (up to 74% in both population groups). It should
be noted that this was driven by a high consumption of candies reported for a limited number of
dietary surveys. This food category had high AFB1 concentrations reported, which may be due to nuts
present in the candies.
Among young population groups, particularly in toddlers and other children, ‘animal and vegetable
fats and oils’ was also an important contributor to the overall AFB1 LB mean exposure. This was
mostly driven by a contribution of peanut butter, which is widely consumed by children in several
European countries (contributing up to 39% for toddlers).
Other food categories noted as important contributors to the overall AFB1 mean exposure were
‘fruit and fruit products’, ‘vegetables and vegetable products’ and ‘products for special nutritional use’.
The detailed contribution of the different food categories at FoodEx level 1 and grouped by age
classes is shown in Annex E, Table E.5. The detailed contribution of the different food categories at
FoodEx level as used for exposure assessment and grouped by age classes is shown in Annex E,
Table E.5 bis (A).
In addition, the CONTAM Panel calculated the main contributors to the overall AFB1 LB mean
exposure for highly exposed individuals identiﬁed as subjects having an individual AFB1 exposure
above the 75th percentile of the overall exposure calculated for the total population. In the highly
exposed adult population groups, peanuts were the major source of AFB1 exposure. Grain-based food
products also contributed considerably, however their contribution is lower as compared to the
assessment carried out for the total adult population. In the young population groups, the main
contributors are in line with those observed for the total population. The detailed contribution of the
different food categories at FoodEx level as used for the exposure assessment and grouped by age
classes calculated for highly exposed subjects is shown in Annex E, Table E.5 bis (B).
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Contribution of individual food categories to the LB mean chronic dietary exposure to
AFM1
The food category ‘milk and dairy products’ was the main contributor to the overall AFM1 LB mean
exposure throughout all age groups. The median LB contribution among surveys accounted for almost
100% in all age groups except in infants, where the ‘food for infants and small children’ food category
also made an important contribution. The main subcategories driving the contribution of the ‘milk and
dairy products’ food category were liquid milk, contributing up to 89% (other children), and fermented
milk products (e.g. yoghurt), contributing up to 87% (infants). ‘Cheese’ contributed up to 72%
(adults). The contribution of ‘snacks, desserts, and other foods’ (represented only by starchy pudding)
was negligible (less than 1% for all age groups).
The food group ‘Animal and vegetable fats and oils’ was not considered for the exposure
assessment. The 26 samples consisted of 25 samples of butter (all left-censored) and 1 sample of
butter oil (quantiﬁed concentration of AFM1). Considering the large inﬂuence of one positive sample on
a broadly consumed food group, these samples were not included in the dietary exposure assessment.
The detailed contribution of the different food categories at the FoodEx level as used for exposure
assessment and grouped by age classes is shown in Annex E, Table E.6 (A). The detailed contribution
of the different food categories at FoodEx level as used for exposure assessment and grouped by age
classes calculated for highly exposed subjects is shown in Annex E, Table E.6 (B). No considerable
differences were noted when compared the main contributors to the overall AFM1 LB mean exposure
between the total population and highly exposed subjects.
Contribution of individual food categories to the LB mean chronic dietary exposure to
AFT+AFM1
Overall, the main contributor to the LB mean chronic dietary exposure to AFT+AFM1 was the food
category ‘grains and grain-based products’ (contributing up to 62% in the very elderly). The main
subcategories driving the contribution of this food category were ﬁne bakery wares, contributing up to
37% for the very elderly, bread and rolls, contributing up to 31% for the elderly and breakfast cereals,
contributing up to 27% for infants.
The ‘milk and dairy products’ food category was only an important source of AFT+AFM1 exposure
for infants, toddlers and other children. The LB contribution of this food category accounted up to 40,
26 and 19%, respectively, while for other age groups it was below 15%.
Other important contributors to the LB mean chronic dietary exposure to AFT+AFM1 were sugar
and confectionery’ (up to 43% in adolescents), mainly driven by non-chocolate confectionery, and
‘legumes, nuts and oilseeds’ (up to 32% in adults), mainly driven by peanuts.
The food categories ‘animal and vegetable fats and oils’, ‘herbs, spices and condiments’ and ‘alcoholic
beverages’ were also identiﬁed as important contributors to the LB mean chronic dietary exposure to
AFT+AFM1, but it was mostly speciﬁcally related to a high or speciﬁc consumption of certain products
(e.g. peanut butter, ﬂavourings or essences, beer and beer-like beverages unspeciﬁed).
The contribution of other food categories was minor.
The detailed contribution of the different food categories at FoodEx level 1 and grouped by age
classes to the LB mean chronic dietary exposure to AFT+AFM1 is shown in Annex E, Table E.7 and to
AFT in Table E.8. The detailed contribution of the different food categories at FoodEx level as used for
exposure assessment and grouped by age classes to the LB mean chronic dietary exposure to
AFT+AFM1 is shown in Annex E, Table E.7 bis (A).
The evaluation of the main contributors to the LB mean chronic dietary exposure to AFT+AFM1
among the highly exposed subjects showed that beside the grain-based food products, peanut and
tree nuts made the most important contribution. The detailed contribution of the different food
categories, at the FoodEx level as used for exposure assessment and grouped by age classes, to the
LB mean chronic dietary exposure to AFT+AFM1 for highly exposed subjects is shown in Annex E,
Table E.7 bis (B).
3.3.1.3. Scenario for short-term dietary exposure to AFB1 from peanut butter
As described in Section 3.1.2.5, AFB1 affects reproductive and developmental parameters in
rodents and these effects may occur following a short-term exposure. To evaluate whether these
effects should be considered in the risk characterisation of aﬂatoxins in humans in the EU, the
CONTAM Panel decided to compare the identiﬁed doses with a scenario of short-term exposure (for
more detail see Section 2.6). Given the limited number of consuming days available in the
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Comprehensive Database, the Panel focused only on the surveys where the peanut butter
consumption was recorded for at least 60 consuming days. Finally, calculations were based on seven
different dietary surveys carried out in four European countries.
The UB mean estimates for short-term dietary exposure to AFB1 from peanut butter across dietary
surveys and age groups ranged from 0.24 ng/kg bw per day to 1.53 ng/kg bw per day. The UB 95th
percentile short-term dietary exposure estimates across dietary surveys and age groups ranged from
0.57 ng/kg bw per day to 3.98 ng/kg bw per day. Detailed UB mean and UB 95th percentile dietary
exposure estimates calculated for each of the selected dietary surveys are presented in Annex E, Table E.9.
3.3.2. Exposure of infants through breastfeeding
For the exposure assessment for breastfed infants under 6 months of age, a median age of 3
months was selected, equivalent to a body weight of about 6.1 kg, with an estimated average daily
milk consumption of about 800 mL and a high consumption of 1,200 mL. The mean occurrence levels
were taken from the scientiﬁc literature (see Appendix IV, Table IV.1). However, it should be noted that
some mean concentrations were calculated using only the samples with concentration > LOD/LOQ. The
calculated dietary exposure ranged from 1 to 23 ng/kg bw per day for average milk consumers and
from 1.5 to 34 ng/kg bw per day for high milk consumers (Table 15). Some authors also calculated
daily exposures based on the detected levels and they are also reported in Table 15.
3.3.3. Previously reported dietary exposure
As summarised in the recently published statement on aﬂatoxins (EFSA CONTAM Panel, 2018), the
CONTAM Panel identiﬁed several dietary exposure assessments carried out by international risk
assessment bodies. The text below describing these dietary exposure assessments is an adapted
version of the corresponding section in the recently published statement on aﬂatoxins. In addition,
three total diet studies (TDS) carried out by European Member States and several scientiﬁc papers
reporting dietary exposure from one or a few food groups in Europe were identiﬁed.
Table 15: Overview of AFM1 concentrations in human milk collected in Europe in 2006 or later
Country
reference
N mothers
Mean
concentration
(ng/L)
Daily exposure (ng/kg bw)
calculated by the CONTAM
Panel
Daily exposure
(ng/kg bw)
reported by the
authorsAverage milk
consumption
High milk
consumption
Cyprus
Kunter et al. (2017)
50 7.84(b) 1.0 1.5
Italy
Galvano et al. (2008)
82 55.35(b) 7.3 10.9
Italy
Valitutti et al. (2018)
35(a) 12(c),(f) 1.6 2.4 1.6
23(a) 9(c,g) 1.2 1.8 1.2
Portugal
Bogalho et al. (2018)
67 7.4(d) 1.0 1.5 0.9–1.1
Serbia
Radonic et al. (2017)
55 175(b,h) 23.0 34.4 2.65(i)
Serbia
Kos et al. (2014)
10 10(e) 1.3 2.0
AFM1: aﬂatoxin M1; bw: body weight.
(a): About nine samples/mother).
(b): Mean of the samples with concentrations > LOD/LOQ.
(c): Calculated as middle bound.
(d): Not speciﬁed how mean is calculated.
(e): Concentration reported as ng/kg.
(f): Mothers with coeliac disease; gluten-free diet.
(g): Healthy mothers (control).
(h): Colostrum.
(i): Daily intake was calculated by the authors using a milk consumption of 60 mL per day and body weight of 3.5 kg.
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International risk assessment bodies
No comprehensive dietary exposure assessment for aﬂatoxins is available in the EU. In 2007, the
CONTAM Panel assessed the average dietary exposure to AFT, truncating the occurrence data to the
current EU MLs and using GEMS/Food Consumption Cluster diets data and data from individual surveys
(EFSA, 2007a). This assessment included exposure from almonds, hazelnuts, pistachios, other nuts,
maize, oilseeds, dried fruit and spices. For adults, this exposure ranged from 0.35 to 1.93 ng/kg bw
per day (minimum LB–maximum UB) and for children from 0.56 to 1.91 ng/kg bw per day (minimum
LB–maximum UB). Similar dietary exposure assessments have been carried out over the years for
different food commodities.
In 2016, JECFA calculated international estimates of chronic dietary exposure using the food
consumption data from the GEMS/Food cluster diets and a standard body weight of 60 kg (FAO/WHO,
2018). The calculations covered the exposure from cereals, nuts, spices, and other foods such as ﬁgs
and soy. The mean UB dietary AFT exposure ranged from 1.3 ng/kg bw per day (cluster G08, comprising
Austria, Germany, Poland and Spain) to 34.8 ng/kg bw per day (cluster G13, comprising African
countries and Haiti). JECFA reported that a similar pattern of exposure was observed under the LB
scenario. The dietary exposure for a high consumer was considered to be twice the mean dietary
exposure. Wheat was the main contributor to the UB dietary AFT exposure (range 37–76.5%) for several
countries, including many European countries. However, for cluster G10 (comprising European countries
such as Italy, Bulgaria, Estonia, Latvia and Lithuania), rice was the main contributor to the UB dietary
AFT exposure (range 34.5–80.3%). No information was provided regarding the major contributors to the
LB dietary AFT exposure. Based on these calculations and on national estimates, JECFA concluded that
with the exception of very high estimates of dietary exposure to AFT for some African countries
(105–850 ng/kg bw), all mean dietary AFT exposure were in the range < 0.01–58 ng/kg bw per day with
high consumer estimates in the range < 0.01–200 ng/kg bw per day. Considering the different foods
included in the exposure assessment, a direct comparison with the results generated by the CONTAM
Panel in 2007 is not appropriate.
Both EFSA and JECFA performed impact assessments of the implementation of different MLs for
speciﬁc food commodities on the dietary exposure. Such assessments are outside the scope of the
current Scientiﬁc Opinion and are therefore not reported in detail.
Total diet studies carried out by EU Member States
In 2006–2007, the French Agency for Food, Environmental and Occupational Health Safety (ANSES;
Agence nationale de securite sanitaire de l’alimentation, de l’environnement et du travail) conducted a TDS
including AFB1, AFB2, AFG1, AFG2 and AFM1. AFB1 was detected in dark chocolate samples, but in none
of the other food matrices. The other aﬂatoxins were not detected in any of the tested food matrices. For
French adults, the mean and P95 dietary exposure to AFB1 were 0.002–0.22 and 0.01–0.39 ng/kg bw per
day (LB–UB), respectively. For French children (3–17 years) the mean and P95 dietary exposure was
0.001–0.39 and 0.008–0.74 ng/kg bw per day (LB–UB), respectively (Sirot et al., 2013).
In 2011–2012, ANSES conducted a TDS particularly targeting children under 3 years old. AFB1 and
AFG2 were only detected in one sample of chocolate and AFB2, AFG1 and AFM1 were not detected in
any of the samples. The exposure to the sum of the ﬁve aﬂatoxins20 was the highest for the youngest
age group (1–4 months), namely 0–4.46 and 0–8.28 ng/kg bw per day (LB–UB) for the mean and P95
dietary exposure, respectively (ANSES, 2016).
A TDS was carried out by the Italian Istituto Superiore di Sanita in 2012–2014 that included AFB1
and AFM1. For AFB1 the LB–UB dietary exposure was 0.020–0.507 ng/kg bw for the whole population.
It should be noted that AFB1 was only detected in three food groups: ‘wheat and ﬂours’, ‘chocolate’,
and ‘cocoa’. AFM1 was only detected in the food group ‘meat, meat products and substitutes’ and the
LB–UB dietary exposure was 0.17–0.23 lg/kg bw. However, the percentage of left-censored data was
high for both substances and the uncertainty in the dietary exposure assessment is consequently
substantial (Cubadda, 2018).
A mycotoxin-dedicated TDS was conducted in the Netherlands in 2013 which included AFB1, AFB2,
AFG1, AFG2 and AFM1. Only AFB1 was detected in two composite samples that contained peanuts but
at a concentration below the LOQ of 0.2 lg/kg. Based on the collected occurrence data, dietary
exposure was calculated for Dutch children aged 2–6 years and the Dutch population aged 7–69 years
old. For Dutch children, the P50 and P95 dietary exposure to AFB1 were 0–0.93 and 0.07–1.67 ng/kg
20 = AFM1/10 + AFB1+AFB2+AFG1+AFG2.
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bw per day (LB–UB), respectively. For the rest of the Dutch population the dietary exposure was lower
(0–0.42 and 0.033–1.03 ng/kg bw per day (LB–UB), respectively) (Lopez et al., 2016; Sprong et al.,
2016a,b).
The Panel noted that the UB exposures reported in these TDS are primarily driven by the LOQs due
to the high percentage of left-censored data.
Dietary exposure for one or a limited number of food groups
Appendix IV, Table IV.3 shows examples of estimated dietary exposures reported in the scientiﬁc
literature. Several papers estimated the dietary exposure to AFM1 in Serbia from milk consumption.
Large differences in dietary exposure were observed between years, due to the large variability in
AFM1 concentrations in milk between sampling years (Torovic, 2015). In Serbian children, a mean
dietary exposure to AFM1 up to 6.5 ng/kg bw per day was reported. For all other aﬂatoxins, the
calculated exposures were typically lower than 0.1 ng/kg bw per day.
3.3.4. Non-dietary sources of exposure
In addition to dietary exposure, people might be exposed to aﬂatoxins from the environment, e.g.
occupational exposure. Depending on the working conditions, individuals can be exposed by inhalation
and potentially dermal and oral routes (e.g. Saad-Hussein et al., 2016; Rushing and Selim, 2019).
While occupational exposure may contribute signiﬁcantly for individual workers, this is not considered
further in this Scientiﬁc Opinion.
3.4. Risk characterisation
3.4.1. Risk characterisation based on animal data
The CONTAM Panel selected the BMDL10 of 0.4 lg/kg bw per day for the induction of HCC by AFB1
in male rats as a reference point for the risk characterisation of aﬂatoxins.
Comparison of the chronic dietary exposure to AFB1 across dietary surveys and age groups
reported above (Table 13) to this BMDL10, results in MOE values (Table 16) (minimum - maximum)
that range from 5,000 to 225 for the mean LB exposure to AFB1 and from 690 to 58 for the mean UB
exposure to AFB1 across dietary surveys and age groups. The MOE values range from 1,143 to 64 for
the P95 LB exposure to AFB1 and from 145 to 29 for the P95 UB exposure to AFB1 across dietary
surveys and age groups.
For substances that are both genotoxic and carcinogenic, the EFSA Scientiﬁc Committee stated that
an MOE of 10,000 or higher, if based on the BMDL10 from an animal carcinogenicity study, would be of
low concern from a public health point of view (EFSA, 2005). The CONTAM Panel noted that the
calculated MOEs are below 10,000, which raises a health concern.
The available data do not make it possible to calculate a BMDL10 for AFM1. However, the CONTAM
Panel agreed to use a potency factor of 0.1 in combination with the BMDL10 of 0.4 lg/kg bw per day
for the induction of HCC by AFB1 for the AFM1 risk assessment. Table 17 shows the calculated MOE
Table 16: Margin of exposure (MOE) values based on dietary exposure to AFB1 for the incidence of
HCC across dietary surveys and age groups
Age groups
MOE calculated from mean dietary
exposure to AFB1
MOE calculated from P95 dietary
exposure to AFB1
Minimum Median Maximum Minimum Median Maximum
LB UB LB UB LB UB LB UB LB UB LB UB
Infants 5,000 690 2,222 199 667 82 1,143 143 541 77 217 31
Toddlers 930 127 625 75 381 58 519 59 274 41 139 29
Other children 851 116 526 81 225 65 342 66 253 46 64 34
Adolescents 1,481 201 1,000 134 323 94 571 123 408 71 87 46
Adults 1,818 296 1,212 186 816 123 645 145 460 94 294 59
Elderly 2,105 303 1,538 211 1,290 137 851 145 645 108 364 76
Very elderly 2,222 284 1,538 193 976 137 952 142 714 104 430 79
AFB1: aﬂatoxin B1; HCC: hepatocellular carcinoma; LB: lower bound; UB: upper bound.
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values for AFM1. They range (minimum–maximum) from 100,000 to 2,564 for the mean LB exposure
estimates, from 66,667 to 2,020 for the mean UB exposure estimates, from 33,333 to 642 for the P95
LB exposure estimates, and from 25,000 to 508 for the P95 UB exposure estimates across dietary
surveys and age groups have been calculated. The CONTAM Panel noted that the calculated MOEs are
below 10,000 for some surveys, particularly for the younger age groups, which raises a health
concern, albeit the high exposure to AFM1 from milk and dairy products may be limited to a short
period in life.
MOE values based on the exposure to the sum of AFT and AFM1 and the BMDL10 of 0.4 lg/kg bw
per day are presented in Appendix V. The calculated MOE values were below 10,000, which raises a
health concern.
3.4.2. Risk characterisation based on human data
The CONTAM Panel also used the cancer potency estimates reported by JECFA for the risk
characterisation. Using model averaging, JECFA calculated potency estimates of 0.017 (mean) and
0.049 (95% UB) per 100,000 person-years per ng/kg bw per day for HBsAg-negative individuals and
0.269 (mean) and 0.562 (95% UB) per 100,000 person-years per ng/kg bw per day for HBsAg-positive
individuals (FAO/WHO, 2018; see Section 1.3.1 for further details). Considering the new evidence
regarding HCV as a risk factor, the CONTAM Panel decided to take also the prevalence of HCV into
account in the risk characterisation.
In 2016, the European Centre for Disease Prevention and Control (ECDC) published a systematic
review on hepatitis B and C prevalence in the EU/EEA (European Economic Area). Studies were
included that measured HBV and HCV markers (HBsAg and anti-HCV antibodies). Based on data from
13 countries, the reported prevalence of HBV for the general population ranged from 0.1 (Ireland) to
4.4% (Romania). For HCV, the prevalence ranged from 0.1 (Belgium, Ireland and the Netherlands) to
5.9% (Italy). Overall, the prevalence of HBV and HCV in the EU/EEA was estimated to be around 0.9
and 1.1%, respectively, corresponding to 4.7 million chronic HBV cases and 5.6 million HCV-infected
subjects (ECDC, 2016). However, no overall data are available regarding the co-infection with HBV and
Table 17: Margin of exposure (MOE) values based on dietary exposure to AFM1 and a potency
factor of 0.1 for the incidence of HCC across dietary surveys and age groups
Age group
Minimum Median Maximum
LB UB LB UB LB UB
MOE calculated from mean dietary exposure to AFM1
Infants 28,571 19,048 7,018 4,938 2,564 2,020
Toddlers 8,889 6,250 5,882 3,810 2,817 2,210
Other children 22,222 14,286 11,429 7,692 5,128 4,000
Adolescents 50,000 33,333 26,667 17,391 16,000 10,811
Adults 80,000 66,667 50,000 33,333 28,571 20,000
Elderly 100,000 66,667 50,000 33,333 28,571 22,222
Very elderly 100,000 66,667 50,000 36,364 26,667 18,182
Pregnant women 44,444 36,364 36,364 26,667 30,769 20,000
Lactating women 28,571 20,000 22,222 16,000 18,182 13,793
MOE calculated from P95 dietary exposure to AFM1
Infants 6,061 4,082 2,703 1,942 642 508
Toddlers 3,810 2,685 2,721 1,835 1,053 825
Other children 9,302 6,452 5,000 3,175 1,852 1,465
Adolescents 18,182 12,903 10,811 6,897 8,333 5,797
Adults 30,769 25,000 16,000 12,500 10,256 7,407
Elderly 33,333 25,000 16,667 12,500 10,526 8,333
Very elderly 23,529 16,000 16,000 12,903 11,765 8,889
Pregnant women 19,048 14,815 14,286 10,526 11,765 8,163
Lactating women 11,765 8,696 10,526 7,843 9,756 7,143
AFM1: aﬂatoxin M1; HCC: hepatocellular carcinoma; LB: lower bound; UB: upper bound.
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HCV in the EU/EEA. In some studies on the prevalence of HBV and HCV, none of the subjects were
found to be co-infected (Bulgaria: Kevorkyan et al., 2015; Italy: Fabris et al., 2008 and Cozzolongo
et al., 2009; Spain: Calleja-Panero et al., 2013) while other studies reported a low number of co-
infected persons. In France, two persons out of 14,413 persons were co-infected (Meffre et al., 2010)
and Pendino et al. (2005) reported that 2 persons were co-infected out of 1645. One study reported a
higher co-infection prevalence of 1.53%. However, it was noted that the overall HBV infection rate was
high in this study (4% compared to 0.7% as the average for Italy) (Squeri et al., 2006). Based on this
information, the CONTAM Panel concluded that the available data are too limited to estimate the
prevalence of co-infection of HBV and HCV in Europe and followed a conservative approach by adding
up the prevalence of HBV and HCV. This sum ranges from 0.2 (Ireland) to 7.6% (Romania) across the
12 European countries for which data were available.
As described in FAO/WHO (2018), the aﬂatoxin-related hepatocellular carcinoma risk is estimated
from the cancer potency estimates using the following equation:
R ¼ (PHBVþÞ  ðAFexposureÞ  ðHBVþÞ þ ðPHBVÞ  ðAFexposureÞ  ð1 HBVþÞ;
where R is the cancer risk
PHBV+ is the potency estimates P for the HBV+ fraction of the population
PHBV is the potency estimates P for the HBV fraction of the population
HBV+ is the population fraction of chronic HBV cases
Based on the mean potency estimates and a prevalence of 0.2%, the CONTAM Panel estimated the
cancer risk from the mean dietary exposure to AFB1 to be between 0.001 and 0.122 aﬂatoxin-induced
cancers per 100,000 person-years, across dietary surveys and age groups (Table 18). In adults, the
estimated cancer risk ranged between 0.004 and 0.057 aﬂatoxin-induced cancers per 100,000 person-
years. The highest exposure and consequent cancer risk were calculated for toddlers. For this age
class, the cancer risk was estimated to be between 0.008 and 0.122 aﬂatoxin-induced cancers per
100,000 person-years. Based on the 95th percentile dietary exposure, the estimated cancer risk
ranged between 0.006 and 0.245.
Based on the UB potency estimates and a prevalence of 7.6%, the CONTAM Panel estimated the
cancer risk from the mean dietary exposure to AFB1 to be between 0.007 and 0.612 aﬂatoxin-induced
cancers per 100,000 person-years, across dietary surveys and age groups (Table 19). In adults, the
Table 18: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFB1, the mean
potency estimates of the cancer risk and a HBV/HCV prevalence of 0.2%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.001 0.010 0.003 0.035 0.011 0.085
Toddlers 0.008 0.055 0.011 0.094 0.018 0.122
Other children 0.008 0.061 0.013 0.086 0.031 0.107
Adolescents 0.005 0.035 0.007 0.052 0.022 0.075
Adults 0.004 0.024 0.006 0.038 0.009 0.057
Elderly 0.003 0.023 0.005 0.033 0.005 0.051
Very elderly 0.003 0.025 0.005 0.036 0.007 0.051
Based on 95th percentile dietary exposure in total population
Infants 0.006 0.049 0.013 0.091 0.032 0.228
Toddlers 0.013 0.119 0.026 0.170 0.050 0.245
Other children 0.020 0.106 0.028 0.152 0.109 0.208
Adolescents 0.012 0.057 0.017 0.098 0.081 0.151
Adults 0.011 0.048 0.015 0.074 0.024 0.119
Elderly 0.008 0.048 0.011 0.065 0.019 0.092
Very elderly 0.007 0.049 0.010 0.068 0.016 0.088
AFB1: aﬂatoxin B1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
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estimated cancer risk ranged between 0.019 and 0.286 aﬂatoxin-induced cancers per 100,000 person-
years. The highest exposure and consequent cancer risk were calculated for toddlers. For this age
class, the cancer risk was estimated to be between 0.038 and 0.612 aﬂatoxin-induced cancers per
100,000 person-years. Based on the 95th percentile dietary exposure, the estimated cancer risk
ranged between 0.031 and 1.233.
To put the cancer risk estimates into context, the WHO Guideline for drinking-water quality (WHO,
2011) was used. According to this guideline, an excess lifetime cancer risk of 105 or less is
considered to be of low risk for health concern.21 Assuming a lifetime expectancy of 70 years, this
corresponds to a yearly excess cancer risk of 0.014 additional cancer cases22 per 100,000 subjects.
Comparing the estimated AFB1-induced cancers calculated with this yearly excess cancer risk, a higher
risk is identiﬁed in several surveys when using the mean dietary exposure and in most surveys when
using the P95 dietary exposure.
The calculated cancer risk calculated from the chronic dietary exposure to AFM1 and AFT+AFM1 are
presented in Appendix V.
Overall, the estimated cancer risks in humans following exposure to AFB1, AFM1 and AFT+M1 are
in line with the conclusion drawn from the animal data.
3.5. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of exposure to aﬂatoxins in food has
been performed following the guidance of the Opinion of the Scientiﬁc Committee related to
uncertainties in dietary exposure assessment (EFSA, 2007b). In addition, the report ‘Characterizing and
communicating uncertainty in exposure assessment’ has been considered (WHO/IPCS, 2008). The
CONTAM Panel took note of the new guidance on uncertainties of the Scientiﬁc Committee (EFSA
Scientiﬁc Committee, 2018), but it was not implemented for this Opinion.
Table 19: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFB1, the upper
bound potency estimates of the cancer risk and a HBV/HCV prevalence of 7.6%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.007 0.051 0.016 0.177 0.053 0.429
Toddlers 0.038 0.277 0.056 0.471 0.092 0.612
Other children 0.041 0.304 0.067 0.434 0.157 0.538
Adolescents 0.024 0.175 0.035 0.262 0.109 0.376
Adults 0.019 0.119 0.029 0.189 0.043 0.286
Elderly 0.017 0.116 0.023 0.167 0.027 0.256
Very elderly 0.016 0.124 0.023 0.182 0.036 0.258
Based on 95th percentile dietary exposure in total population
Infants 0.031 0.245 0.065 0.456 0.162 1.146
Toddlers 0.068 0.598 0.128 0.853 0.253 1.233
Other children 0.103 0.531 0.139 0.766 0.547 1.045
Adolescents 0.062 0.286 0.086 0.494 0.407 0.758
Adults 0.055 0.243 0.077 0.373 0.120 0.597
Elderly 0.041 0.243 0.055 0.327 0.097 0.463
Very elderly 0.037 0.247 0.049 0.340 0.082 0.444
AFB1: aﬂatoxin B1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
21 An excess lifetime cancer risk of 10_5 is equivalent to one additional case of cancer per 100,000 of the population ingesting
drinking water containing the substance at the guideline value for 70 years (WHO, 2011). This risk level is used by the WHO
to set guidance values for chemicals in drinking water.
22 The yearly extra risk was calculated by dividing the excess lifetime cancer risk of 10_5 by the lifetime expectancy of 70 years
and expressing it per 100,000 subjects.
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3.5.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.5.2. Exposure scenario/exposure model
The exposure assessment was based on aﬂatoxin occurrence data collected in numerous EU
countries; however, most of them (~ 65%) were collected in only three Member States while some
other countries submitted only a limited number of data. Most of the imported foods, such as nuts and
fruits, were sampled in harbour areas and afterwards transported throughout Europe, therefore it is
believed that the data for these foods properly covers the EU market. This seems not to be the case
for the other food categories largely contributing to the exposure to aﬂatoxins, in particular ‘grains and
grain-based products’ and ‘milk and milk products’. For these food categories, there is uncertainty
around possible regional differences in aﬂatoxin contamination and the data set is likely not to be fully
representative of food for the EU market.
The available occurrence data have been in part collected via a risk-based monitoring strategy and
this may overestimate the background aﬂatoxin levels.
The CONTAM Panel noted high mean concentrations in fresh ﬁgs. However some samples may
have been miscodiﬁed, resulting in uncertainty whether these samples were actually fresh or dried.
When considered appropriate, occurrence data and consumption events for solid forms of certain
foods (e.g. tea leaves, cocoa powder, etc.; for more detail see Section 2.6) were adjusted by an
appropriate dilution factor. Assumptions applied for this conversion may, however, not be accurate and
representative for all possible commercial products. This may lead to an overestimation or
underestimation of exposure.
Processing was not considered in the dietary exposure assessment since the relevant information as
to whether the samples were taken from batches subject to sorting, other physical treatment, or from
batches intended for direct human consumption was only provided for a limited number of samples. In
this context, processing includes milling, sorting, cleaning, heat treatment of cereals and roasting of
nuts. This may lead to an overestimation of the exposure, bearing in mind that processing may reduce
the aﬂatoxin concentration.
The large proportion of analytical results with left-censored data (values below LOD/LOQ)
introduced considerable uncertainties to the exposure estimates. The use of the LB in this Opinion
tends to underestimate, while UB tends to overestimate the dietary exposure. The limited number of
available analytical results for some food categories adds uncertainty to the representativeness of the
mean concentration values used to estimate the exposure. The occurrence data for AFT were
calculated from the analytical results of the individual aﬂatoxins (for more detail see Section 2.3.2). For
the left-censored data, the UB AFT sum concentrations were in most of the cases based on the LOQ
values reported for AFB1. This approach has introduced uncertainty to the calculated UB AFT
occurrence values. This may lead to an overestimation or underestimation of exposure.
Uncertainties and limitations related to the use of the EFSA Comprehensive Food Consumption
Database have already been described by EFSA (EFSA, 2011b) and are not further detailed in this
Opinion.
3.5.3. Model input (parameters)
There are no prescribed ﬁxed ofﬁcial methods for the analysis of aﬂatoxins and laboratories can use
any appropriate method of analysis, provided it can be demonstrated in a traceable manner that they
fulﬁl the requirements according to Commission Regulation (EC) No 401/2006. This may have added to
the uncertainty in the analytical results but only to a minor extent.
3.5.4. Other uncertainties
The CONTAM Panel selected the study by Yeh et al. (1989) as the pivotal study. Nevertheless,
considerable uncertainty is due to the fact that the exposure assessment was done at the community
level and not at the individual level. Regarding the presence of confounders, Yeh et al. (1989)
investigated the association between aﬂatoxin exposure and hepatocellular cancer while also taking
into consideration the role of HBV infection (through HBsAg) which can function as a major
confounder. However, no other confounding factors that could impact the liver (e.g. HCV, alcohol
consumption) were taken into account. These limitations of the study add to the uncertainty in the
hazard and risk characterisation.
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The CONTAM Panel used the cancer potencies calculated by JECFA at its 83rd meeting. The liver
cancer potencies were calculated using an epidemiological study where the lowest exposure group had
an estimated exposure of 12 ng AFB1/kg bw (FAO/WHO, 1999, 2018). The potencies were expressed
as the liver cancer cases per 100,000 person-years per ng aﬂatoxin. Applying these potency estimates
for AFB1 exposure of around 1 ng/kg bw per day and below implies an extrapolation outside the dose-
range. However, considering that AFB1 is a carcinogen showing a linear dose–response in the range of
low doses tested in experimental studies (FAO/WHO, 2018), the CONTAM Panel concluded that this
extrapolation is appropriate, but is uncertain at very low doses and might overestimate the risk.
The cancer potencies were calculated by JECFA for both HBsAg-positive and HBsAg-negative
individuals. The cancer potency for HBsAg-negative individuals is based on relatively few cases and is
therefore more uncertain than the estimated potency for HBsAg-positive subjects.
The use of UB cancer potencies may cause an overestimation of the cancer incidence.
There are limited data regarding the prevalence of co-infection with HBV and HCV in the EU, that
do not allow to estimate a reliable prevalence of co-infection of HBV and HCV in Europe. However,
considering that the prevalence of co-infection seems low, the CONTAM Panel followed a conservative
approach and assumed no co-infection.
Despite the accumulating evidence, the relevance for human risk assessment of endpoints related
to child growth is not clear due to the methodological constrains of the currently available evidence.
In experimental animals, most studies use AFB1. Therefore, it is uncertain whether the other
aﬂatoxins also exhibit short-term toxicity such as inhibition of growth, liver and kidney damage and
changes in the microbiota. An uncertainty linked to the use of animal data is the fact that the HBV and
HCV status cannot be taken into account as a risk factor.
The CONTAM Panel also characterised the risk based on animal data and selected the study by
Wogan et al. (1974). In this study, different study durations were applied for different dose groups
and a time adjustment of the doses was made. However, a BMD analysis of the non-adjusted doses
resulted in the same BMDL10 value of 0.4 lg/kg bw per day (when rounded to one signiﬁcant number;
data not shown) as when time-adjusted doses were used. Therefore, the uncertainty caused by the
time adjustment is low. Despite the fact that this study was carried out before OECD test guidelines
were put in place, full histological examinations and detailed autopsies were performed. Highly puriﬁed
crystalline AFB1 was used and diets were prepared under controlled conditions. A clear dose-response
relationship was observed conﬁrming previous reports of AFB1 as a potent liver carcinogen. No study
performed in accordance with current OECD guidelines is available.
For the calculation of the terminal half-life, it is recommended to use a period of collection (of blood
and urine sample) of at least ﬁve times the estimated half-life. In the study by Jubert et al. (2009), the
follow-up period was 72 h, while the calculated terminal half-life was 64 h. This introduces uncertainty
in the calculated terminal half-life and consequently may inﬂuence the conclusion regarding possible
accumulation in the longer term.
Although the available evidence suggests differences in potencies between AFB1, AFB2, AFG1 and
AFG2, the available data do not make it possible to identify potency factors. The CONTAM
Panel assumed equal potencies for the four compounds, which leads to an overestimation of the risk
for AFT. In addition, there is inadequate evidence about the interaction of AFB2, AFG1, and AFG2 with
HBV and HCV as most studies have used biomarkers of exposure that relate to AFB1 exposure.
However, the CONTAM Panel noted that the conclusions regarding the risk based on AFB1 alone and
on the AFT+AFM1 are in-line, showing that the inﬂuence of these assumptions on the conclusion
regarding the risk related to the presence of aﬂatoxins in food is small.
This risk assessment is conﬁned to AFB1, AFB2, AFG1, AFG2 and AFM1. However, also other
mycotoxins such as aﬂatoxicol and AFM2 may add to the risk for public health related to the presence
of aﬂatoxins in food.
3.5.5. Summary of uncertainties
In Table 20, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
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The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of
aﬂatoxins in food is moderate and that the assessment is likely to be conservative.
4. Conclusions
Hazard identiﬁcation and characterisation:
• Most of the available data are on AFB1 and information on the other aﬂatoxins is scarce and
mentioned when available.
• AFB1 is readily absorbed and distributed to the liver.
• CYP enzymes convert AFB1, AFG1 and AFM1 to the equivalent 8,9-epoxides, which are capable
of binding to both DNA and proteins while AFB2 and AFG2 cannot form the 8,9-epoxide.
• AFB1 and its metabolites are both excreted via the faecal and urinary routes. AFM1 is also
excreted in breast milk.
• In short-term toxicity studies, AFB1 has multiple negative effects on rodents including
inhibition of normal growth, and liver and kidney damage as well as sustained alterations in
the intestinal microbiota.
• The new studies reported in this opinion add to the weight of evidence that AFB1 is genotoxic
and limited new information has become available regarding the genotoxicity of the other
aﬂatoxins.
• In liver cells (HepG2), the genotoxic potency can be summarised as AFB1 > AFG1  aﬂatoxicol
> AFM1. AFB2 and AFG2 did not induce genotoxicity in three human cell lines (i.e. HepG2,
colorectal carcinoma and renal carcinoma).
• Pregnancy appeared to enhance the sensitivity of mother mice to the genotoxicity of AFB1.
• In utero exposure in mice resulted in lower DNA adduct levels in the fetus than the mothers,
but to a higher relative mutation frequency in the fetus.
• In humans, a mutational signature for aﬂatoxin exposure has been identiﬁed in HCC.
• AFB1 affects reproductive and developmental parameters (i.e. brain development, shortened
time to delivery, low birth weight and adverse effects on spermatogenesis and folliculogenesis)
at low doses (≥ 4 lg/kg bw per day) in rodents and these effects may occur following a short-
term exposure.
• Aﬂatoxins impair the immune response, particularly at the cellular level. NOAELs for these
effects are around 30 lg/kg bw per day in rodents.
• AF-alb (AFB1-lys), urinary AF-N7-gua and urinary AFM1 are all biomarkers of exposure that
have been validated against dietary intake of aﬂatoxin. However, the levels of these biomarkers
cannot be converted reliably into dietary exposures in individuals.
Table 20: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of aﬂatoxins in food
Sources of uncertainty Direction(a)
Extrapolation of the occurrence data to the whole of Europe for certain food categories +/
Potential reduction of the aﬂatoxin concentration due to processing not considered for some
samples
+
Use of analytical data from targeted sampling +
Large proportion of left-censored data in the data set +/
Assumptions from the summing of the individual aﬂatoxins at the level of sample +/
Uncertainty in the exposure assessment in the study by Yeh et al. (1989) +/
Estimated cancer potency for hepatitis B surface antigen negative subjects is more uncertain
because based on relatively few cases
+/
Use of upper bound cancer potencies +
Assumption on the co-infection of HBV and HCV in Europe +
The HBV and HCV status cannot be taken into account when using animal data for the risk
characterisation
+/
Cancer potency and reference point for aﬂatoxin B1 applied to ‘aﬂatoxin total’ +
+ : uncertainty with potential to cause overestimation of exposure/risk; : uncertainty with potential to cause underestimation of
exposure/risk.
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• The studies reported since 2006 have added to the weight of evidence that aﬂatoxin exposure
is associated with a risk of HCC, with a higher risk for people infected with either HBV or HCV.
• High AFB1 exposure causes acute aﬂatoxicosis with a high mortality rate. Lower levels of
chronic exposure to AFB1 are associated with cirrhosis and indicators of liver dysfunction.
• There is currently insufﬁcient evidence to causally associate aﬂatoxin exposure with gall
bladder cancer and stomach cancer. Likewise, there is insufﬁcient evidence for a possible
interaction between HIV and aﬂatoxin exposure.
• Child health is an emerging area of interest for aﬂatoxin-related hazard identiﬁcation. There is
currently insufﬁcient evidence to support the use of child growth as an endpoint in risk
assessment.
• AFB1 induces oxidative stress, which might compromise critical AFB1 detoxiﬁcation pathways
and/or induce DNA oxidation. The Nrf2 signalling pathway plays a role in the suppression of
AFB1 toxicity.
• In vitro and in vivo studies provide evidence that AFB1 exposure results in a decline of global
DNA methylation together with hypermethylation of several tumour suppressor genes.
• There is increasing evidence that AFB1 affects the expression of key enzymes in hormone
homeostasis, particularly steroid hormone homeostasis, which may lead to disturbance of
regulatory mechanisms in fertility. Transport processes across the placenta may also be
affected.
• Some genetic polymorphisms are associated with increased risk of aﬂatoxin-related liver
cancer, such as GSTM1.
• Liver carcinogenicity of aﬂatoxins, both in experimental animals and in humans, remains the
critical effect for the risk assessment. The epidemiological study by Yeh et al. (1989) on
mortality from liver cancer in several provinces in China, and the two-year carcinogenicity
study in male Fischer rats by Wogan et al. (1974), remain the most suitable studies for dose–
response analysis.
• Based on the study in rats, the CONTAM Panel used model averaging to calculate a BMDL10 of
0.4 lg/kg bw per day for the incidence of HCC to be used in an MOE approach for the risk
characterisation.
• For human data, the CONTAM Panel used the cancer potencies estimated by JECFA in 2016.
The cancer potencies were 0.017 (mean) and 0.049 (95% UB) per 100,000 person-years per
ng/kg bw per day for HBsAg-negative individuals and 0.269 (mean) and 0.562 (95% UB) per
100,000 person-years per ng/kg bw per day for HBsAg-positive individuals.
• Differences in carcinogenic potency are reported for AFB2 and AFG2 compared with AFB1 and
AFG1.
• In vivo there is insufﬁcient evidence to derive potency factors for AFB2 and AFG2.
• There are indications of differences in the cancer potency between AFB1 and AFG1 in the liver
with AFB1 being more potent. In the kidney, AFG1 has a higher cancer potency than AFB1.
Again, the available data are not sufﬁcient to be able to derive an individual potency factor
that can be used in the risk assessment.
• In the absence of new in vivo data to quantify differences between the individual aﬂatoxins the
CONTAM Panel applied equal potency factors for AFB1, AFB2, AFG1 and AFG2 as used in
previous assessments.
• No new evidence has become available that necessitates a change of the potency factor of 0.1
for AFM1.
Occurrence/exposure for the EU population:
• The highest AFB1 and AFT mean concentrations were obtained for the food category ‘legumes,
nuts and oilseeds’ (in particular for pistachios, peanuts and ‘other seeds’). As expected, the
highest AFM1 mean concentrations were reported for ‘milk and dairy products’ and milk-based
foods belonging to the food category ‘food for infants and small children’.
• The highest LB mean exposure to AFB1 was estimated in other children with a maximum
exposure of 1.8 ng/kg bw per day, while the highest UB exposure was observed for toddlers
(7.0 ng/kg bw per day). The highest LB 95th percentile exposure to AFB1 was for other
children with estimates of 6.2 ng/kg bw per day and the highest UB 95th percentile exposure
was estimated for toddlers (14 ng/kg bw per day).
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• The highest estimated mean LB and UB exposure to AFM1 was in infants with a maximum LB/
UB exposure of 1.6/2.0 ng/kg bw per day. The highest LB/UB 95th percentile exposure to
AFM1 was also observed for infants with estimates of 6.2/7.9 ng/kg bw per day.
• Overall, ‘grains and grain-based products’ made the largest contribution to the LB mean
chronic dietary exposure to AFB1 in all age classes. The subcategories driving the contribution
of this food category were ‘grains for human consumption’ (in particular corn grain), ‘bread
and rolls’ and ‘ﬁne bakery wares’.
• The food categories ‘liquid milk’ and ‘fermented milk products’ were the main contributors to
the overall AFM1 mean exposure throughout all age groups.
Risk characterisation
• Based on a BMDL10 of 0.4 lg/kg bw per day for the induction of HCC by AFB1 in male rats,
MOE values (minimum–maximum) that range from 5,000 to 225 for the mean LB exposure to
AFB1 and from 690 to 58 for the mean UB exposure to AFB1 across dietary surveys and age
groups. The MOE values range from 1,143 to 64 for the P95 LB exposure to AFB1 and from
145 to 29 for the P95 UB exposure to AFB1 across dietary surveys and age groups. The
calculated MOEs are below 10,000, which raises a health concern.
• For AFM1, based on the BMDL10 of 0.4 lg/kg bw per day derived for AFB1 and a potency
factor of 0.1, MOE values that range from 100,000 to 2,564 for the mean LB exposure
estimates, from 66,667 to 2,020 for the mean UB exposure estimates, from 33,333 to 642 for
the P95 LB exposure estimates, and from 25,000 to 508 for the P95 UB exposure estimates
across dietary surveys and age groups have been calculated. The CONTAM Panel noted that
the calculated MOEs are less than 10,000 for some surveys particularly for the younger age
groups, which raises a health concern. However, the high exposure to AFM1 from milk and
dairy products may be limited to a short period in life.
• Based on the mean potency estimates of the cancer risk in humans and a HBV/HCV prevalence
of 0.2%, the cancer risk was estimated to range from 0.001 to 0.122 aﬂatoxin-induced cancers
per year per 100,000 persons based on the mean dietary exposure to AFB1 and from 0.006 to
0.245 based on the 95th percentile exposure to AFB1. Based on the UB potency estimates of
the cancer risk in humans and a HBV/HCV prevalence of 7.6%, the cancer risk was estimated
to range from 0.007 to 0.612 aﬂatoxin-induced cancers per year per 100,000 persons based
on the mean dietary exposure to AFB1 and from 0.031 to 1.233 based on the 95th percentile
exposure to AFB1.
• The estimated cancer risks in humans following exposure to AFB1 are in-line with the
conclusion drawn from the animal data. This conclusion also applies to AFM1 and AFT+AFM1.
5. Recommendation
• Data are needed to clarify the genotoxic and carcinogenic potential of AFG2.
• In order to derive potency factors for AFG1 and AFB2 relative to AFB1, and for AFG2 if
required, more data are needed.
• Research designed to quantify the relationship between biomarker levels and dietary intake at
the individual level, integrating dietary exposure over time with biomarker levels, is
recommended. Such study would be performed in populations with an indigenous dietary
exposure to aﬂatoxin resulting in measurable biomarker levels.
• More data are needed regarding the occurrence of aﬂatoxicol and AFM2.
• Aﬂatoxin occurrence should continue to be monitored in the light of potential increases due to
climate change using methods with high levels of sensitivity for detection.
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Abbreviations
8-OHdG 8-hydroxydeoxyguanosine
ACHN renal carcinoma cells
AIC Akaike information criterion
AF-alb aﬂatoxin albumin adduct
AFB1 aﬂatoxin B1
AFB1-FAPY aﬂatoxin B1 formamidopyrimidine adduct
AFB1-lys aﬂatoxin B1 lysine adduct
AFB1-N7-gua aﬂatoxin B1-N7-guanine
AFB2 aﬂatoxin B2
AFG1 aﬂatoxin G1
AFG2 aﬂatoxin G2
AFG5 aﬂatoxin G5
AFM1 aﬂatoxin M1
AFM2 aﬂatoxin M2
AFP1 aﬂatoxin P1
AFQ1 aﬂatoxin Q1
AFT aﬂatoxin total
AhR aryl hydrocarbon receptor
AKR NADPH-dependent aldo-keto-reductase
ALARA as low as reasonably achievable
ALP alkaline phosphatase
ALD advanced liver disease
ALT alanine aminotransferase
ANSES French Agency for Food, Environmental and Occupational Health Safety
AST aspartate transaminase
ATPase adenosine triphosphatase
BER base excision repair
BMD benchmark dose
BMDL benchmark dose lower conﬁdence limit
bm breast milk
BMR benchmark response
bw body weight
CAR constitutive activated/androstane receptor
CCCF Codex Committee on Contaminants in Food
CI conﬁdence interval
CONTAM EFSA Panel on Contaminants in the Food Chain
CYP cytochrome P450
DATA Unit EFSA former EFSA Dietary and Chemical Monitoring Unit
Aﬂatoxins in food
www.efsa.europa.eu/efsajournal 91 EFSA Journal 2020;18(3):6040
DMSO dimethyl sulfoxide
DNMT DNA methyltransferase
EBV Epstein–Barr virus
EEC European Economic Community
ELISA enzyme-linked immunosorbent assay
ERa estrogen receptor alpha
FAO Food and Agriculture Organization
FD ﬂuorescence detection
FFQ food frequency questionnaire
Fpg formamidopyrimidine-DNA glycosylase
FSH follicle-stimulating hormone
GBC gall bladder cancer
GC gas chromatography
GDc gestation day
GGT c-glutamyl transpeptidase
GI gastrointestinal
GSH glutathione
GST glutathione S-transferase
HAD height-for-age difference
HAZ height-for-age z-score
HBeAg hepatitis B e antigen
HBGV health-based guidance value
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
hpf hours post-fertilisation
HPLC high-performance liquid chromatography
HSD3B 3b-hydroxysteroid dehydrogenase
HSD17B3 17b-hydroxysteroid dehydrogenase enzyme
IARC International Agency for Research on Cancer
IFN interferon
IGFBP3 insulin-like growth factor-binding protein 3
IGF-1 insulin-like growth factor 1
IL interleukin
i.p. intraperitoneal
IQR interquartile range
JECFA Joint FAO/WHO Expert Committee on Food Additives
LAZ length-for-age z-score
LB lower bound
LBW low birth weight
LCD left-censored data
LC–MS liquid chromatography coupled to mass spectrometry
LC–MS/MS liquid chromatography coupled to tandem mass spectrometry
LC-FD liquid chromatography coupled to ﬂuorescence detector
LFA3 lymphocyte function-associated antigen 3
LD50 lethal dose killing 50% of the animals
LH luteinising hormone
LOAEL lowest-observed-adverse-effect-level
LOD limit of detection
LOQ limit of quantiﬁcation
ML maximum level
miRNA microRNA
MOE margin of exposure
MS mass spectrometry
N/A not applicable
NF-jB nuclear factor kappa-light-chain-enhancer of activated B cells
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NK natural killer (cell)
NOAEL no-observed-adverse-effect-level
Nrf2 nuclear factor erythroid 2-related factor 2
OR odds ratio
PBPK physiologically based pharmacokinetic
PND postnatal day
PXR pregnane X receptor
ROS reactive oxygen species
RUNX3 runt domain-relator factors 3
SD standard deviation
SGA small for gestational age
SOP standard operational procedure
SNP single nucleotide polymorphism
StAR steroidogenic acute regulatory protein
TAS total blood antioxidant status
TDS total diet study
TGFb transforming growth factor b
TK toxicokinetics
TLR Toll-like receptor
TNF tumour necrosis factor
UB upper bound
UGT uridine 5’-diphospho-glucuronosyltransferase (UGT)
UPLC ultra performance liquid chromatography
UV ultraviolet
WHO World Health Organization
WAZ weight-for-age z-score
WHZ weight-for-height z-score
WLZ weight-for-length z-score
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Appendix I – Identiﬁcation and selection of evidence relevant for the risk
assessment of aﬂatoxins in food
I.1. Literature search for hazard identiﬁcation and characterisation
A. Web of Science
Used search string: TOPIC: (aﬂatoxin*); Time span=2006–2018; Search language=Auto
Results: 8,741
B. PubMed
Used search string: (“aﬂatoxins”[MeSH Terms] OR “aﬂatoxins”[All Fields] OR “aﬂatoxin”[All Fields])
AND (“2006/01/01”[PDAT] : “3000”[PDAT])
Results: 4,126
C. Sci Finder
Aﬂatoxin B1; year 2006-; reﬁned for adverse effect including toxicity; 2,116 results
Aﬂatoxin B2; year 2006-; reﬁned for adverse effect including toxicity; 322 results
Aﬂatoxin G1; year 2006-; reﬁned for adverse effect including toxicity; 318 results
Aﬂatoxin G2; year 2006-; reﬁned for adverse effect including toxicity; 275 results
Aﬂatoxin M1; year 2006-; reﬁned for adverse effect including toxicity; 273 results
Aﬂatoxin M2; year 2006-; reﬁned for adverse effect including toxicity; 16 results
D. Scopus
Used search string: TOPIC: (aﬂatoxin*); Time span=2006–2018; 8,805 results
E. Total
After removal of all duplicates, 11,981 papers were screened for relevance based on title and
abstract.
I.2. Exclusion criteria for abstracts
The titles and abstracts of the references retrieved from the literature search described in
Section I.1 were screened to identify the relevant papers for the sections on hazard identiﬁcation and
characterisation. Papers on the following subjects were excluded:
• Papers not related to hazard identiﬁcation and characterisation.
• Papers reporting only levels of biomarkers for populations outside Europe.
• Studies in experimental animals using routes of exposure other than oral or in which only one
dose was tested. This criterion was not applied for genotoxicity and mechanistic studies.
• Studies in which experimental animals are exposed to mixtures that include substances other
than aﬂatoxins.
• Studies designed to evaluate substances or extracts for anticancer therapy.
• Studies in which aﬂatoxins are solely used for the purpose of a positive control.
I.3. Literature search for processing
In addition, a literature search was conducted in June 2019 to identify papers regarding the effect
of roasting on nuts. The following search string was used:
TOPIC: (aﬂatoxin*) AND TOPIC: (roasting) AND TOPIC: (nut); Time span: All years. Indexes: SCI-
EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC.; 29 results
were obtained.
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Appendix II – Summary tables hazard identiﬁcation and characterisation
Table II.1: Summary of oral short-term toxicity studies for aﬂatoxin B1
Species (n)
Route of administration
dosage (mg/kg bw per day)
Duration/time of
observation
Outcome NOAEL (LOAEL) Reference
Inbred Fischer
F344 rats (newly
weaned)
Diet
0, 0.12, 0.6, 1.2, 2.4 mg/kg bw
per day
6 weeks Hepatotoxicity and liver injury but not liver
failure. Stunting and wasting and
suppression of GH signalling
(0.12 mg/kg bw per
day)
Knipstein et al. (2015)
Male Albino rat
(100–150 g)
Gavage
0, 0.25, 0.5, 1.0 mg/kg bw per
day
In olive oil
7 days Altered lipid metabolism: increased plasma
and liver cholesterol, triglycerides and
phospholipids
0.5 mg/kg and 1.0 mg/kg downregulation
of hepatic Cpt1a and increased plasma FFA
and triglycerides
Dose-dependent decrease in relative
expression of Ahr, Lipc and Lcat and
increase in Scarb1
(0.25 mg/kg bw per
day)
Rotimi et al. (2017)
Male Wistar rats
(190–220 g)
Gavage
0, 0.5, 1.0, 2.0 mg/kg bw per day
In 8% alcoholic solution
7 days Decrease TAS value being most at highest
dose. Increase in uric acid, second line
antioxidant defence
(0.5 mg/kg bw per
day)
Wojtowicz-Chomicz et al.
(2011)
Male Sprague–
Dawley rats
Gavage
0, 0.5, 1.0 mg/kg bw per day
In corn oil
+/cypermethrin
Daily for 10, 20, 30,
40 days
Depression, decreased body weight and
feed intake, loose faeces and toxicity in liver
and kidney
Potentiation of toxic response with
combination
(0.5 mg/kg bw per
day)
Hussain et al. (2009)
Male Swiss Albino
mice (30–35 g)
(n = 10)
Gavage
0.75 and 1.5 mg/kg bw per day
In olive oil
30 days Decreased bw and increased organ and
kidney weight
At higher dose increased ALT, AST, acid
phosphatase and serum creatinine
Decreased ATPase, ALP, succinate
dehydrogenase and serum protein
(0.75 mg/kg bw per
day)
Jha et al. (2014)
Male Fischer F344
rats
Gavage
0, 0.005, 0.025, 0.075 mg/kg bw
per day in DMSO
4 weeks 5 days/week 12 samples analysed (3/group) Controls –
phylogenetically diverse microbiota,
increasing AFB1 doses decreased diversity
but increased evenness of community
composition. Some lactic acid bacteria were
signiﬁcantly depleted by AFB1. AFB1
modiﬁes gut microbiota in a dose-
dependent manner
(0.005 mg/kg bw per
day)
Wang et al. (2016a)
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Species (n)
Route of administration
dosage (mg/kg bw per day)
Duration/time of
observation
Outcome NOAEL (LOAEL) Reference
Male Fischer F344
rats
Gavage
0, 0.005, 0.025, 0.075 mg/kg bw
per day in DMSO
Daily for 4 weeks The levels of faecal short-chain fatty acids
were signiﬁcantly reduced after a 2-week
exposure in all treated groups. The
reduction was >70% in the highest dose
group. In addition, data on levels of organic
acids in the faeces show that aﬂatoxin
exposure affects the gut-dependent
metabolism
(0.005 mg/kg bw per
day)
Zhou et al. (2018)
Male Wistar rats
(240–300 g)
Gavage
150 mg/kg, 300 mg/kg
Twice per week,
5 weeks
(cumulative dose
1.5 mg/kg and
3 mg/kg)
Decreased bw and dose-related decreases
in expression of NPY, POMC, SgII and
orexin mRNA. AgRP, MCH, CART and TRH
expression decreased. Number of EM66-IR
neurons decreased
(1.5 mg/kg) Trebak et al. (2015)
Kunming mice Gavage
0, 0.1, 0.16 and 0.4 mg/kg bw per
day(a)
In ethanol/water mixture
2 months (twice per
day)
AFB1 decreased both genera and phyla of
intestinal bacteria. Lactobacillus and
Bacteroides were the dominant ﬂora.
Signiﬁcant differences in the relative
abundance of intestinal bacterial ﬂora
among groups. Most bacteria decreased,
but several beneﬁcial and pathogenic
bacterial species increased signiﬁcantly
(0.1 mg/kg bw per
day)
Yang et al. (2017)
Male Fischer rats
(100–120 kg)
Gavage
0, 5, 10, 25, 75 lg/kg bw
5 days/week for 5
weeks
Decreased body weight, GST-P+ cells and
foci, bile duct proliferation and periportal
necrosis
(5 lg/kg bw) Qian et al. (2013)
Kunming mice SPF
pathogen-free
Gavage
0, 0.1, 0.16 and 0.4 mg/kg bw per
day(a)
In ethanol/water mixture
2 months (twice per
day)
Number of bacteria increased in all dose
groups. Biﬁdobacterium increased in the
highest dose group. Amylase activity
increased in all groups and zylanase and
cellulose increased in the highest dose
group
(0.1 mg/kg bw per
day)
He et al. (2018)
NOAEL: no-observed-adverse-effect-level; LOAEL: lowest-observed-adverse-effect-level; bw: body weight; n: number of animals per group; ATPase: adenosine triphosphatase; ALP: alkaline
phosphatase; ALT: alanine aminotransferase; AST: aspartate transaminase; SOD: superoxide dismutase; AFB1: aﬂatoxin B1; DMSO: dimethyl sulfoxide.
(a): 0, 2.5, 4 and 10 lg/mL; 0.4 mL was given twice a day. This is equivalent to 0, 0.05, 0.08 and 0.2 mg/kg bw per shot based on a body weight of 20 g.
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Table II.2: Experimental design of in vivo genotoxicity studies, including details of the outcome
Test system Animals Concentration/treatment
Details of the outcome not speciﬁed in
the text
Reference
Micronuclei in the bone
marrow; single strand
breaks
Male Fischer rats Single oral dose of 0.25 mg/kg bw Corcuera et al.
(2015)
Mutation frequency
analysis
Pregnant gpt delta B6C3F1 mice Single dose either i.p. or orally on GD
14: 6 mg/kg bw in DMSO
Chawanthayatham
et al. (2015)
Adduct formation Pregnant gpt delta B6C3F1 mice Single dose i.p. on GD 14: 5 mg/kg
bw in DMSO
Level of AFB1-N7-gua and AFB1-FAPY in the
liver tissue 6 h after application:
– mother:
18.8  2.5 and 45  6 adducts/106
nucleotides (mean  SD), respectively
– fetus: 0.31  0.25 and 0.30  0.19
adducts/106 nucleotides, respectively
Chawanthayatham
et al. (2015)
Single dose orally on GD 14: 5 mg/kg
bw in DMSO
Level of AFB1-N7-gua and AFB1-FAPY in the
liver tissue 6 h after application:
– mother:
6.2  0.8 and 19.1  0.4 adducts/106
nucleotides, respectively
– fetus: 0.07  0.04 adducts/106 nucleotides
and < LOD, respectively
Adduct formation C57BL/6 J mice (pregnant and
non-pregnant controls)
Single i.p. dose of 6 mg/kg on GD 14
in DMSO
Sriwattanapong et al.
(2017)
Mutational patterns Four-day old male gpt delta
B6C3F1 mice
6 mg/kg bw by i.p Chawanthayatham
et al. (2017)
DNA adduct formation and
mutational patterns
Four-day old gpt delta B6C3F1
mice
Single dose (6 mg/kg bw, i.p.) Woo et al. (2011)
Mutational patterns Four-day old gpt delta B6C3F1
mice
Single dose (6 mg/kg bw, i.p.) + post-
dosing period of 3 and 10 weeks
Wattanawaraporn
et al. (2012)
GD: gestation day; LOD: limit of detection; i.p.: intraperitoneal; SD: standard deviation; AFB1: aﬂatoxin B1; DMSO: dimethyl sulfoxide; bw: body weight.
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Table II.3: Summary of in vivo developmental and reproductive toxicity studies for aﬂatoxin B1
Reference Species Treatment Effects
Hasanzadeh and Amani
(2013)
Female Wistar rats 0, 4, 8 or 16 lg/kg bw per day by gavage for 25 days Reduction in the population of healthy primordial, primary,
secondary and tertiary ovarian follicles; dose-dependent at
all doses
Hasanzadeh et al. (2011) Male Wistar rats 0, 4, 8 or 16 lg/kg bw per day by gavage for 48 days Decreased LH and testosterone; increased FSH and
prolactin; dose-dependent effects at all doses
Hasanzadeh and
Rezazadeh (2013)
Male Wistar rats 0, 4, 8 or 16 lg/kg bw per day by gavage for 48 days Spermatogonia and spermatozoa decreased in all test
groups (p < 0.001); primary spermatocytes and spermatids
decrease (p < 0.01) only in high-dose group
Mohammadi et al. (2014) NMRI mice 0, 100 or 700 lg/kg bw per day by gavage for 35 days DNA damage and chromatin abnormalities of sperm cells
with low fertilisation rate and retarded embryonic
development; effects at all doses
Murad et al. (2015) Adult rats 15, 30 or 45 lL of AFB1/kg (three times/week) orally for 40
days
Available information does not make it possible to calculate
the dose
Dose-dependent increase in testicular and sperm
abnormalities
Tanaka et al. (2015) SD female rats Dietary exposure to AFB1 at 0, 0.1, 0.3, or 1.0 mg/kg from
GD 6 to day PND 21. Examination at PND 21 and 77
Dose during gestation period: 0, 7.1, 20.7 or 66.7 lg/kg bw
per day
Dose during lactation period: 0, 13.6, 41.7 and 132.7 lg/kg
bw per day
Maternal AFB1 exposure reversibly affects hippocampal
neurogenesis targeting type-3 progenitor cells; NOAEL for
offspring neurogenesis was 7.1–13.6 mg/kg bw per day
(corresponding concentration in the diet: 0.1 mg/kg)
Wang et al. (2016b) ICR female mice 0, 50, 500, 5,000 lg/kg bw by gavage for 4 days (from GD
13.5 to 16.5)
Shortened time to delivery and low birth weight in mice
treated with 0.5 and 5 mg /kg bw; NOAEL at 50 lg/kg bw
NOAEL: no-observed-adverse-effect-level; bw: body weight; AFB1: aﬂatoxin B1; PND: postnatal day; GD: gestation day; LH: luteinising hormone; FSH: follicle-stimulating hormone
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Appendix III – Benchmark dose analysis of the incidence of HCC in male
Fisher rats
The text below describes the benchmark dose (BMD) analysis of the incidence of HCC in male rats
using model averaging. BMD analysis was done according to the EFSA guidance (EFSA Scientiﬁc
Committee, 2017).
III.1. Data description
Data from male Fischer rats treated with AFB1 in feed for up to 105 weeks (Wogan et al., 1974).
Doses used in this BMD analysis were corrected for the shorter study duration in some groups.
III.2. Selection of the benchmark response
A default benchmark response (BMR) of 10% (extra risk) and a 90% interval around the BMD were
selected as recommended by EFSA Scientiﬁc Committee (2017).
III.3. Software used
Results are obtained using the EFSA web tool for BMD analysis
• Fitting benchmark dose models is based on the R-package PROAST, version 66.38.
• Averaging results from multiple ﬁtted benchmark dose models is based on the methodology in
Wheeler and Bailer (2008).
III.4. Speciﬁcation of deviations from default assumptions
General assumptions
No deviation from the recommended defaults (e.g. gamma distributional assumption instead of log-
normal, heteroscedasticity instead of homoscedasticity) was made.
Dose–response models
No deviation from the recommended defaults. Default set of ﬁtted models:
Model Number of parameters Formula
Null 1 y = a
Full No. of groups y ¼ group mean
Logistic 2 y ¼ 11þexp abxð Þ
Probit 2 y ¼ pnorm x  að Þ  bð Þ
Log-logistic 3 y ¼ aþ 1a
1þexp clog bxð Þð Þ
Log-probit 3 y ¼ aþ 1 að Þ  pnorm c  log xb
  
Weibull 3 y ¼ aþ 1 að Þ 1 exp  xb
 c  
Table III.1: Data on the incidence of HCC used for BMD analysis
Time-adjusted dose (lg/kg bw per day)(a) N N total
0 0 18
0.05 2 22
0.22 1 22
0.69 4 21
1.97 20 25
2.60 28 28
bw: body weight; N: number of animals.
(a): Time adjustment based on time of appearance of earliest tumour as performed by the CONTAM Panel in 2007 (i.e. if a
1-year exposure is corrected to a 2-year exposure, then the dose is multiplied by a factor or 0.5).
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Model Number of parameters Formula
Gamma 3 y ¼ pgamma bx; cð Þ
Two-stage 3 y ¼ aþ 1 að Þ 1 exp  xb c xb
 2  
Exp model 3 3 y ¼ a  exp bxd 
Exp model 5 4 y ¼ a  c  c  1ð Þexp bxd  
Hill model 3 3 y ¼ a  1 xd
bdþxd
 
Hill model 5 4 y ¼ a  1þ c  1ð Þ xd
bdþxd
 
For the Exp and Hill family, models were ﬁt with 3 and 4 parameters as listed in the table. The
3-parameter model is selected if the difference in AIC is smaller than 5, otherwise the 4-parameter
model is selected.
Procedure for selection of BMDL
There was no deviation from the procedure described in the ﬂow chart to obtain the ﬁnal BMD
conﬁdence interval.
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III.5. Results
Figure III.1: Flowchart for selection of BMDL
Table III.2: Result for the incidence of HCC in male Fisher rats using model averaging
Model
Number of
parameters
Log-
likelihood
AIC
Accepted
AIC
BMDL BMDU BMD Converged
null 1 91.77 185.54 NA NA NA NA
full 6 33.51 79.02 NA NA NA NA
two.stage 3 36.25 78.50 No NA NA 0.471 Yes
log.logist 3 36.77 79.54 No NA NA 0.649 Yes
Weibull 3 35.67 77.34 Yes 0.371 1.680 0.674 Yes
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Estimated model parameters
two.stage
estimate for a- : 0.03904
estimate for BMD- : 0.4706
estimate for c : 1e+12
log.logist
estimate for a- : 0.04983
estimate for BMD- : 0.6495
estimate for c : 3.659
Weibull
estimate for a- : 0.05056
estimate for BMD- : 0.6742
estimate for c : 2.673
log.prob
estimate for a- : 0.0501
estimate for BMD- : 0.6525
estimate for c : 2.157
gamma
estimate for a- : 0.04974
estimate for BMD- : 0.6467
estimate for cc : 4.933
logistic
estimate for a- : -3.296
estimate for BMD- : 0.5515
probit
estimate for a- : -1.866
estimate for BMD- : 0.4972
EXP
estimate for a- : 1.507
estimate for CED- : 0.69
estimate for d- : 1.432
estimate for th(ﬁxed) : 0
estimate for sigma(ﬁxed) : 0.25
HILL
estimate for a- : 1.5
estimate for CED- : 0.7001
estimate for d- : 1.744
estimate for th(ﬁxed) : 0
estimate for sigma(ﬁxed) : 0.25
Model
Number of
parameters
Log-
likelihood
AIC
Accepted
AIC
BMDL BMDU BMD Converged
log.prob 3 36.50 79.00 No NA NA 0.653 Yes
gamma 3 36.15 78.30 No NA NA 0.647 Yes
logistic 2 35.96 75.92 Yes 0.410 0.730 0.552 Yes
probit 2 35.72 75.44 Yes 0.377 0.649 0.497 Yes
LVM: Expon.
m3-
3 35.40 76.80 Yes 0.324 1.360 0.690 Yes
LVM: Hill m3- 3 35.69 77.38 Yes 0.353 1.290 0.700 Yes
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
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Conﬁdence intervals for the BMD are based on 5,000 bootstrap data sets. the BMDL is the 5th
percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.
Table III.3: Mode weights used in model averaging
two.stage log.logist Weibull log.prob gamma logistic probit EXP HILL
0.06 0.03 0.1 0.04 0.06 0.21 0.26 0.13 0.1
Table III.4: Calculated BMDL and BMDU values (lg/kg bw per day) for the incidence of
hepatocellular carcinomas reported by Wogan et al. (1974)
BMDL BMDU
0.37 1.2
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Visualisation
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Appendix IV – Summary tables occurrence and exposure
Table IV.1: Overview of aﬂatoxin biomarker concentrations in the European population in urine samples collected in 2006 or later
Country Sample Compound Sampling period Population n
Concentration (ng/mL)
%LC Analytical method Reference
Range l
Belgium Morning
urine
AFM1 n.r. Adults 239 < LOD / 100 LC–MS/MS
LOD: 0.002 ng/mL
Heyndrickx et al. (2015)
Children 155 < LOD / 100
Germany Urine AFM1 n.r. Healthy
volunteers
101 < LOQ / 100 LC–MS/MS
LOQ: 0.0013 ng/mL
Gerding et al. (2014)
Germany Urine AFM1 2013–2014 Healthy adults 50 < LOQ / 100 LC–MS/MS
LOQ: 0.01 ng/mL
Gerding et al. (2015)
Italy Urine AFM1 March–April 2014 Workers
occupationally
exposed
29 < LOD–0.399 0.035(a) 29 HPLC-FLD
LOD: 0.002 ng/mL
Ferri et al. (2017)
Control group 30 < LOD–0.259 0.027(a) 23
Italy Morning
urine
AFM1 April 2011 Not speciﬁed 52 < LOQ–0.146 0.068(b) 94 LC–MS/MS
LOQ: 0.02 ng/mL
Solfrizzo et al. (2014)
Portugal Serum AFB-alb January–February
2015
Workers
occupationally
exposed
30 < LOD–4.03 1.73(b) 53 ELISA
LOD: 1 ng/mL
Viegas et al. (2016)
Control group 30 < LOD / 100
AFM1: aﬂatoxin M1; LC: left-censored; LOD: limit of detection; LOQ: limit of quantiﬁcation; LC–MS/MS: Liquid chromatography coupled to tandem mass spectrometry; HPLC: high-performance
liquid chromatography.
(a): Calculated as lower bound.
(b): Mean of the samples with concentrations > LOD/LOQ.
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Table IV.2: Overview of AFM1 concentrations in human milk collected in Europe in 2006 or later
Country Sampling period N mothers % LC
Concentration (ng/L)
Comment Analytical method Reference
Range Mean
Cyprus March–May 2015 50 20 < 5–28.44 7.84(b) ELISA (commercial kit)
LOD: 5 ng/L
Kunter et al. (2017)
Italy 2006 82 95 < 7–140 55.35(b) HPLC-FLD
LOD: 3 ng/L; LOQ: 7 ng/L
Galvano et al. (2008)
Italy 2011–2013 35(a) 63 < 7–340 12(c) Mothers with coeliac
disease; gluten-free
diet
HPLC-FLD
LOQ: 7 ng/L
Valitutti et al. (2018)
23(a) 76 < 7–67 9(c) Healthy mothers
(control)
Portugal 2015–2016 67 67 < 5–10.6 7.4(d) ELISA (commercial kit)
LOD: 5 ng/L
Bogalho et al. (2018)
Serbia 2013–2014 55 64 < 5–503 175(d) Colostrum ELISA (commercial kit)
LOD: 4.3 ng/L
LOQ: 5 ng/L
Radonic et al. (2017)
5 0 58–570 n.r. Collected 4–8 months
after delivery
Serbia April 2013 10 40 < 5–22(e) 10 (e) ELISA (commercial kit)
LOD: 1.5 ng/kg
LOQ: 5 ng/kg
Kos et al. (2014)
AFM1: aﬂatoxin M1; LC: left-censored; LOD: limit of detection; LOQ: limit of quantiﬁcation; ELISA: enzyme-linked immunosorbent assay; LC–MS/MS: Liquid chromatography coupled to tandem
mass spectrometry; HPLC: high-performance liquid chromatography; LOD: limit of detection; LOQ: limit of quantiﬁcation.
(a): About nine samples/mother).
(b): Mean of the samples with concentrations > LOD/LOQ.
(c): Calculated as middle bound.
(d): Not speciﬁed how mean is calculated.
(e): concentration reported as ng/kg.
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Table IV.3: Examples of dietary exposure assessments of the European population published in the scientiﬁc literature since 2013
Population Country Food
Exposure (ng/kg bw per day) Analytical method;
Treatment of left-censored
data if reported
Reference
Mean High
AFM1
Children 1–3 years Portugal Breakfast cereals, infant
cereals, biscuits
0.052–0.069 0.203(a) HPLC-FLD; LB-UB Assunc~ao et al. (2018)
Children 1–5 syears Serbia milk 6.26–6.45 ELISA (commercial kit) Kos et al. (2014)
Children 5–15 years Serbia milk 1.86–2.34 ELISA (commercial kit) Kos et al. (2014)
15–25 years Serbia milk 0.42–1.26 ELISA (commercial kit) Kos et al. (2014)
25–55 years Serbia milk 0.49–0.56 ELISA (commercial kit) Kos et al. (2014)
> 55 years Serbia milk 0.51–0.69 ELISA (commercial kit) Kos et al. (2014)
Adults Serbia milk 0.5–1.4 LC–MS/MS Skrbic et al. (2014)
Adult Serbia heat-treated milk; sampling
2013
0.54–0.6 HPLC-FLD Torovic (2015)
Adults Serbia heat-treated milk; sampling
2014
0.06 HPLC-FLD Torovic (2015)
AFB1
Children 1–3 years Portugal Breakfast cereals, infant
cereals, biscuits
0.011–0.012 0.055(a) HPLC-FLD; LB-UB Assunc~ao et al. (2018)
Children Serbia Biscuits with fruit ﬁllings 0.05–0.09 LC–MS/MS; LB-UB Skrbic et al. (2017)(b)
Adolescents Serbia Biscuits with fruit ﬁllings 0.04–0.08 LC–MS/MS; LB-UB Skrbic et al. (2017)(b)
Adolescents Spain Coffee 0.001 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
Adults Portugal Nuts 0.0069–0.089 LC–MS/MS; LB-UB Cunha et al. (2018)
Adults Spain Bread 0.03–0.035 LC–MS/MS; LB-UB Saladino et al. (2017)
Adults Serbia Biscuits with fruit ﬁllings 0.03–0.06 LC–MS/MS; LB-UB Skrbic et al. (2017)(b)
Adults Spain Coffee 0.003 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
AFB2
Children 1–3 years Portugal Breakfast cereals, infant
cereals, biscuits
0.001–0.003 0.01(a) HPLC-FLD; LB-UB Assunc~ao et al. (2018)
Adolescents Spain Coffee < 0.001 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
Adults Portugal Nuts 0.0002–0.0643 LC–MS/MS; LB-UB Cunha et al. (2018)
Adults Spain Bread 0.022–0.026 LC–MS/MS; LB-UB Saladino et al. (2017)
Adults Spain Coffee 0.001 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
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Population Country Food
Exposure (ng/kg bw per day) Analytical method;
Treatment of left-censored
data if reported
Reference
Mean High
AFG1
Children 1–3 years Portugal Breakfast cereals, infant
cereals, biscuits
0.002–0.016 0.048 (a) HPLC-FLD; LB-UB Assunc~ao et al. (2018)
Adolescents Spain Coffee 0.001 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
Adults Portugal Nuts 0–0.0529 LC–MS/MS; LB-UB Cunha et al. (2018)
Adults Spain Bread 0.008–0.018 LC–MS/MS; LB-UB Saladino et al. (2017)
Adults Spain Coffee 0.006 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
AFG2
Adolescent Spain Coffee 0.003 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
Adult Portugal Nuts 0.0273–0.095 LC–MS/MS; LB-UB Cunha et al. (2018)
Adults Spain Coffee 0.014 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
AFT
Adolescent Spain Coffee 0.008 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
Adults Spain Bread 0.021–0.078 LC–MS/MS; LB-UB Saladino et al. (2017)
Adults Spain Coffee 0.036 LC–MS/MS; LB Garcıa-Moraleja et al. (2015)
AFM1: aﬂatoxin M1; AFB1: aﬂatoxin B1; AFB2: aﬂatoxin B2; AFG1: aﬂatoxin G1; AFG2 aﬂatoxin G2; AFT: aﬂatoxin total; bw: body weight; ELISA: enzyme-linked immunosorbent assay; HPLC: high-
performance liquid chromatography; LB: lower bound; UB: upper bound.
AFT: sum of AFB1, B2, G1 and G2.
(a): P95 calculated via a probabilistic approach in which the left-censored data were replaced by random values from a uniform distribution with zero as minimum and the LOD as maximum.
(b): Calculated exposures for AFB2, G1 and G2 are not shown since all samples were left-censored.
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Appendix V – Risk characterisation
Table V.1: Margin of exposure (MOE) values based on dietary exposure to AFT+AFM1 for the
incidence of HCC across dietary surveys and age groups
Age groups
MOE calculated from mean dietary
exposure to AFT+AFM1
MOE calculated from P95 dietary
exposure to AFT+AFM1
Minimum Median Maximum Minimum Median Maximum
LB UB LB UB LB UB LB UB LB UB LB UB
Infants 2,222 455 952 155 396 40 615 99 345 54 122 14
Toddlers 541 79 325 44 195 32 310 48 172 26 90 15
Other children 460 75 328 46 208 32 235 53 174 25 91 17
Adolescents 930 139 625 77 381 57 377 83 284 35 156 30
Adults 1,143 175 727 100 500 61 482 92 320 44 174 28
Elderly 1,429 190 870 109 690 61 615 91 396 53 252 32
Very elderly 1,290 158 930 107 667 61 548 78 421 45 278 30
AFM1: aﬂatoxin M1; AFT: aﬂatoxin total; HCC: hepatocellular carcinoma; LB: lower bound; UB: upper bound.
Table V.2: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFM1, the mean
potency estimates of the cancer risk and a HBV/HCV prevalence of 0.2%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.002 0.004 0.010 0.014 0.027 0.035
Toddlers 0.008 0.011 0.012 0.018 0.025 0.032
Other children 0.003 0.005 0.006 0.009 0.014 0.018
Adolescents 0.001 0.002 0.003 0.004 0.004 0.006
Adults 0.001 0.001 0.001 0.002 0.002 0.004
Elderly 0.001 0.001 0.001 0.002 0.002 0.003
Very elderly 0.001 0.001 0.001 0.002 0.003 0.004
Pregnant women 0.002 0.002 0.002 0.003 0.002 0.004
Lactating women 0.002 0.004 0.003 0.004 0.004 0.005
Based on 95th percentile dietary exposure in total population
Infants 0.012 0.017 0.026 0.036 0.109 0.138
Toddlers 0.018 0.026 0.026 0.038 0.067 0.085
Other children 0.008 0.011 0.014 0.022 0.038 0.048
Adolescents 0.004 0.005 0.006 0.010 0.008 0.012
Adults 0.002 0.003 0.004 0.006 0.007 0.009
Elderly 0.002 0.003 0.004 0.006 0.007 0.008
Very elderly 0.003 0.004 0.004 0.005 0.006 0.008
Pregnant women 0.004 0.005 0.005 0.007 0.006 0.009
Lactating women 0.006 0.008 0.007 0.009 0.007 0.010
AFM1: aﬂatoxin M1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
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Table V.3: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFM1, the upper
bound potency estimates of the cancer risk and a HBV/HCV prevalence of 7.6%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.012 0.018 0.050 0.071 0.137 0.174
Toddlers 0.040 0.056 0.060 0.092 0.125 0.159
Other children 0.016 0.025 0.031 0.046 0.069 0.088
Adolescents 0.007 0.011 0.013 0.020 0.022 0.033
Adults 0.004 0.005 0.007 0.011 0.012 0.018
Elderly 0.004 0.005 0.007 0.011 0.012 0.016
Very elderly 0.004 0.005 0.007 0.010 0.013 0.019
Pregnant women 0.008 0.010 0.010 0.013 0.011 0.018
Lactating women 0.012 0.018 0.016 0.022 0.019 0.026
Based on 95th percentile dietary exposure in total population
Infants 0.058 0.086 0.130 0.181 0.548 0.693
Toddlers 0.092 0.131 0.129 0.192 0.334 0.427
Other children 0.038 0.055 0.070 0.111 0.190 0.240
Adolescents 0.019 0.027 0.033 0.051 0.042 0.061
Adults 0.011 0.014 0.022 0.028 0.034 0.048
Elderly 0.011 0.014 0.021 0.028 0.033 0.042
Very elderly 0.015 0.022 0.022 0.027 0.030 0.040
Pregnant women 0.018 0.024 0.025 0.033 0.030 0.043
Lactating women 0.030 0.040 0.033 0.045 0.036 0.049
AFT: aﬂatoxin total; AFM1: aﬂatoxin M1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
Table V.4: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFT+AFM1, the
mean potency estimates of the cancer risk and a HBV/HCV prevalence of 0.2%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.003 0.015 0.007 0.045 0.018 0.174
Toddlers 0.013 0.089 0.022 0.160 0.036 0.219
Other children 0.015 0.093 0.021 0.151 0.034 0.220
Adolescents 0.008 0.050 0.011 0.091 0.018 0.122
Adults 0.006 0.040 0.010 0.070 0.014 0.116
Elderly 0.005 0.037 0.008 0.064 0.010 0.114
Very elderly 0.005 0.044 0.008 0.066 0.011 0.116
Based on 95th percentile dietary exposure in total population
Infants 0.011 0.071 0.020 0.130 0.057 0.517
Toddlers 0.023 0.144 0.041 0.268 0.078 0.473
Other children 0.030 0.131 0.040 0.281 0.077 0.401
Adolescents 0.019 0.084 0.025 0.202 0.045 0.230
Adults 0.015 0.076 0.022 0.160 0.040 0.249
Elderly 0.011 0.077 0.018 0.133 0.028 0.216
Very elderly 0.013 0.089 0.017 0.155 0.025 0.234
AFT: aﬂatoxin total; AFM1: aﬂatoxin M1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
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Table V.5: Cancer risk estimates(a) calculated from the chronic dietary exposure to AFT+AFM1, the
upper bound potency estimates of the cancer risk and a HBV/HCV prevalence of 7.6%
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Based on mean dietary exposure in total population
Infants 0.016 0.077 0.037 0.227 0.089 0.873
Toddlers 0.065 0.448 0.108 0.804 0.180 1.101
Other children 0.077 0.468 0.107 0.759 0.169 1.103
Adolescents 0.038 0.253 0.056 0.457 0.092 0.614
Adults 0.031 0.201 0.048 0.352 0.070 0.581
Elderly 0.025 0.186 0.040 0.324 0.051 0.573
Very elderly 0.027 0.223 0.038 0.330 0.053 0.582
Based on 95th percentile dietary exposure in total population
Infants 0.057 0.355 0.102 0.654 0.288 2.601
Toddlers 0.114 0.726 0.205 1.349 0.392 2.380
Other children 0.150 0.660 0.202 1.415 0.387 2.017
Adolescents 0.093 0.423 0.124 1.015 0.225 1.157
Adults 0.073 0.384 0.110 0.806 0.202 1.249
Elderly 0.057 0.387 0.089 0.667 0.140 1.086
Very elderly 0.064 0.450 0.084 0.779 0.127 1.174
AFT: aﬂatoxin total; AFM1: aﬂatoxin M1; HBV: hepatitis B virus; HCV: Hepatitis C virus; LB: lower bound; UB: upper bound.
(a): Expressed per 100,000 person-years.
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Annex A – Dietary surveys per country and age group available in the EFSA
Comprehensive Database, considered in the exposure assessment
The excel ﬁle containing the dietary surveys per country and age group is available on the EFSA
Knowledge Junction community on Zenodo at: https://doi.org/10.5281/zenodo.3607186
Annex B – Occurrence data on aﬂatoxins
The excel ﬁle containing the occurrence data on aﬂatoxins is available on the EFSA Knowledge
Junction community on Zenodo at: https://doi.org/10.5281/zenodo.3607186
Annex C – Proportion of left-censored data and the mean concentrations of
the quantiﬁed analytical results of AFB1 for pistachios, hazelnuts, peanuts,
other nuts and dried ﬁgs
The excel ﬁle containing the proportion of left-censored data and the mean concentrations of the
quantiﬁed analytical results of AFB1 for pistachios, hazelnuts, peanuts, other nuts and dried ﬁgs is
available on the EFSA Knowledge Junction community on Zenodo at: https://doi.org/10.5281/zenodo.
3607186
Annex D – AFB1 and AFM1 concentrations reported for organic farming
and conventional farming in selected food categories
The excel ﬁle containing the AFB1 and AFM1 concentrations reported for organic farming and
conventional farming in selected food categories is available on the EFSA Knowledge Junction
community on Zenodo at: https://doi.org/10.5281/zenodo.3607186
Annex E – Mean and high chronic dietary exposure to aﬂatoxins per survey
and the contribution of different food groups to the dietary exposure
The excel ﬁle containing the mean and high chronic dietary exposure to aﬂatoxins per survey and
the contribution of different food groups to the dietary exposure is available on the EFSA Knowledge
Junction community on Zenodo at: https://doi.org/10.5281/zenodo.3607186
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